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Today, genetically modified animals are a routine biomedical technology, used as research models 
and test subjects in drug development. The vast majority of such experiments relies on transgenic 
mice that carry experimentally introduced foreign genes. Overwhelmingly, they are produced by 
direct injection of isolated DNA into a one-cell embryo through a minute glass needle. In 1980–81, 
six laboratories reported the successful use of the procedure, called pronuclear injection, al-
though researchers had tried to insert new genes into mice in various ways since the 1960s. De-
spite the gradual decrease in animal research in American and European laboratories since the 
passage of updated laboratory animal legislation between the mid-60s and the mid-80s, these 
modified rodents have shown consistent growth (Fig. i). Today, the production of transgenic mice 
has been outsourced to quasi-commercial academic ‘core facilities’ and for-profit providers, with 
a sizeable industry around them. Throughout the 1980s, however, these mice were made in a few 
hundred laboratories that combined the necessary funding, equipment and expertise. 
Transgenic mice were invented during dramatic shifts in the organisation, funding and commu-
nication of biomedical research. This thesis is the first extended history of their invention and 
early adoption, leading up to the 1988 US patent on the ‘Harvard mouse’ or OncoMouse, a trans-
genic animal modified to carry cancer-causing oncogenes and the first animal – though not the 
first organism – to be patented.1  I place these animals within the changes in biology, transforma-
tions in science funding and the altered vectors of scientific communication. I consider the di-
verse audiences to which transgenic mice were communicated, the modes of production and ex-
change of molecules, modified embryos and mice, as well as how this invention has been remem-
bered. Rather than follow one theme or approach, I bring multiple perspectives and literatures to 
bear on the history of these animals. This introduction will consider existing histories of trans-
genic animals and their place in the biotechnology story; histories of animals in science and be-
yond; perspectives on innovation and invention; the role of media in science and changes in sci-
1
1 I allude to, but do not cover subsequent developments, most notably knockout mice, available since 1989, in 
which specific genes could be removed through stem cell manipulation. These were the subject of the 2007 Nobel 
Prize.
ence journalism in the period covered; studies of knowledge and materials and transit; and finally, 
moral economies of science. 
With multiple actors involved in the early events, the scientists’ reviews and memories, while 
emphasising diﬀerent research trajectories as key, all graciously acknowledge the multiple inven-
tion of transgenesis and highlight the diversity of agendas at stake.2 Science and technology stud-
ies (STS) scholars, lawyers and historians, by contrast, have concentrated on the OncoMouse. 
These studies have tended to focus on the embodiment of novel forms of biocapitalism, on 
changes in intellectual property law within ‘knowledge economy’ discourses and on how trans-
genic mice undermine boundaries between the natural and the artificial.3 Yet in many ways, On-
2
2 Gordon 1983, Palmiter & Brinster 1985, Wagner 1990, Papaioannou 1998, Brinster & Arechaga 1998, Graham 
2000, Hanahan, et al. 2007.
3 Moga 1994, Haraway 1997, Knorr Cetina 1999, Fuller 2008, Robins 2008, Murray 2010.
Fig. i. Use of animals in scientific experiments in the UK, 1960–2012. The vast majority of genetic 
modification experiments was carried out with mice, and the species represents 75% of all procedures 
carried out in recent years. ‘Harmful genetic mutations’ refers to breeding animals with serious pa-
thologies through conventional means. The Home Office statistics includes only vertebrates.
Source: Understanding Animal research, 
www.understandinganimalresearch.org.uk/resources/image-library/1674/times-series-data-of-procedures-1960-2013, accessed 
on 28 August 2014. Latest official statistics from the Home Office can be found at 
www.gov.uk/government/collections/statistics-of-scientific-procedures-on-living-animals. 
coMouse was a commercial failure, though its multiple versions and strains are still in use.4  As 
Fiona Murray has shown, the restrictive licensing policy that conflicted with the common modes 
of exchanging experimental animals was partly to blame.5 While her account conflates the di-
verse and emergent disciplinary communities around these animals into ‘mouse geneticists’, she 
usefully highlights the resistances to patenting among scientists and its eﬀects on adoption and 
use. Despite the initial excitement, Harvard and DuPont misjudged the potential market for can-
cer models; in the late 1980s and early 90s, inbred mouse strains were seen as good enough and 
more reliable. The history of the invention of transgenic mice and their resulting production, still 
concentrated in academic labs, goes some way towards explaining how these animals came to be 
seen as a commercially promising path for the biotech industry and how their production and 
established uses of transgenic mice impeded commercialisation.
As an important yet not straightforwardly profitable innovation, transgenic mice are a peculiar 
case in the history of biotechnology. Invented in academic institutions when universities were 
actively encouraged to secure intellectual property, they highlight the changing purposes of uni-
versity science and the increasing permeability between academic and industrial biomedicine. 
Beyond extended work on regulation, scholars have surveyed the longue durée history of bio-
technology and established the importance of industrial interests in biology throughout the twen-
tieth century.6 But the 1970s transformed molecular biology in dramatic ways and on a large scale. 
As I show, these changes were not limited to what came to be defined as recombinant DNA tech-
niques, but built on multiple research programmes and institutional changes. In the USA, the role 
of state and federal government in supposedly “private science” went beyond regulation and de-
regulation in response to the dramatic controversies over recombinant DNA. The Carter and espe-




6 On regulating biotechnology, see Krimsky 1984, Wright 1994, Gottweis 1998. On placing biotechnology within 
longer history of industrialising biology, see Bud 1993, 2010. For a historiographical review of continuities and 
changes in biotechnology, see Gaudillière 2009. On the historical importance of industry to biomedical research, 
see the essays in Löwy & Gaudillière 1998b.
changing patent law and practice, brokering international agreements and oﬀering generous seed 
funding – strategies that were to some extent emulated in Britain.7 
Beyond patenting, the increased entanglement between academic laboratories, emergent biotech 
and its big pharmaceutical and chemical backers also aﬀected practices of sharing and communi-
cating research. The dramatic controversy over the first uses of what came to be know as “recom-
binant DNA” was key to this environment. Safety issues culminated in the Asilomar conference of 
1975 and subsequent NIH guidelines that required containment and extensive regulation of ex-
periments with genetically modified bacteria.8 In response, scientists and industry representa-
tives became much more engaged in communicating their work and trying to direct the 
response.“Cloning by press conference” – a phrase coined to criticise the aggressive PR of new 
biotech ventures – became increasingly common in respectable academic institutions, expanding 
the scope of acceptable media through which scientists could successfully promote their work, as 
well as the general interest in scientific news.9 As I will show, these strategies created an envi-
ronment where transgenic mice could be seen as safe animals that could be used to discuss the 
future of genetic engineering and its application to humans. 
Histories of human-animal relationships have emphasised the importance of other animals in 
analysing human culture.10 More recently, some scholars under the loose rubric of animal studies 
have sought to restore the agency of animals in the stories we tell about them. The projects to re-
construct animal agency, while fascinating, are troubled by their reliance on human sources that 
survive, or have to build on too many assumptions about animal psychology.11  So like much his-
torical work that deals with animals, this thesis is primarily a story about people who worked 
with mice. Laboratory organisms are now a standard topic in history of biology, thanks especially 
4
7 Sell 2003, Parry 2004, Cooper 2008. On the British story, see de Chadarevian 2011.
8 Krimsky 1984, Wright 1994.
9 Andreopoulos 1980, Anon. 1980b, Nelkin 1995, Yi 2011, Hughes 2011.
10 See e.g. Ritvo 1989, Robbins 2002. On the mouse, see Rader 2007. 
11 Fudge 2002, Daston & Mitman 2005. For attempts to theorise animal agency, see Haraway 2007, essays in 
Freeman, et al. 2011: Part III.
to Robert Kohler’s Lords of the Fly, a study of early Drosophila genetics.12 Kohler showed how a 
common fruit fly colonised genetics laboratories in the 1910s and became a tool, a “breeder reac-
tor” generating multiple mutants for T. H. Morgan’s genetic work, and how the laboratory in turn 
became its ecological niche. Focusing on the material world of fly genetics, Kohler argues that the 
practical and mundane problems of record-keeping and the need to update neo-Mendelian no-
menclature and formulas shaped Morgan’s celebrated chromosomal mapping project.13
Histories of other key genetic species have also tended to focus on their contingent domestication 
and genetic standardisation as a way to make reliable knowledge that could generate new prac-
tices and infrastructures.14 These animals are now routinely referred to as ‘model organisms’ – 
although this term was rarely used before the genome projects that started in the late 1980s – and 
there is a lively scientific debate as to the advantages and disadvantages of limiting research to a 
handful of well-studied organisms, especially with the rise of evo-devo.15  More recent historical 
work has highlighted alternative ways to standardise laboratory animals, and how debates about 
standardisation strategies could help generate new communities and fields.16 Similarly, and by 
contrast with histories of domestication, this thesis considers how a well-established laboratory 
animal was modified to move into new fields of inquiry and modes of production. 
Geneticists first domesticated mice at Harvard’s Bussey Institution for Applied Biology at the turn 
of the twentieth century as they relied on the supply of exotic strains of mice as ‘fancy animals’.17 
Finding a new home at the Jackson Laboratory in Bar Harbor, Maine, inbred strains of mice were 
shipped globally though quasi-commercial networks of exchange. In the atomic age after World 
War II, mice became central to the study of mutation and the biological eﬀects of radiation, with 




14 On ‘model organisms’, see Ankeny 2001 Ankeny & Leonelli 2011. On other species, see Clause 1993, Rader 
2004, Gurdon & Hopwood 2000, de Chadarevian 1998, Ankeny 2000, Leonelli 2007.
15 See e.g. Gilbert 2009, Hopwood 2011.
16 Leonelli, et al. Forthcoming, 2014, Kirk 2008, 2010, 2012.
17 Rader 1998, 2004.
such as at Oak Ridge, Tennessee and Harwell in the UK.18  In other areas, however, the mouse re-
mained marginal, notably in embryology. It was not until the 1950s that embryologists did serious 
mouse work – a transition aided by their interest in appropriating genetic knowledge and tools. 
This adoption was made possible by the newly available culture media that allowed in vitro ma-
nipulation of embryos, but as I show, the development of these techniques was driven by the low 
cost of mice, widespread breeding infrastructure and a growing interest in the role of develop-
mental factors to explain significant physiological variation within genetically standardised 
mouse lines. The importance of molecular explanations in the 1960s and 1970s extended to work 
with embryos. The mouse became the key mammal, and one of the handful of species, both novel 
and familiar – Drosophila, the frog Xenopus, the nematode Caenorhabditis elegans – featured in pro-
ductive discussions about using molecular approaches. 
In the 1970s, mouse embryologists and molecular biologists connected at the bench, too. These 
new alliances overwhelmingly relied on interdisciplinary collaboration and various strategies of 
combining embryological and molecular expertise. Disciplinary identities played out in diverse 
ways depending on the audiences: thus, scientists routinely referred to themselves as ‘embryolo-
gists’ at the bench, while the more cumbersome yet modern-sounding ‘developmental biology’ 
drove the agenda for meetings, textbooks and funding bodies.19  The first project to introduce 
genes into mouse embryos came from a variety of disciplinary agendas. Following the adoption of 
transgenic technology, a new generation of researchers had been trained in both embryological 
and molecular techniques through a lively set of courses, personal contact and independent tink-
ering, and technical expertise was much more defining in career path and the kind of experimen-
tal labour a scientist could do.
Like many histories of biomedical technologies, this thesis is about innovation and its early adop-
tion. David Edgerton has forcefully argued that our view of technology relies too heavily on inven-
tion and that following use is more illuminating when it comes to explaining technological 
6
18 de Chadarevian 2006, Rader 2004, Gaudillière 2004. On the influence of the atomic age on biology, see also 
Lindee 1994, Creager 2013.
19 On developmental biology, see Oppenheimer 1966, Gilbert 1996, Keller 1995, 2000, Crowe, et al. Under review.  
change.20 Yet Edgerton’s call is not to abandon studies of innovation, but to rethink approaches 
alongside accounts of use.21  My take on the invention of transgenic mice stresses the ambiguity of 
assigning priority, investigates how communication around distributing credit contributed to 
making transgenic mice a new experimental tool, and shows that priority has been fluid and open 
for re-interpretation. In the community of scientists involved in transgenic research, the multiple 
invention narrative remains recognised by all parties, but diﬀerent contributions are highlighted 
and others omitted, depending on whom one asks. The very identity of the technology was made 
and remade, as a novel experimental procedure was recast into a powerful instrument to raise 
and answer pertinent biological questions.
In examining the invention of transgenic mice, I revisit Robert Merton’s call to study multiple dis-
coveries and his argument that ‘singleton’ inventions are the exception to the rule in modern 
science.22 The question has been largely ignored in history of science with the decline of Merton’s 
normative approach.23 I approach multiple invention with a practice-oriented set of tools, show-
ing how context-specific experimental work, communication and distribution of credit resulted 
in transgenic mice being made in diﬀerent places within a year and subsequently accepted as a 
multiple invention. I argue that the diverse interests, technological backgrounds and organisation 
of the pioneer groups contributed to the rapid enthusiasm about transgenic mice and their adop-
tion by a considerable range of institutions. This mix of stakeholders created an environment 
where a new technology could succeed. 
This thesis is about the circulation of materials, the knowledge that travels with them, and the 
claims about new animals and methods used to produce them. After the ‘turn to practice’ in late 
1980s history of science and the explosion of laboratory ethnographies, we have multiple ac-
counts of local knowledge production and adoption. However, communication and circulation 
need further attention if we are to combine accounts of local practices that move beyond specific 
7
20 Edgerton 2007, 2010. On the role of users in technology, see also Oudshoorn & Pinch 2003.
21 Edgerton 2010: 685.
22 Merton 1973.
23 But see Cozzens 1989.
sites and may scale up and down again through their histories. Rather than selecting specific labo-
ratories to follow, my analysis considers the multiple actors involved in the making of transgenic 
technology. This account focuses on the USA and Britain – the key locations where transgenic 
mice were invented and produced. I take seriously the call to look at knowledge-in-transit, how 
and where it travels, and crucially, how it changes in the process, and to pay careful attention to 
communication as an inherent attribute of making knowledge.24
The work of Ludwik Fleck, a bacteriologist and philosopher of medicine is a helpful starting 
point, especially his emphasis on how knowledge acquires credibility and gravitas as it moves be-
tween ‘esoteric’ and ‘exoteric’ circles.25  Without embracing the division as a dichotomy – it was 
not clear-cut for Fleck, in any case – the audiences considered in this thesis ranged from fellow 
bench-workers, experts in diﬀerent disciplines and interested biologists to university administra-
tors, patent lawyers, congresspeople, activists, readers of glossy magazines and tabloids and 
watchers of the evening news. I do not view this list of the actors as the gradient between “sci-
ence” and “society”, that is still occasionally implicit in discussions of “popularisation” despite the 
now-commonplace critiques of diﬀusion models in the field.26 While a distinction between scien-
tific and popular communication existed as an actors’ category, it blurred for some scientists in 
the 1980s and they actively recognised the utility of broad communication. Bruce Lewenstein’s 
metaphor of the “sphere of communication”, proposed in his influential study of cold fusion, in-
terrupts this implicit gradient of popularisation and shows how knowledge claims travel through 
unexpected routes and in many directions, generating competing narratives that may succeed or 
fail.27  In an age of strongly organised science, driven by the commercial promises of biotechnol-
ogy, appealing to diverse audiences was not dangerous or disreputable but advantageous. A num-
ber of sociologists labelled this trend the ‘medialisation’ of science.28  Even between 1945 and 1970, 
a period of unprecedented authority for university science and rapidly expanding funding, re-
8
24 Secord 2004.
25 Fleck 1935/1981, esp. 93–106.
26 On critiques of the ‘diffusion model’, see Hilgartner 1990, Bucchi 1998, Secord 2004.
27 Lewenstein 1995.
28 Franzen, et al. 2012, Hilgartner 2012.
cruiting new audiences remained useful, and while there are stories of reputations destroyed by 
publicity-seeking, thorough studies tend to find diﬀerent explanations.29 What changed in the age 
of genetic engineering was the willingness of scientists to announce innovations to the media in 
parallel with communicating them to their peers, as well as the growing interest of journalists in 
covering basic science. The attention to genetic engineering in the late 1970s coincided with the 
expansion of science journalism. 
While science writing had been expanding and professionalising since World War II, publishers 
were increasingly willing to venture into popular science.30 Debates around recombinant DNA 
generated dramatic interest in biological research, and growing ambivalence about science 
helped create a new market. With dwindling profits for print media as audiences drifted to televi-
sion and radio,31  science and technology became a promising direction, especially in the United 
States where, as one editor put it, “the Sputnik generation [was] now of the magazine buying 
age.”32 In 1978, a dedicated science section appeared in the New York Times, in parallel with a flurry 
of new upmarket popular science magazines.33  Newspaper and magazine editors and science 
writers publicly criticised slow journal publication cycles and defended their right to report new 
discoveries in advance of peer-reviewed publication.   
Traditional modes of publishing science, with added loopholes and shortcuts, were thus supple-
mented with unexpected connections, contingent and seldom well-orchestrated – a press confer-
ence given by two bemused postdocs, a mid-western university president who knew the president 
of the National Academy of Science, a celebrated television comedian responding to a fresh sci-
ence story.34 As a result, multiple communication eﬀorts came together to aﬀect the responses to a 
9
29 For recent studies of science-media relations in twentieth-century biology and medicine, see Nelkin 1995, Tur-
ney 1998, Nathoo 2009, Hansen 2009, Kirby 2011, Wilson 2011.
30 Lewenstein 1989.
31 Emery, et al. 2000.
32 Edward Edelson, quoted in Anon. 1980b: 48.
33 Asimov 1980, Nisbet & Lewenstein 2002, Bauer 2012.
34 To borrow Steven Hilgartner’s metaphor of public science as a theatre of credibility, improvisation was an im-
portant part of communicating even before university PR departments were firmly institutionalised. See Hilgart-
ner 2012.
new kind of mouse, whose properties and promises were made in the process, in journal articles 
and television interviews alike. 
In reconstructing how an invention was made almost simultaneously in diﬀerent places that were 
not directly in contact, circulation of knowledge is key. Knowledge about progress, experiments 
and techniques travelled between multiple laboratories. Some ended up making transgenic mice 
and some did not. The circulation metaphor invokes location and brings up questions of proxim-
ity and distance. For some scientists, being in the right place at the right time was crucial. Thus, 
Rudolph Jaenisch, a molecular virologist interested in expanding his work to mammals, benefited 
from commuting between Princeton, where he held a postdoctoral fellowship, and Fox Chase In-
stitute for Cancer Research outside Philadelphia, where Beatrice Mintz taught him to manipulate 
mouse embryos. His subsequent position at the Salk institute in San Diego brought him in touch 
with the leading genetic engineers and allowed him to learn unpublished techniques. 
On the other hand, distance – geographic or conceptual – was not always an obstacle to be over-
come, but a key and sometimes productive property of circulation. Mario Biagioli’s study of the 
discovery of the Medicean stars shows how partial ignorance, lack of familiarity and need to 
make conclusions based on speculative reputation contributed to Galileo’s success despite prob-
lems that appeared insurmountable closer to home.35 The distance and very limited communica-
tion between the laboratories involved in trying to transfer genes into mouse embryos suggested 
the pursuit was an attractive goal for which credit had yet to be taken, even if it came hand-in-
hand with skepticism about the possibility of success. Distance could also play a role in sustaining 
eﬃcient divisions of labour between molecular biological and embryological work, with animals, 
their organs and data about them travelling between sites. One of the most successful and prolific 
collaborations in early transgenic research, between Ralph Brinster at the University of Pennsyl-
vania and Richard Palmiter at the University of Washington in Seattle, happened through courier 
services and weekly phone calls for over a decade. Keeping molecular and embryological expertise 
separate allowed the two labs to play to their strengths and avoid internal tensions. 
10
35 Biagioli 2006. See also Howlett & Morgan 2011, and essays on ‘agnotology’ in Proctor & Schiebinger 2008 – 
although these mostly focus on the construction of ignorance among lay audiences.
Material objects moved hand-in-hand with knowledge. Animals, cells, DNA molecules and culture 
media moved via the postal system, cars and scientists’ suitcases, despite alarm about the biohaz-
ards of genetically modified molecules and organisms. Sharing materials and techniques had a 
long tradition in biological research, particularly within emerging fields such as experimental 
organism communities or phage genetics.36 Through liberal exchange, plasmids – bacterial mole-
cules into which genes could be inserted and the resulting products then transferred into cells – 
travelled widely, often following the contingent relocations of highly mobile postdocs, and 
reached far and wide beyond the key sites of recombinant DNA research. Knowledge, techniques 
and expertise required to deal with these molecules had to be cultivated or recruited for success-
ful experiments.37
Kohler’s Lords of the Fly is again pertinent here, for the way it turned the attention of historians of 
science to a ‘moral economy’, describing the unspoken rules that governed the behaviours of dro-
sophilists and helped forge a powerful community.38  The major success of Drosophila, Kohler ar-
gues, lay both in the ability to generate a great number of new mutants and in Morgan’s Fly Room 
at Columbia as a centre for circulating strains. Kohler suggests that these exchanges were gov-
erned by three rules: reciprocity, disclosure and the communal sharing of tools and techniques. At 
the same time, recognition and proper ways of attribution were developed. Trying to account for 
the way these rules work, Lorraine Daston links moral economy with individual values that stand 
in a defined relationship to one another, and draws on theories of aﬀect to link the social order of 
science with its routine practices that are “more about self-discipline than coercion”.39 By contrast 
with Mertonian norms, moral economies place scientists’ conduct historically and recognise its 
mutability. 
11
36 Kohler 1994, Rader 2004, Kelty 2012b, Kay 1993.
37 On knowledge and expertise traveling with material objects, see Latour 1999, Hopwood 2000, Santesmases 
2009, Creager 2013.
38 Kohler 1994. See especially Chapter 5. ‘Moral economy’ is borrowed from E. P. Thomspon’s classic study of 
eighteenth-century bread riots, Thompson 1971.
39 Daston 1995. For a case study contemporary to my account that explores the moral economies of cataloguing 
gene and protein sequences, see Strasser 2011.
Recombinant DNA molecules were exchanged between molecular biologists in the context of 
heavy regulation and anxiety about containment, but reached unexpected addressees, including 
developmental biologists and geneticists, usually within collaborations. The NIH regulations, 
while falling short of federal legislation that most scientists were eager to avoid, ended up limit-
ing the exchanges to facilities with suﬃcient funding and commitment to adhering to the con-
tainment requirements. Yet unlike the earlier case studies, no single centre existed for exchange 
of plasmids. Despite attempts to limit sharing and create central repositories and supply centres, 
the enormous interest they generated and the sheer scale of molecular biological work in the 
1970s made these molecules remarkably mobile. 
Once transgenic mice were produced, they came to be a resource-intensive and limited venture. 
The main interest in making them revolved around studying specific genes, so most were pro-
duced from scratch for a particular experiment. Courses, conferences and personal contacts were 
established to meet the demand for new techniques, continuous with the older traditions of mo-
lecular biology – it is no coincidence that Cold Spring Harbor became the key site of such training, 
as it had been for phage genetics and the recombinant DNA methods. However, while owing their 
birth to the great mobility of molecules, the mice themselves were rarely exchanged outside 
committed collaborations. The diﬃculties of production and the limited utility of already-
published strains kept the circulation low and it was not until the 1990s that established mouse 
providers supplied transgenic strains.
By that point, these mice were subject to a series of patent restrictions and unusual limitations on 
breeding and further commercial exploration, in a hybrid economy that encouraged spin-oﬀs 
from publicly funded research. As Angela Creager’s work on radioisotopes shows, from a model of 
generous exchange from a cyclotron at Berkeley, these chemicals came to be produced in 
government-run nuclear facilities and were subjects of diplomatic negotiations, poster children 
for the Atoms for Peace policies and drivers for privatising nuclear industries.40 Similarly, 
through extensive media exposure and the debates surrounding the patenting of OncoMouse, 
transgenic mice became icons of genetic engineering and biotechnology in the 1980s, even if their 
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role and production remained expensive and modest by comparison to other tools, and their 
commercial success proved limited. 
This thesis is organised chronologically. Chapter 1 considers the emergence of the mouse embryo 
as a subject of experimental manipulation after World War II and focuses on the species politics of 
embryology and the scientific and communicative work that enabled the mouse to become an im-
portant embryo for developmental biology. Chapter 2 revisits the rise of recombinant DNA in the 
1970s and shows how genetic engineering was pursued and adopted by communities working 
with multicellular organisms. By focusing on the collaboration between Beatrice Mintz and Ru-
dolf Jaenisch, who inserted viral DNA into a mouse embryo before the ‘cut-and-paste’ recombi-
nant techniques were available, it oﬀers alternative genealogies to genetic engineering and ex-
plores the moral economy of molecular biology in the 1970s.  
Chapter 3 then discusses the simultaneous inventions of transgenic mice in 1979–81 that relied on 
using isolated genes. I argue that the diverse goals and partial knowledge about competitors were 
productive for developing a new biological entity, and highlight the diversity of approaches and 
imagined uses for putting genes into mice. Chapter 4 then examines the initial communication of 
transgenic mice to a variety of audiences, largely lauded as a medical breakthrough. Journals may 
have been the key medium to claim priority, but other avenues of communication were impor-
tant: newspapers, television programmes and patent applications all carried new claims about an 
as-yet uncertain set of experiments.
Finally, in Chapter 5 I focus on the adoption of transgenesis in the 1980s. Publicity that sur-
rounded these animals, most prominently the giant ‘supermice’ made in 1982, played a significant 
role in attracting scientists and funders to the new technology. Commercial promises created new 
spaces and alternative networks, often geared to agricultural applications, even though most work 
still took place in academic labs, some with industrial money. Despite the lively interest in these 
mice, however, they remained at odds with the logic of large-scale genetics, and their production, 
concentrated in molecular and developmental laboratories, became a boutique operation.
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Note on sources
Historians of the late twentieth century are faced with a maddening range of materials, but also 
gaps on the record that are hard to map. I undertook a series of oral history interviews with the 
key actors, mostly scientists, but also journalists and biotechnology entrepreneurs. Their stories 
have been extremely helpful alongside textual traces in directing my work and helping me recon-
struct practice and laboratory life. Two of the key primary investigators in this story – Beatrice 
Mintz and Ralph Brinster – declined to participate in the oral history project. Dr Brinster referred 
me to an extensive published interview and his reviews,41  while Dr Mintz explained her doubts 
about this project over a fascinating two-hour phone call. I have been able to interview their col-
leagues and postdocs, however.
I was oﬀered a variety of perspectives on the events, and the oral history side of my project made 
me reflect more on the partiality of communication and the instability of innovation narratives 
that Chapters 3 and 4 elaborate on. In addition, I have recruited memories from subscribers of 
transgenic-list, an email newsletter for transgenic mouse practitioners where they have been 
sharing tips, news and job ads since 1996. My brief questionnaire was met with a very enthusias-
tic response. I have already acknowledged those who were willing to spare their time and talk to 
me, but would like to reiterate my gratitude here. I tried to remain critical and treat oral history 
as yet another source, heavily based on memories, and my interviewees were aware that their 
memories of specific events were not always reliable. 
I am extremely glad to have had the privilege to collect memories from living actors that could be 
otherwise lost. With this in mind, published materials proved most useful, and I tried to read 
them in multiple ways to reconstruct networks and think of them as artefacts of material com-
munication as well as texts. Handbooks, textbooks, conference proceedings, newspaper and 
magazine articles, newsletters and directories, institutional reports and promotional magazines 
came together to inform this account. While no central archives or laboratory notebooks are 
available for the key part of this story, I have benefited from the scattered archival evidence listed 
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in the reference section. While triangulating my sources, I tried to keep remaining uncertainties 
on the surface. I am of course fully aware that as further documents may come to light and con-
siderably alter some of the details. However, as much communication happened in person and 
over the telephone, and as scientists routinely throw away their papers, it is not clear to me that 
such evidence might become available.
15

Chapter 1. The rise of the mouse embryo, 1941–1970
Despite their molecular and genetic connotations and uses, transgenic animals were made possi-
ble by the experimental tradition of embryo manipulation. Yet, while routinely used by geneti-
cists and cancer researchers since the 1920s, the mouse was marginal among embryologists until 
the 1960s, when its importance in developmental research surged .1 Even among other mammals, 
the mouse had been seen as a diﬃcult embryological subject, and rabbit, pig and human embryos 
were much more popular before the war. Existing histories of mammalian embryology focus on 
the mammalian embryo as a monolithic experimental subject, justifiably as cross-species com-
parisons were readily made.2 However, explaining the rise of the mouse embryo as the dominant 
experimental subject is essential to understanding the origins of genetically modified animals.    
As historians of laboratory animals have argued, such organisms are domesticated and adapted to 
new environments in multiple ways. Their bodies and heredity are changed dramatically to fit 
experimental purposes.3  They become subjects of extensive standardisation and of negotiations 
to make them mobile and comparable across widely distributed sites.4  In tracing the domestica-
tion of the laboratory mouse and the early history of the Jackson Lab, Karen Rader suggested that 
the mouse came to embody the genetic approach to medical research, rising to dominance as the 
gene became increasingly valued in American science and culture. Her work explores standardi-
sation as a resource for community building. Referring to an older meaning of “standard” – a mili-
tary banner marking a rallying point – Rader argued that the new community of “mousers” and 
their mascot animal marched across disciplines, with the gene as their weapon. The mouse of-
fered a way of asking genetic questions through an established and expanding set of practices. 
Moreover, as a mammal it oﬀered evolutionary kinship with humans.5    
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Standardisation, while a key resource enabling communication and exchange, could also be chal-
lenged, and in the process new research questions and experimental subjects promoted. In the 
1950s, several scientists interested in mouse development, husbandry and physiology questioned 
the claim that inbred mouse lines were the best tool for any experiment.6  A number of agencies 
and researchers also recruited the reinterpretation of genetic purity to advocate for laboratory 
animal science as an autonomous field.7 As I will show here, a similar strategy enabled 
genetically-oriented physiologists to elaborate programmes for the study of the eﬀects of the ma-
ternal environment on developing mice and through this process, to turn the mouse embryo into 
a viable experimental object. 
Finally, addressing the quality of versatility, I will examine the expansion of molecular thinking 
about development into the mouse. I will argue that the rise and institutionalisation of ‘develop-
mental biology’ as a new way of working with embryos in the 1950s provided a communicative 
space that allowed molecular biologists to enter the conversation, and embryologists to embrace 
molecular instruments and discourse. Transition to the agendas of developmental biology, and the 
growing importance of combining embryology with molecular biolow gy and genetics, went 
hand-in-hand with changing uses of laboratory organisms. Jamie Davies’s survey of papers pub-
lished in developmental biology journals since 1965 (Fig. 1-1) shows the dramatic surge of work 
done with the mouse and Drosophila, both paragon genetic animals, and a steady decline of the 
chick favoured by classical embryology.8  The mouse could become a viable choice for some of 
these scientists because several mammalian embryologists – at the time emerging as a new iden-
tity – had actively promoted it, and because new experimental systems applied the petri-dish 
practices of molecular biology to the complexities of eukaryotic life.   
18
6 Gaudillière & Löwy 2003a, Löwy & Gaudillière 1998a.
7 Kirk 2010.
8 Davies 2007
§1. The genetic mammal
In 1941, the Jackson Laboratory in Bar Harbor, Maine, published a sizeable book, Biology of the 
Laboratory Mouse.9  Founded in 1929 by C. C. Little, the Jackson Lab had become the centre of 
mouse genetics in the United States and a key supplier of inbred strains. The handbook, edited by 
George Snell, was its first major publication. It reviewed the achievements of mouse genetics, 
catalogued known genes and traits and featured practical advice on husbandry, breeding and 
record-keeping. Unusually, it was organised “vertically” around the central organism, rather than 
oﬀering a multi-species discipline-centred textbook account. Indeed, the introduction stated that 
the intention was to help researchers cross disciplinary boundaries, carrying mice with them as 
they did so: 
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Fig. 1-1. Year-by-year (A) and cumulative (B) number of publications in developmental biology for the 
top ten organisms used today. 
From Davies 2007.
At the present time there are, for example, increasingly well beaten paths between 
genetics and embryology, between endocrinology and cancer research, between cancer 
research and bacteriology, between bacteriology and genetics. It is a major purpose of 
this book, by gathering together the fundamental knowledge about the mouse from sev-
eral fields of study, to make it easier for the research worker using mice as his experi-
mental material to traverse these interconnected paths of science.10 
The handbook established the authority of the Jackson Lab over the mouse, and defended mouse 
genetics as the prime subject for future investigations. Oﬀering a comprehensive overview of the 
animal, its focus was overwhelmingly on genetics, but it was also to serve as a guide for setting up 
mouse colonies elsewhere. It was also designed to synthesise the papers that appeared in a stag-
gering variety of journals (and languages), not straightforwardly found in smaller libraries. 
The volume started at conception, with the first chapter dedicated to the early embryology. Snell, 
who authored the chapter, claimed to have undertaken “a complete reinvestigation of the whole 
field.”11 While the claim dramatised the novelty of Jackson’s contribution, it was not far oﬀ. Among 
embryologists, mice had long been marginal animals. The most consistent account of its early de-
velopment approaching a normal table was a series of turn-of-the-century articles by the German 
anatomist Johannes Sobotta, scattered through the Archiv für mikroskopische Anatomie.12 A trun-
cated description of early mouse development was also available from the Carnegie Institution of 
Washington Department of Embryology, a centre for human embryo collection and standardisa-
tion, where Warren Lewis and Elsie Wright had published multiple images of normal and abnor-
mal mouse development in 1935, using the latest techniques of tissue culture and microcinema-
tography that they had successfully employed to describe early rabbit development in 1929.13  Still, 
by comparison with the lower vertebrates, the mammalian embryo was inaccessible and opaque 
as it developed inside the body, concealed further by the zona pellucida, a thick membrane sur-




12 E.g. Sobotta 1895, Sobotta 1902, Sobotta 1911. A normal table is a standard depiction of embryonic develop-
ment for a species, used as a reference – see Hopwood 2007. 
13 Lewis & Wright 1935. See Landecker 2004. On the Carnegie Department of Embryology, see other essays in 
Maienschein, et al. 2004, Morgan 2009.
gists strategically focused on lower vertebrates, while medical schools favoured the pig and the 
increasingly available human embryos for morphological work. 
After the First World War, mammalian eggs and early embryos attracted the attention of a diﬀer-
ent group of scientists drawn to questions of reproductive physiology in farm animals and 
humans.14 In these studies, however, the mammal in general was of interest, and species were 
interchangeable. A major early account synthesising this research and setting further questions 
was The Eggs of Mammals (1936) by Gregory Pincus, the future co-inventor of the pill then based at 
Harvard.15 Following other scientists interested in reproduction, he promoted the rabbit as a ro-
bust species best suited for embryological investigation:
Among the laboratory mammals the rabbit is by far superior, and for one very simple 
reason, namely, rabbit ova seem to withstand the process of handling better than other 
ova. Mouse, rat and guinea pig ova, for example, begin to fragment very soon after re-
moval from the tubes...16
The structure of the book and the liberal use of citations brought together experiments per-
formed on a variety of mammals – mice, rats, guinea pigs, dogs, cats, even ferrets. Moreover, the 
serial plates that showed egg maturation featured several species to establish a continuous 
‘mammalian’ development.
Snell’s chapter on the early embryology thus oﬀered a convenient reevaluation. Yet its potential 
utility went beyond oﬀering a complete biological view of the organism or showcasing the work 
that he carried out with his embryologically-adept technicians. It spoke directly to the burgeoning 
interest in using mouse embryos to extend genetic knowledge, when the study of developmental 
mutations was drawing interest among American and British geneticists. Developmental or 
physiological genetics had been pursued in Germany throughout the early twentieth century 
alongside ‘transmission genetics’ with its focus on mapping, which was favoured in the USA and 
most closely associated with T. H. Morgan, an embryologist-turned-geneticist who built and ran 
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the Columbia Fly Room.17  With the elaboration of Morgan’s mapping, the emphasis on develop-
ment – a prominent feature of early genetics, asking how phenotypes arise from genotypes – was 
receiving new attention. 
Alongside Drosophila, the mouse was useful for developmental genetics.18 In the 1930s, mutants 
that could be studied before birth were travelling across the Atlantic via a series of biologists. The 
most prominent and mystifying series of tailless and lethal mutations, subsequently mapped to 
the ‘T complex’, were first described by Nadezhda Dobrovolskaya-Zavadskaya, a Russian emigré 
geneticist at the Institut Pasteur. In 1930, while lecturing in New York, she met Lesley Dunn at 
Columbia University and told him about the odd mutations, sending mice soon afterwards.19  Dunn 
had been Little’s peer at Harvard’s Bussey Institution, where the mouse was first used for genetic 
studies, and while his peers subsequently embraced a wide variety of organisms, he remained a 
“mouser”. In 1928, he inherited Morgan’s position at Columbia, making mouse genetics a new sta-
ple of the institution renowned for its fly work. With another emigré, Salome Gluecksohn,20 Dunn 
undertook a series of studies that tried to tie the lethality of T genes at embryonic stages. Glueck-
sohn, a German Jewish woman, had trained with the eminent embryologist Hans Spemann at the 
University of Freiburg and fled Nazi Germany in 1933. With Dunn, she proposed to answer the 
pertinent embryological question – that of induction – with the very genetic tools that Spemann 
had dismissed. In 1938, she published her first paper on the T mutations in Genetics. Even though 
it was not the first publication to deal with the genetics of the T locus, nor the first to show their 
embryonic eﬀect, it explicitly addressed disciplinary concerns and heralded an integrated ap-
proach to mouse development. 
Mouse developmental work attracted a few more geneticists in the 1940s, among them another 
German Jew fleeing National Socialism, Hans Grüneberg, who had found refuge at University Col-
lege, London (UCL). His choice of the organism was also accidental – Grüneberg had trained as a 
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Drosophila geneticist but switched organisms on his move to London, on J. B. S. Haldane’s sugges-
tion. In the war years, despite paper shortages, Grüneberg published a major monograph, The 
Genetics of the Mouse, devoting space to developmental genetic and the T mutations in particular.21  
The book, negotiated with Snell to avoid extensive overlaps with the Jackson handbook, was an 
important contribution to the field, but even before it was published Grüneberg was already in 
the middle of the transatlantic mouse genetics network, having been elected to the international 
mouse Nomenclature Committee alongside Dunn and Snell.22   
Grüneberg, Snell and Dunn all had reservations about mouse research becoming exclusively 
about cancer, and stressed that the revived Mouse Newsletter should to incorporate broader genetic 
projects.23 Dunn and Gluecksohn were also heavily involved in remodelling this publication. 
Founded by Little at Cold Spring Harbor in the 1920s, it was revived by Snell as Mouse Genetic 
News, a way to summarise available strains and mutations, but only two issues appeared in 1941 
and 1945. Based heavily on the Drosophila Information Service, and responding to the demand ex-
pressed by mouse geneticists, Dunn and Gluecksohn turned it into a regular circular that encour-
aged the exchange of strains and techniques, and reified the dominance of Jackson as the place 
where all strains were held.24  As Christopher Kelty argues, organism newsletters did more than 
encourage circulation – they also defined the new collective knowledge and lines of inquiry. These 
periodicals, aimed widely at the newly defined community, helped build disciplinary identities 
and open up informal exchanges beyond letter-writing. At the same time, they established new 
boundaries by excluding outsiders – both lay and scientific – from the network, and defined the 
notions of “property and propriety” when it came to speedy circulation of facts and advice, giving 
credit for the information submitted but also claiming communal property over the knowledge, 
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By 1950, interest in studying mutations in mouse embryos as well as adult animals had been 
firmly established among geneticists, and some of the key proponents of this research occupied 
strategic locations in transatlantic mouse networks. Moreover, with the expansive use of mice in 
studying the eﬀects of radiation after World War II, they became widely available and attracted 
significant research funding. Major mouse colonies were established in biological institutions 
attached to experimental nuclear reactors, at Oak Ridge Laboratory in Tennessee and at the Uni-
versity of Edinburgh in collaboration with the MRC Radiobiology Unit in Harwell, Oxfordshire, 
where the project eventually moved.26With this expansion of mouse work, and the growing im-
portance of genetics across the biological sciences, mouse embryology received broader attention. 
In the 1950s and early 1960s, this interest crystallised new questions about mouse development 
and encouraged work on new techniques of embryo culture and manipulation.     
§2. Standards and embryos
Inbred mice produced in Jackson are a paragon of mid-twentieth-century biological standardisa-
tion, and were promoted and marketed as such. The language and practices of standardisation 
were convincing enough to enabled productive communication, while the uncertainty and local 
diﬀerences were exploited to adapt mice to new institutions and questions.27 However, the stan-
dards of genetic purity in mouse research were never completely settled. They were renegotiated 
and challenged throughout the twentieth century, often by new collectives seeking to adapt exist-
ing experimental systems to new uses.28 As this section will show, in the 1950s, opening up ac-
cepted standards of genetic purity allowed for productive exchanges among a new group of biolo-
gists whose work centred around the mouse embryo. 
Despite the practices of genetic purity for which the Jackson Lab had become famous, Snell’s stud-
ies of the mouse embryo relied on outbred animals – he claimed their ‘hybrid vigour’ made these 
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embryos more robust to the sectioning and preparation techniques. The idea of hybrid vigour – 
that organisms bred from distant strains were healthier and better adapted – has a long history in 
breeding and the study of heredity, but as the focus on standardising animals for disease research 
overtook hybridisation agendas, pure lines became the dominant instrument of mammalian 
genetics.29 However, further explorations of this phenomenon, also known as heterosis, contin-
ued, notably by Snell, who published a review of human heterosis in 1951, using the mixed ances-
try of American luminaries to make his case.30
The hybrid vigour of the recalcitrant mouse embryos challenged the standardisation practices of 
mouse genetics. However, in the 1950s a loose group of researchers, most of them British, empha-
sised the importance of maternal eﬀects on the phenotype to raise the profile of developmental 
genetics and propose alternative means of controlling variation.31  In the 1950s, Hans Grüneberg 
conducted an extended series of genetic experiments on skeletal development. His results sug-
gested that the supposedly ‘pure’ inbred mice showed striking variation in number of vertebrae 
and when these formed during development. Grüneberg’s vocal argument and his position in ge-
netic networks – British and global – was recruited by the MRC Laboratory Animal Bureau to 
make a case for establishing laboratory animal science as an international discipline. If the mice 
supplied to researchers in great numbers were not uniform, and the problems did not reside en-
tirely with husbandry and disease management, a new kind of expertise was required.32  
The issue was followed up by several younger biologists: Anne McLaren, her husband Donald 
Michie (Fig. 1-2), and John Biggers. In 1954, Nature published a number of their letters and brief 
papers that questioned the physiological homogeneity of inbred lines.33  Backed by Grüneberg’s 
more extensive article in the journal, these pieces claimed an extensive variation within inbred 
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strains in a number of physiological traits beyond skeletal development, for instance in their re-
action to anaesthetics. Hybrid mice produced by crossing two inbred strains were oﬀered as a 
possible solution and a better experimental tool for physiological work. This was not equivalent to 
using outbred animals – the first generation or F1 hybrids were valued in particular, while subse-
quent generations of hybrids showed more variation.34 This solution did not challenge the possi-
bility of genetic standardisation per se, but rather sought to improve the existing practices for 
diﬀerent kinds of experiments, providing ways to control variation for diﬀerent experimental 
designs.   
McLaren had trained in Zoology at Oxford and went on to complete her PhD with Peter Medawar 
at UCL, working on rabbit genetics and murine viruses. Michie had had a fascinating career as a 
coder at Bletchley Park during the war, and afterwards moved on to study mammalian genetics at 
Oxford, before returning to artificial intelligence research in Edinburgh later in his career. Big-
gers, a British-born physiologist, had worked on sex hormones in Sydney, and was introduced to 
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Fig. 1-2. Anne McLaren and Donald Michie, on a laboratory visit in Prague, 1956.
Courtesy of Jonathan Michie.
McLaren and Michie by Grüneberg at his UCL oﬃce shortly after the articles appeared. By that 
point, the couple had moved from UCL to the Royal Veterinary College in Camden Town, London, 
where more space was available for their mouse colonies in the ‘canine block’. On his visit, Biggers 
was invited to take up a position there, which he accepted. They would work next to each other, to 
open up the early mouse embryo for culture.35  
The problem with embryo culture largely lay with the use of media that had been borrowed from 
tissue culture studies. Rabbit embryos, surrounded by a mucous membrane unlike most mam-
mals, had been cultured successfully starting with Walter Heape’s 1890–91 experiments in 
Cambridge.36 In mice, several attempts were performed at Jackson, embedded in genetic studies. 
Elizabeth Fekete, who had helped Snell with the embryology chapter of the Jackson handbook, 
worked with C. C. Little on transplanting mouse embryos in the 1940s. Using Locke’s solution, a 
physiological medium containing salts and glucose, Fekete moved early mouse embryos between 
the more and less cancer-prone strains to study maternal eﬀects on tumour incidence.37 
Subsequently, as her career blossomed, McLaren often fashioned herself as a geneticist who be-
came fascinated by the environmental eﬀects that the mammalian embryo faced in the uterus, 
and she worked extensively with Biggers on embryo culture and observing the variation within 
genetically bred mice. While the experiments were largely on the early embryos, the importance 
of genetic questions allowed her to defend the mouse, an organism in which she had consistently 
invested as the right tool for the job. McLaren, Michie and Biggers relied on a new medium pub-
lished in 1956 by Wesley Whitten at the Australian National University in Canberra, who had at-
tempted to culture mouse embryos in vitro. Replacing the egg elements with bovine serum albu-
min, a protein readily available from the meatpacking industry, Whitten cultured an 8-cell em-
bryo to blastocyst, and a year later, by replacing calcium chloride with lactate, reported that an 
even earlier 2-cell embryo could be cultured to the blastocyst stage.38 McLaren and Biggers used 
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this medium to culture 8-cell embryos to blastocyst and implant them into a surrogate mother of 
a diﬀerent strain, resulting in the birth of live mice. 
These claims to embryo transfer were not entirely new. Beyond Walter Heape’s 1891 paper, multi-
ple attempts had been publicised, most notably Pincus’s work with the rabbit, claiming in vitro 
fertilisation, embryo transfer and artificial parthenogenesis – initiation of development without 
fertilisation. As multiple claims co-existed and were met with publicity, doubt and failures to rep-
licate the experiments, a set of criteria was being articulated in response.39  Moreover, claims for 
the mouse embryo transfer had been made by Fekete, and the geneticist Alan Beatty in Edinburgh 
even produced a film demonstrating eggs could be transplanted through the cervix and mice born 
as a result of the procedure.40 Culturing embryos was a key claim for McLaren and Biggers, as was 
showing that the medium did not interfere with development so live mice could be born. To rule 
out the pups coming from the surrogate mother, McLaren and Biggers used a genetic marker as 
they relied on the coat colour of newborn mice. 
The new experiments attracted some media attention. On 6 October 1958, just over a week after a 
brief letter in Nature announced the results, a column in The Daily Telegraph described the new 
animals as ‘Brave New Mice’.41As Biggers recalled, the publicity raised some academic eyebrows, 
but also enabled the scientists to promote their work and delineate its implications though more 
legitimate means. However, it was by no means the first time they had appealed to broader audi-
ences. With McLaren, Biggers contributed a chapter to a volume in Penguin’s New Biology series, 
highlighting the work on hybridisation for physiological research.42  Michie was also a contributor 
to a fancy animal publication and penned articles for boys on how to keep fancy mice.43
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McLaren and Biggers were approached by the editor of Discovery, a London popular science peri-
odical, to write about their work.44  Their piece described the development of the early mammal-
ian embryos and the experiments, and discussed the implications. Biggers and McLaren engaged 
with the newspaper coverage by finishing their article with a provocative subheading, ‘Brave New 
World’, where they distanced their work from any human extensions reminiscent of Aldous Hux-
ley’s novel – a long-standing cultural reference that had also followed Pincus.45  Instead, they em-
phasised the utility of culturing mouse embryos to foster exchange of laboratory animals and 
possible agricultural uses. McLaren was funded by the Agricultural Research Council, so she was 
eager to argue for the relevance of her mouse work and showcase the utility of Whitten’s medium. 
The scientists suggested embryos could be stored and exchanged in lightly-refrigerated culture 
media, and cited their successful posting of embryos to the Cambridge School of Agriculture.46 
The mobility of embryos, fragile and recalcitrant to culture, was a desired feature that could build 
on the extensive exchanges of mouse strains among geneticists.   
The interest in circulating embryos reflected a commitment to reinforcing the new network of 
researchers exploring mammalian embryos, and McLaren, Biggers and to a lesser extent Grüne-
berg participated in interdisciplinary conversations in Britain and the USA. Other biologists in 
Britain, most of them with a strong genetic background, were moving to work with mouse em-
bryos. Thus, the human IVF pioneer Robert Edwards started his career as a mouse geneticist at the 
Institute for Animal Genetics at the University of Edinburgh, working on inducing ovulation with 
hormones – as he later claimed, to adapt the animals to his own social timetable and not have to 
wait for them to breed at night.47 
Moreover, discussions on the role of maternal eﬀects in development were happening in the USA, 
with the Jackson Lab playing a central role and expanding collaborations with embryologists, 
even though funders who wanted to push the Lab into providing mice for large-scale cancer re-
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search dismissed this line of investigation.48 One of the converts to the mouse, attracted by the 
genetic knowledge it could oﬀer, was Beatrice Mintz. Like Gluecksohn, Mintz was a classically 
trained embryologist who shifted her focus to mice in the 1950s. She trained at the University of 
Iowa with Emil Witschi, a German emigre amphibian embryologist with an interest in germ cell 
diﬀerentiation. In 1946, Mintz accepted an assistant professorship at the University of Chicago, 
where she worked with frogs, salamanders, leghorn fowl and chicks. In the early 1950s, her move 
to mice was cemented when she started a collaboration with Elizabeth ‘Tibby’ Russell at the Jack-
son, aiming to trace the origin of germ cells by genetic tools. Their work, first presented in 1955 
and published in full in 1957, showed a new kind of union between embryological and genetic ap-
proaches in the mouse. If the tradition of developmental genetics tended to use mouse embryos to 
answer questions about genes and their eﬀects, the Russell-Mintz paper also used the alleles in 
the W (white-spotted) locus to trace the fate of germ cells.49
This work relied on painstaking serial sections and staining of the embryos, with the assistance of 
two technicians. However, with the availability of culture media, Mintz moved her focus onto the 
living mouse embryo. In 1960, she was oﬀered a position at the Institute for Cancer Research in 
Fox Chase, a suburb of Philadelphia, where she gladly moved to avoid undergraduate teaching.50 
The institution was a prime place where investigations into embryology were believed to com-
plement cancer research.51 In charge of a small laboratory, Mintz worked on culturing the early 
embryo and removing the zona pellucida, a thick membrane surrounding the embryo and keeping 
cells together until blastulation. 
The considerable number of high-profile women in twentieth-century embryology has been 
noted, and the mouse tended to be the organism most of them studied.52 Gluecksohn, McLaren 
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and Mintz, and to a lesser extent Fekete, represented an early generation of eminent scholars and 
leaders in the field they were creating. It is possible, though debated, that these pioneering 
women attracted more female scholars in the 1960s and 70s.53 Mammalian embryology, associated 
with a woman’s body but without the controversial aspects of men-dominated reproductive sci-
ences, may have been viewed as an appropriate trajectory for a middle-class woman.54  The labori-
ous, protracted and unpredictable practice of embryology made it a less attractive subject un-
likely to bring immediate reputational gains. The disciplinary marginality of mouse work is thus 
a more plausible explanation, as many women found work in new and obscure fields earlier in the 
twentieth century, for instance plant and fly genetics.55
By 1960, the mouse embryo had moved from a marginal curiosity to one of the promising objects 
of investigation. The development of culture techniques and the new promise of manipulation 
that they oﬀered played a significant part in this transition. However, similar high-profile ex-
periments were made with other mammalian species, notably the rabbit. In 1959, Min Chueh 
Chang, a former colleague of Pincus, published an account of in vitro fertilisation in rabbit egg, his 
account gaining more traction than Pincus’ original 1935 claim that had not been replicated. What 
placed the mouse in an advantageous position was its status as a genetic animal and mammal, and 
an ability to bring researchers across disciplinary boundaries. If the rabbit was firmly a reproduc-
tive animal, the mouse had an established place in genetics, teratology and cancer research. De-
spite the investment into rabbits, their embryos proved much more resilient to the kind of ma-
nipulations that new culture media allowed in the 1960s, pushing the mouse further towards be-
ing the mammal of choice for experimental embryology. Finally, with the expansion of large-scale 
work on the eﬀects of radiation, these rodents were widely available and cheap, with most major 
biomedical research institutions eager to invest into a mouse facility.
Through engagement with environmental eﬀects on the organism and exploration of culture me-
dia, a group of embryologists and reproductive physiologists emphasised the interest mouse em-
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bryo could pose to geneticists and reproductive physiologists. Challenges to standardisation nar-
ratives of the large-scale screening genetics enabled this group to develop a strong published 
voice that also spread beyond the professional periodicals into the press. Similarly, using genetics 
to approach development by moving beyond treating the mouse embryos as phenotypes of spe-
cific mutations and promising manipulation techniques enabled this group to raise the status of 
their animal among embryologists. Furthermore, in the 1960s new dynamic networks of re-
searchers working with mouse embryos were established. These incorporated reproductive 
physiologists, embryologists and some curious geneticists, and as I will argue below, they were 
successful at incorporating the mouse as a key mammal under the ultra-disciplinary banner of 
developmental biology.     
§3. Manipulating development
As Mintz was beginning her collaboration with Elizabeth Russell, she edited a short volume dedi-
cated to the Environmental Influences on Prenatal Development, a summary of papers and conversa-
tions at a Jackson Lab conference.56 This was one of numerous meetings on ‘developmental biol-
ogy’ in the summer of 1956. The more extensive and generalist first International Congress on 
Developmental Biology was held at Brown University, and the Jackson Lab hosted another meet-
ing, ‘Immunology and Development’. These were sponsored by the US National Science Founda-
tion (NSF) and represented a new disciplinary alignment in the funding of biomedical sciences in 
the USA, and the study of embryos in particular. As some projects of embryology – in particular, 
the organiser as a source of induction – were seen to be in decline or replaced by biochemical in-
vestigations, ‘developmental biology’ came to represent a new direction of research, and a disci-
plinary identity that researchers chose to adopt depending on context and audience.57
Jane Oppenheimer’s lecture at the 1966 meeting of the Society for Developmental Biology (which 
had only just changed its name from Society for the Study of Growth and Development) placed the 
origins of this field in the Society’s symposia that began in 1939. These became an important space 
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for interdisciplinary communication where embryological agendas were expanded to include 
methods and questions from genetics, evolution, biochemistry, endocrinology and general 
physiology.58  However, while there was considerable talk of development and diﬀerentiation in 
these meetings, the category of ‘developmental biology’ was not in wide use until the 1960s; no 
textbooks and handbooks treated the subject, and among the few relevant journals, Growth 
changed its name to Developmental Biology in 1959. Wider recognition came even later: the first 
graduate course to use the label was oﬀered in 1972.59 
At the level of practice, the story is more complex. Thus, for Donald Brown, one of the key players 
of molecular studies of development, the field “came of age” only in 1990s with the molecular 
techniques and interpretations, of which transgenic mice were a significant example.60  While 
“coming of age” narratives are a common trope in negotiating disciplinary histories, Brown’s lec-
ture oﬀers an interesting counterpoint to more self-congratulatory accounts. Stating that 
“[d]evelopmental biology is above all a set of questions. It is not a discipline”, Brown argued that 
“from the 1930s into the 1960s developmental biology was isolated, with its own theories, meth-
ods, and even experimental animals... a third-world scientific community, blissfully doing our 
thing in isolation.”61 
However, long before textbooks on the subject were published and societies updated their names, 
developmental biology became a category that defined science funding in the USA. The NSF, es-
tablished in 1950 as the American federal government decided to invest heavily into the life sci-
ences after the war, listed ‘Developmental Biology’ as one of its major funding categories. It incor-
porated “growth and diﬀerentiation, reproduction, fertilization, growth and reproduction of sub-
cellular units and of cells, morphogenesis, regeneration, senescence”, and was to correspond with 
the traditional disciplines of “embryology, experimental morphology, gerontology, oncology”.62 
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velopment and Growth and editor of Growth, who proposed revising funding areas so as to em-
phasise the unity of biology, arguing that the old categories entrenched irrelevant boundaries be-
tween plants, animals and microorganisms and were no longer helpful.63  As Toby Appel shows, 
this bold ‘one biology‘ agenda impressed the NSF management and allowed them to separate their 
scope from the overlapping domains of the NIH.64    
Beyond US funding arrangements and a new label, globally, the research under the rubric of de-
velopmental biology expanded and diversified in the late 1950s.65 By bringing together a diverse 
group of biologists working with a variety of experimental systems, from mathematical model-
ling and viruses to humans, these changes in the networks of research represented new opportu-
nities in the species politics of embryology. Even at the first Symposium on Development and 
Growth, the fly geneticist Curt Stern juxtaposed his animal of choice to the amphibian embryo:
There have been many who complained, “If only the amphibians, ideal for developmen-
tal studies, were more easily accessible from the genetic angle!” and who added, “if only 
Drosophila, revealer of genetic secrets, could be treated in the embryologists’ fashion”.66
Ambitiously, Stern argued that those voices had finally been silenced, showing how his work on 
mosaicism in the fly could combine embryological and genetic tools. The emphasis on integrating 
the diﬀerent approaches in one species persisted as developmental biology created a space where 
disciplinary crossings were becoming more straightforward. The mouse had an established ge-
netic status, which set it aside from other mammals. With the more straightforward culture me-
dia and a growing interest from embryologists, manipulation took centre stage in the 1960s. 
In Britain, funding models were not at stake for these changes, but similar discussions were tak-
ing place, driven in part by significant transatlantic communication as well as stronger links with 
continental institutions. The informal London Embryologists’ Club founded in 1948 had explored 
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the possibility of experimental embryology in organisms beyond the amphibians.67 From its early 
days, it built links with the private Hubrecht Laboratory in the Netherlands associated with Insti-
tut Internationale d’Embryologie, publisher of GEIS. With theoretically-inclined embryologists 
such as Joseph Needham and C. H. Waddington, the Club was engaging with diverse topics, in-
cluding a meeting on “Development and DNA” in 1960. In 1964, the body went national, becoming 
the Society for Developmental Biology, adding British to the title after the U.S. based Society for 
the Study of Growth and Development took the same name in 1965.68
McLaren was an active member of the London Club. In 1959, after failing to secure funding for an 
ARC research unit on reproduction at the Royal Veterinary College, McLaren moved to C. H. Wad-
dington’s Institute for Animal Genetics in Edinburgh, while Biggers secured a position at the Wis-
tar Institute and a parallel professorship in reproductive sciences at the University of Pennsylva-
nia. There, he focused on making robust standard media that could be easily made in any labora-
tory. One of his first graduate students was Ralph Brinster who had trained as a veterinary physi-
cian at Penn. His project involved defining a medium chemically, following Whitten, by avoiding 
biologically-derived reagents such as blood serum or egg yolk. Brinster’s choice of mice was not 
self-evident, but his experiments required large quantities, and mice by that point were cheaper 
and widely available, and Biggers had expertise in using them. In discussing the properties of the 
early rabbit embryo, Brinster highlighted how the thick mucinous coat that surrounds the egg, 
while probably responsible for the robustness of the rabbit embryos in culture, made it less 
analogous to humans and domestic animals, whose embryos had a thin clear coat like mice.69
The group published the new medium in 1962 and 1963, with the chemical definition as its key 
selling point. A standard medium would enable embryo culture to become predictable and attract 
new researchers to work on mice. Brinster argued that although mammalian embryos had been 
cultured for decades, the new standard could remove the uncertainties and local variation in-
volved in embryo work. As a testament to the eﬃciency of his technique, Brinster could demon-
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strate an embryo developing from the two-cell stage to the blastocyst, achieving the notoriously 
diﬃcult early divisions in vitro. Moreover, the chemically defined medium allowed an in-depth 
biochemical study of the needs of developing embryos, which Brinster pursued in the years fol-
lowing his PhD.   
Yet even before the wide spread of Brinster’s medium, as it was called, the approaches to culture 
resulted in a new kind of manipulation to make genetically mosaic mice. In 1961, a Polish embry-
ologist, Andrzej Krzysztof Tarkowski,70  reported that early mouse embryos could be combined 
once the zona pellucida – the membrane that holds the early embryo together – had been re-
moved. Relying on a scientific exchange grant from the Rockefeller Foundation that sought to 
strengthen scientific connections across the Iron Curtain, Tarkowski did most of this work at the 
University College of North Wales (now Bangor University). Despite his permanent position in 
Warsaw, Tarkowski came to Britain often and was well placed in the country’s community of em-
bryologists and reproductive physiologists.71
Tarkowski relied on squeezing the embryo though a carefully sized pipette to remove the zona 
pellucida. Unbeknownst to Tarkowski, Mintz was also working on culturing the early mouse em-
bryo and removing the zona at Fox Chase. Her method, however, relied on the enzyme mixture  
pronase rather than mechanical manipulation, and where Tarkowski could report only foetuses 
with clear mosaicism, Mintz had adult mice with the characteristic blotchy coat-colour pattern to 
show (Fig. 1-3). Both announced the results at the 1962 meeting of the American Society of Zoolo-
gists. Like McLaren and Biggers, Mintz and Tarkowski both recruited the rhetoric of manipula-
tion as something that had been lacking but could then open mammals up to proper embryology. 
Their parallel discovery is well recorded and accepted, yet Mintz’s more adaptable pronase 
method was more widely used as the production of fused embryos continued. The naming pat-
terns, however, reflect some of the tendencies in credit allocation. For Mintz, these embryos were 
genetic mosaics and she used the term allophenic to stress the diﬀerent cellular phenotypes that 
could be linked to genotypes. Tarkowski, by contrast, called the mice chimaeric, building on a rec-
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Fig. 1-3. Above, Beatrice Mintz at a dissection microscope at the Institute for Cancer Research, Fox 
Chase. The poster at the back reads, in French, “All our eggs are guaranteed to have been candled [i.e. 
inspected for embryonic viability]”. Below, an allophenic or chimaeric mouse with patches of black 
and white fur from different genetic lineages, next to a control animal. No date, likely c. 1965.
Image made available online under a CC license by the Smithsonian Institution. Acc. 90-105 – Science Service, 
Records, 1920s–1970s, Smithsonian Institution Archives.
ognised use in hybrid studies that referred to the Greek monster – a term Mintz detested. In fact, 
in a 1974 review of the field, she argued ‘chimaera’ was a “metaphor inapt for harmoniously inte-
grated, nonfictional, genotypic mosaics. According to the ancient Greeks, Bellerophon overcame 
and slew the chimera; may it rest in peace.”72 However, chimaera stuck despite Mintz’s insistence 
on using allophenic – for convenience, as well as because of Tarkowski’s stronger links with mouse 
embryologists, still concentrated in Britain.  
The new kinds of experiment performed on mouse embryos in the early 1960s were localised in a 
few laboratories in Britain and the USA, but the disciplinary identities of the players were fluid. 
McLaren referred to herself as a geneticist who became a reproductive physiologist through an 
interest in the eﬀects of maternal environment on the developing embryo. Mintz was an experi-
mental embryologist with a keen interest in using genes as instruments for understanding the 
mechanics of developmental events. On his move to Philadelphia, Biggers was appointed Profes-
sor of Reproduction, and Brinster was a reproductive physiologist who maintained his veterinary 
roots. Between 1955 and 1965, most papers appeared in journals with general scope: the British 
Nature, as well as occasional papers in Science; the Journal of Reproduction and Fertility carried a 
number of articles from Biggers and McLaren, but the Journal of Experimental Zoology was by far 
the dominant specialist publication. 
Conferences at which these scientists presented can give a better idea of the work that went into 
building productive communication, drawing from the dramatic interest in the problems of over-
population and fertility. The first meeting to attract an illustrious set of speakers working explic-
itly on early mammalian development took place in London in 1963. Titled ‘Preimplantation 
Stages of Pregnancy’, it was envisioned and seen through by Biggers and McLaren on her visit to 
Philadelphia. By aligning mammalian embryology with problems of human fertility, and couching 
the meeting in terms of pregnancy, McLaren secured funding from the Ciba Foundation, the char-
ity arm of the Swiss pharmaceutical company that had an oﬃce in London and funded small con-
ferences. While some physicians who reviewed the published proceedings commented on the lack 
of immediate clinical relevance, they and the more laboratory-minded reviewers deemed the 
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event and its published proceedings a success. The meeting has also been lauded as a landmark in 
actors’ histories.73 C. H. Waddington chaired, and as he observed, McLaren and Biggers had 
“brought together quite an army of gladiators.”74 Gregory Pincus and Colin “Bunny” Austin from 
Cambridge were also present, alongside Brinster, Tarkowski and Mintz.75  
The Ciba conference brought together diverse perspectives on the mammalian embryo. Already, 
most of the work presented was on mice. Of 16 talks, nine were on the mouse; two on the rabbit; 
one on the rat; one talk juxtaposed mice and rats, while three more were comparative studies of 
several mammalian species. Mintz and Tarkowski announced their early results with chimeras. 
Brinster, as well as Mintz in her second paper, also reported the progress in defining the bio-
chemical requirements for the early embryo and stages of nucleic acid production after fertilisa-
tion. While the general discussion touched on the need to improve culture methods for other spe-
cies, including admissions of failure to make hamster and rat embryos develop in culture, the 
mouse took centre stage. The major issue was the challenge of culturing embryos at the earliest 
stages through the first division of a fertilised egg. In existing media, it would undergo the first 
cleavage, but then slowly deteriorate, even if a two-cell embryo could develop to blastocyst. The 
process, eventually labelled ‘two-cell block’, represented a gap in the desired ability to culture the 
early embryo from fertilisation to implantation.    
As Sarah Franklin has argued, the ethos of experimental embryology lies with manipulation and 
control over living objects through tools, and an embryologist explores and expands the frontier 
as a toolmaker.76  New methods were consistently developed and updated, but were often diﬃcult 
to replicate. Local instruments were improvised at the bench, new media prepared and tested. Yet 
with increased communication around the mouse embryo, existing techniques and instrument 
designs were being exchanged as new ones were constantly designed. Thus, Mintz’s pronase 
method was adopted by several researchers, notably in Bigger’s laboratory at the University of 
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Pennsylvania, and there were several fraught attempts to extend its use to other organisms. Both 
Mintz and Tarkowski relied on local versions of the Whitten medium with ovalbumin, and Mintz 
also used a biological medium with foetal calf serum for some of her work. While ‘chemical defini-
tion’ made preparation more straightforward, it did not do away with local diﬃculties of embryo 
culture. Not every batch seemed to work, or work in the same way, and various explanations were 
employed to deal with the recalcitrance of the embryo. Thus, the source of water was commonly 
invoked, and Bar Harbor and Oxford water seemed particularly favourable.77 Through his career, 
Tarkowski would request portions of BMOC (one of Brinster’s media), alongside a great number 
of biochemicals, from Oxford colleagues for his underfunded Warsaw laboratory.78  
With a growing range of questions, new methods to make chimeric mice were being attempted. 
Thus, in 1968, Richard Gardner’s group in Oxford published a method to make chimeras at the 
later blastocyst stage (see Fig. i, p. vii), by replacing the inner cell mass through a micropipette. 
Other forms of micromanipulation were devised. Teh Ping Lin used micropipettes to inject inert 
substances into the mouse egg in the anatomy department of the University of California, San 
Francisco. Reporting this work in 1966, Lin suggested that the ability to inject fertilised mouse 
eggs brought the animal closer to the investigations possible in amphibia, with the added advan-
tage of having standard genetic lines.79
As techniques were accumulated and adopted by scientists working on mammalian development, 
they began to be codified in handbooks. The first manual of experimental technique under the 
explicit developmental biology label was the 1967 Methods in Developmental Biology.80  The book was 
in two parts, the first outlining the practicalities of maintaining specific experimental animals, 
and the second describing techniques. The mouse was listed first and was the only mammal. A 
technique chapter dedicated to manipulation of mammalian eggs was written by Mintz, and she 
made clear that for her ‘mammalian’ meant ‘murine’:
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And, while interesting mutations are increasingly coming to light in a number of verte-
brate species, the mouse at present far outranks all other vertebrates in the total potenti-
alities which it offers for genetic analysis... 
Among laboratory mammals, the mouse combines the largest number of advantages for 
the study of development. It is, as already indicated, excellent material from a genetic 
point of view; it is easily maintained and bred; and its embryos can now be grown in vitro 
from two-cell stage to blastocyst, and during part of the postimplantation period.81
The chapter covered culture techniques, biochemical requirements of the embryo, ways of mak-
ing mosaic mice and the recent experiments by Lin. Overall, the emphasis on the mouse embed-
ded its status as the most promising mammal with which to ask developmental questions. While 
much reproductive work continued on the rabbit, manipulation proved diﬃcult. The early rabbit 
embryo was easier to culture and grew much larger than the mouse, reaching 3mm at the blasto-
cyst stage, but chimeric embryos failed to develop, which was subsequently explained by the 
rapid expansion of the blastocyst and inability for the rabbit embryo to implant without the 
zona.82 With mice increasingly available for large-scale genetic tests, complete with extensive 
husbandry know-how, their use was also more economical. 
In the early 1960s, the scope and focus of embryology were in transition and as new scientists 
were entering the field, the choice of organism was open for renegotiation. While other verte-
brate species still dominated the field, the genetic status of mice, their availability and the new 
techniques for culture and manipulation made them an attractive option for new work, especially 
among mammals. In the late 1960s, with the growing engagement of molecular biologists in dis-
cussions about development, mice received a further boost. 
§4. Molecular promises
As embryology was increasingly labelled developmental biology, more and more molecular biolo-
gists participated in debates concerning higher organisms. While the field diversified and ex-
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panded before significant molecularisation had taken place, the growing dominance of molecular 
approaches helped give developmental biology a coherent identity.83  In the process, the range of 
species used to study development shifted. New organisms such as the nematode worm Caenor-
habditis elegans entered laboratories, while others like the chick or the rabbit were becoming less 
relevant. The sustained interest of mouse embryologists and the new availability of cell lines gave 
the mouse the potential to combine not only genetic, but also molecular analysis with answering 
questions about mammalian – and therefore human – development. While several laboratories 
adopted mice – most famously François Jacob at the Institut Pasteur – in the late 1960s, molecular 
thinking about mouse embryos mostly happened at cross-disciplinary conferences and in specu-
lative publications: lectures, reviews and introductions to new journals. However, it was by no 
means limited to them. Discussions about cloning, the future of human genetics and engineering 
the germline spread widely beyond scientific audiences.84 
As several historians have argued, the discovery of the DNA structure in 1953 was less significant 
to 1950s biology than retrospective accounts would have it, notably James Watson’s The Double 
Helix.85 It was the expansive research on the genetic code – how the DNA sequence corresponds to 
proteins – that pushed DNA centre-stage in the 1960s. The focus on the regulation of genes was a 
dominant feature of high-profile research, with the ‘lac operon’ elaborated by Jacob and Jacques 
Monod showing how bacterial genes respond to changes in the level of the protein for which they 
code.86 Having ‘solved’ the regulation of phage genes and the lac operon of E. coli, some molecular 
biologists argued that the time was ripe for expanding their focus to higher organisms.87  A crucial 
diﬀerence was multicellularity and the mechanisms that regulate the growth of an embryo from a 
cell to an organism – the question of development. 
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Long before actively pursuing higher organism research at the bench, molecular biologists en-
tered the conversation about the role of genes and gene expression in regulating diﬀerentiation. 
The Symposia on Development and Growth had oﬀered some space for biochemical interpreta-
tions of diﬀerentiation, and debates about the roles of enzymes in the cytoplasm and genes in the 
nucleus reprised older discussions in embryology and genetics. Both biochemists working with 
microorganisms such as Sol Spiegelman and theoretically minded embryologists such as C. H. 
Waddington readily embraced the new ways of discussing problems in terms of enzymes.88 Fur-
thermore, with the experimentally-supported consensus that genes do not change between cells 
and therefore their activity must be regulated during development, the language of genetic pro-
grammes, building on the earlier ideas of ‘gene action’ replaced the search for the chemical nature 
of the organiser as a key priority. With the elaboration of the mechanisms and principles of gene 
regulation in bacteria and viruses, and theoretical constructs inspired by information science – if 
not straightforwardly derived from it, – similar frameworks were often fitted onto the higher 
animals. 
Thus, as Lily Kay shows, Marshall Nirenberg had in mind grand questions of fertilisation, diﬀer-
entiation and the role of genes in development as he was working on unravelling the genetic code 
in E. coli.89  Similar questions drove the new stars of molecular biology at the Institut Pasteur, 
where the iconic lac operon model was elaborated in the late 1950s. The lac operon referred to a 
series of genes controlled by a repressor, a DNA-binding protein that blocked transcription of en-
zyme genes when the substrate (lactose) was unavailable.90 At the 1961 Cold Spring Harbor Sym-
posium on gene expression, Francois Jacob, Monod and André Lwoﬀ delivered a series of  influen-
tial papers on messenger RNA, gene expression and possible models of control of diﬀerentiation 
in higher organisms, interpolating from bacterial work. These speculative ventures into multicel-
lular organisms were welcomed by some conference organisers who often invited a token molecu-
lar biologist to illuminate discussion on development. Thus, Jacob and Monod attended the meet-
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Genes in Development in New York featured wide-ranging discussions that incorporated the new 
knowledge of DNA, RNA and proteins, as well as the informatic metaphor. The meeting was spon-
sored by the New York Heart Foundation – a surprising patron – but as its president noted in the 
proceedings published in the Journal of Experimental Zoology, the topic’s tenuous relevance to heart 
disease “has been of little concern to the New York Heart Association. It is our conviction that the 
most important advances in biological and medical science will come from investigations which 
are not too narrowly conceived in terms of current notions as to the nature of disease.”91
Mintz was present at the meeting alongside two other developmental biologists, Clement Markert 
and Donald Brown. Advocating wider use of the mammalian embryo, she drew on recent work to 
make her case:
The mammalian embryo, though it is an object of considerable potential interest, has 
remained largely at the periphery of experimental investigation into problems of early 
development. Many practical difficulties concerning availability of material and its han-
dling outside the maternal organism have continued to deter inquiry. Recent attempts to 
surmount these obstacles have begun to yield information and to disclose possibilities 
for further exploration.92 
Citing accumulating evidence on DNA, RNA and protein synthesis in the early mouse embryos, 
Mintz placed her work on allophenic mice within the theoretical concepts of gradients and de-
termination of cell fate.
Mintz was one of the few voices to promote the mouse from within the embryological community 
in the USA. However, other biologists were being convinced. When Current Topics in Developmental 
Biology was launched in 1966, to aid interdisciplinary communication among biologists,93 the edi-
tors invited Joshua Lederberg to open the first issue. The eminent E.coli geneticist and recipient of 
the 1958 Nobel Prize claimed that:
Right now is a particularly awkward time to frame any useful commentary on develop-
mental biology. The field has had enough fancy; more recently its methodology has been 
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under enormous pressure to accommodate the inspirations of molecular biology and the 
models of development that can be read into microbial genetic systems.94
Lederberg may have underplayed his expertise in the field by claiming his invitation stemmed 
from an unguarded remark that “embryology should be studied with embryos” – as opposed to 
elaborate quasi-developing bacterial systems. Yet he presented a bold vision for a new way of ap-
proaching the embryo, emphasising the theoretical ambiguities in classical approaches and sug-
gesting that molecular frameworks could bring clarity:
Despite the mechanistic flavor of the now classic work on tissue induction, embryology 
has historically had more than its share of mysticism, with some mysterious property of 
"organization" always in the background to inhibit bold experiments... For the most part, 
organization seems to be turning out to be quite comprehensible, even to the unaided 
human mind, as one more level of macromolecular chemistry.95
This phrase echoed another molecular biologist, Sol Spiegelman, and his frustration with the 
mystique of development voiced in 1958 when he had an imaginary collective embryologist ex-
claim, “My God, this [problem of morphogenesis] is wonderful, it is so complicated that we will 
never understand it.”96 For him, the solution lay not only in changing the metaphors, but also in 
the choice of organism.  Spiegelman’s proposal was thus to direct the collective eﬀort at one or-
ganism, be it a yeast or a sea urchin.97 Lederberg was keener to emphasise the mammals:
If any single experimental system in developmental biology had a fraction of the conver-
gent attention that was given the T phages, we might be more optimistic about the pace 
of further work, but embryology suffers from being a traditional field, and seems to need 
the impulse of more novelty than frog gastrulae would now offer... I have little doubt in 
my own mind that the mouse should be that central material, but this is a prejudice pos-
sibly based on expectations of utility from and for genetics, biochemistry, cytology, im-
munology, psychology, oncology, and medicine rather than on any significant personal 
experience. At the other pole, some very simple system like a rotifer or a nematode 
needs to be conventionalized...98
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The possible contribution of the mouse to understanding development in molecular terms was 
being increasingly tied to the possibility of molecular intervention. The promise of inserting 
genes into animals, including humans, flourished in speculative reviews, essays and speeches – a 
genre into which prominent scientists with established reputations could aﬀord to venture.99 One 
prominent example is Edward Tatum’s 1958 Nobel lecture – he shared the prize with Lederberg – 
which went as far as suggesting the possible means of introducing the molecules into the genome:
Perhaps within the lifetime of some of us here, the code of life processes tied up in the 
molecular structure of proteins and nucleic acids will be broken. This may permit the 
improvement of all living organisms by processes which we might call biological engi-
neering.
This might proceed in stages from the in vitro biosynthesis of better and more efficient 
enzymes, to the biosynthesis of the corresponding nucleic acid molecules, and to the 
introduction of these molecules into the genome of organisms, whether via injection, 
viral introduction into germ cells, or via a process analogous to transformation.100
Through the 1960s, the idea was promoted by Tatum and other prominent biologists, including 
Lederberg. Others were not as enthusiastic, however. Around 1968, a strong sense of a new “bio-
logical revolution” was gaining ground, and the future uses of envisioned technologies ques-
tioned, in the context of the strong opposition to the Vietnam War and student protest in Europe. 
Salvador Luria, one of the founding figures of molecular biology and an outspoken anti-war activ-
ist, published an article expressing concern about the new biology in the left-wing The Nation in 
1969, the same year he was awarded the Nobel Prize. In the article, he called modern biology a 
“terrifying power”, and argued for a social policy that would direct the potential application of the 
growing control over human heredity. As an epitome of these technologies, Luria envisioned ge-
netic engineering of humans and other animals.
Concerns about the potential of biology – especially on the molecular and reproductive frontiers – 
were also expressed by science writers addressing much broader audiences. In 1968, Gordon Rat-
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tray Taylor’s The Biological Time Bomb was published in London.101  As the title implies, the book 
oﬀered an uneasy mix of hopes and fears about the biological future – from medical applications 
and genetic improvements to more putative discussions of mind control. Taylor was no sensa-
tionalist hack. He was educated in natural sciences and the editor of BBC science documentaries, 
and the book was reviewed by the likes of Robert Edwards and Waddington.102 Published in the US 
next year, it was widely read on both sides of the Atlantic.103   
In the Biological Time Bomb, Taylor picked up on some obscure work including experiments by 
Sergey Gershenzon in Soviet Ukraine, who induced mutations in Drosophila by bathing them in 
calf DNA as early as 1939. Another example was Teh Pin Lin’s 1966 Science article on using micro-
scopic needles to inject inert substances into mouse oocytes.104 Lin’s elaborate work received little 
attention and was barely cited until well into the 1970s, but Taylor saw a potential there: 
Dr Teh [sic] chose globulin as being a harmless substance... But obviously the technique, 
once established, will be used to introduce many other agents, in order to explore their 
influence on development and thus help unravel the problems of embryology. Such 
agents will no doubt include hormones, and substances known to have a specific effect 
on development, such as thalidomide, and they will undoubtedly include DNA.105 
As molecular biologists were contemplating mouse work, the idea of inserting DNA into mam-
mals was thus in circulation, as were visions of gene therapy or a new eugenics. They implied a 
connection between the new embryology and the new molecular biology, with practitioners from 
both fields increasingly interacting in the spaces created under the aegis of developmental biol-
ogy. Yet despite the growing influence of molecular ideas on embryologists, and the ventures of 
molecular biologists into higher organisms, by 1970 few connections had been made at the level of 
practice. John Gurdon and Donald Brown’s work on nucleic acids in Xenopus ococytes, Eric David-
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son’s interest in sea urchin DNA and Sydney Brenner’s C. elegans project are the few examples of 
practical work that emerged in the late ’60s. 
Many of these experiments responded to doubts as to the applicability of Jacob and Monod’s bac-
terial models of gene expression to higher organisms.106  By the 1970s, the assumption that 
eukaryotic genes were regulated by repressor mechanisms similar to the lac operon model – 
summarised by that often-quoted assertion of Monod’s, “anything found to be true of E. coli must 
also be true of Elephants”107 – had come under pressure. Growing attention to eukaryotic cells and 
especially their RNA produced new models of gene actions in development, most famously those 
elaborated by Davidson and the molecular biologist Roy Britten, first published in Davidson’s 1968 
Gene Activity in Early Development.108  Responding to observation of large-scale RNA production in 
embryos, it suggested a much higher level of genomic organisation in eukaryotes, with “batteries” 
of non-contiguous genes, on a much greater scale than an operon, activated by a signal event or 
external signal, with whole families of regulatory genes controlling these cascades. Such new mo-
lecular explanations, embedded in the peculiarities of eukaryotic cells and genomes, were more 
palatable to developmental biologists. Thus, in response to Britten and Davidson, Waddington 
wrote that theirs was “the first speculation about the molecular mechanisms that control epigene-
sis of higher forms that begins to make sense to an embryologist who has been thinking along 
those lines for 30 years or more.”109 Jacob and Monod themselves lost faith in the universality of 
their bacterial models by 1970s. In pursuit of new regulatory explanations, Jacob converted to a 
higher organisms, picking the mouse as his animal of choice.     
Jacob recalls deciding to settle on a new multicellular organism around 1967. According to his 
memoirs, unable to choose between the usual animals of embryology, he wrote down the list of 
features for his perfect animal, only to find it did not exist.After flirtations with the flatworm Pla-
naria, Drosophila and Brenner’s nematode, Jacob settled on mice. He reconstructs two reasons for 
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this. First, the mouse had close scientific and rhetorical connections with humans and was used 
across a range of disciplines, and it was the smallest mammal with a short reproductive cycle. 
Second, Jacob claimed to have been adamant about staying at the Institute Pasteur, and adapting 
his laboratory to work on the mouse made the most sense, both because there was other work on 
the organism carried out there, and because it was relevant to the Institute Pasteur’s ultimate fo-
cus on human pathology. With the institution’s expansion of the animal facilities in the early 
1970s, Jacob had to fight to make the mouse a species of choice, using the promise of genetic 
analysis and his position to convince local immunologists to shift their attention from rabbits. 
However, a key factor in Jacob’s mouse project was a new technician who could help him through 
the species transition.110 This was Hedwig Jakob, who had built expertise in mouse cell culture in 
Gif-sur-Yvette, working with Boris Ephrussi, most famous as a Drosophila developmental 
geneticist.111  
The cells that Jacob settled on were teratocarcinoma cells, derived by Leroy Stevens at the Jackson 
Lab from a bizarre mouse tumour that seemed to resemble embryonic cells. A geneticist working 
on carcinogenesis, Stevens bred the “129 strain” that developed a specific cancer, teratoma, with 
high frequency. Teratomas manifested as highly unusual encapsulated tumours, containing a va-
riety of anatomically normal cells of tissue types that were not expected in the testes, such as hair 
follicles, teeth, and even eye or limb cells. These tumours also contained undiﬀerentiated cells 
that gave rise to those tissues, which closely resembled the inner cell mass of the blastocyst. The 
parallels between the tumour and embryonic cells led Stevens to speculate that these were de-
rived from embryonic tissues that failed to diﬀerentiate. For Jacob, these cells oﬀered an interme-
diate system that could combine a study of diﬀerentiating mammalian cells with culture tech-
niques familiar to a molecular biologist working with bacteria.112  
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In the 1970s, Jacob’s lab pursued the study of the T complex, that central enigma of mouse devel-
opmental genetics, building alliances with the Cornell mouse geneticist Dorothea Bennet, whose 
student Karen Artzt was hired by Jacob in 1972.113 With the expansion of molecular discussion 
around the mouse, present in speculative commentary and embedded in concerns about the fu-
ture of biology, Jacob’s transition is informative at the level of practice. While the mouse was in-
creasingly seen as a useful system for asking developmental questions with a molecular twist, 
much more mundane challenges had to be met. Infrastructure and technical expertise continued 
to be crucial factors in changing species, as was being able to aﬀord the time and costs such a 
change of direction would incur. As the next chapter will show, it took the circulation of postdocs 
with diverse scientific backgrounds and increasingly mobile careers, as well as the emergence and 
institutionalisation of easily mobile tools to make molecular intervention in mouse embryos vi-
able in the 1970s. 
Conclusion
In 1970, Keen Raﬀerty’s Methods in Experimental Mouse Embryology was published. It was the first 
handbook to deal exclusively with mouse embryology.114 Extensively illustrated with line draw-
ings, it targeted biology and medical students and was based on a course for first-year medical 
students Raﬀerty had organised at Johns Hopkins. While some reviewers found the volume too 
challenging and impractical for undergraduate students, it was well received and recommended 
for graduate courses and even experienced researchers.115 With considerable coverage of mouse 
husbandry, equipment and culture media, as well as very recent embryological techniques, Raf-
ferty’s volume announced that the mouse embryo had become so prominent that it could be in-
cluded in routine university teaching. The preface presented the case: “Among mammals, the 
mouse has been singled out for exclusive attention for the related reasons that the animal is easily 
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the most economical and has been the object of far more attention than any other mammal.”116 
Only a decade earlier, such a statement would have lacked any credibility. During the 1960s, the 
mouse took centre stage in the study of mammalian development. In 1972, a detailed atlas of 
mouse development appeared in print, accompanied by black-and-white photographs. Authored 
by Karl Theiler, an embryologist at the University of Zurich, and it standardised the events in 
mouse developments as specific normal stages.117
The extensive standardisation of the mouse, both genetic and physiological, was a resource that 
made the species widely appealing, but also oﬀered an opportunity in that it was open for chal-
lenge. A few biologists, McLaren, Biggers and to a lesser extent Grüneberg, made their careers by 
investigating the alternatives to the pure lines espoused by Jackson Lab. In the process, the mouse 
embryo became a viable and promising object for laboratory culture and intervention, bringing 
together expertise in genetics, reproductive physiology, embryology and biochemistry. With the 
rise of developmental biology, the species landscape had become unstable and open for renegotia-
tion. With the new manipulation techniques and rhetoric, the mouse was taking a place alongside 
the other key embryos, and the wide range of the networks that the mouse held together made it a 
promising choice for the jobs that were often yet to be articulated. 
While other species had had more sway in reproductive and embryological research, the mouse 
became attractive because of its position at the boundaries of multiple research agendas. The 
mouse embryo was made into a particularly successful boundary object, better than its more ‘ro-
bust’ analogues. The wide-ranging availability of techniques, husbandry know-how, genetic 
knowledge and pre-existing fora for exchanging facts and materials also made it into an exem-
plary laboratory species. Yet the boundary crossing that is significant to this story – that between 
embryologists and molecular biologists – was not yet realised as practical collaborations or 
straightforward exchanges of techniques. These transitions took place in the 1970s, and coincided 
with the rise of recombinant DNA techniques.
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Chapter 2. Recombinant networks: The moral economy of genetic engineer-
ing in the 1970s
Many accounts treat transgenic mice as one application of new molecular methods under the la-
bel of ‘recombinant DNA’.1 These techniques, invented in 1973, allowed researchers to isolate, 
splice and insert genetic material from any species into a circular bacterial DNA molecule known 
as a plasmid that could then be taken up by cultured cells – usually bacteria. On surface, the state-
ment is not inaccurate – all the groups that reported gene transfer into mice animals in 1980–81 
relied on these methods. Yet treating transgenic mice as a case of such straightforward molecu-
larisation is misleading for two reasons. First, the earliest experiments to introduce genetic mate-
rial into mouse cells and embryos predated these methods, and stemmed from alternative ex-
perimental programmes. Second, the genealogy and coherence of recombinant DNA is anything 
but straightforward, and more recent histories of biotechnology explored continuities with older 
research programmes and alternative genealogies for the methods. As I will argue here and in the 
following chapter, means of inserting genes into mice predated recombinant DNA. These new 
methods did, however, make an essential contribution as they streamlined existing experimental 
practices, scaled up the work on gene transfer and generated new scientific networks through 
which techniques and molecules circulated. 
Existing histories of recombinant DNA and the biotechnology industry focus on E. coli, the pow-
erhouse bacterium of molecular biology that became at the centre both the dramatic safety de-
bates and the spectacular early industrial applications.2 The possibility that modified E. coli might 
escape into the environment drove extremely public controversy, with scientists on both sides, 
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that culminated at the 1975 Asilomar conference, with subsequent guidelines published by the 
NIH that required stringent containment from any grant receiver, with requirements gradually 
relaxed by 1980. First success stories of the biotech start-ups – synthesis of somatostatin, human 
growth hormone and insulin – were also performed in bacteria. Yet despite the focus on applica-
tion in bacteria, the study of eukaryotic cells and genes were important for the adoption of re-
combinant techniques.3 New experimental systems were explored with cultured cells of humans, 
mice, hamsters and monkeys were the key mammalian species (see Fig. 2-1).
This chapter revises the history of recombinant DNA research in two ways. First, I examine alter-
native genealogies of moving genes between species, in particular gene transfer work with cul-
tured cells, somatic cell genetics and animal virus research. One of these experiments, a collabo-
ration between a molecular virologist Rudolf Jaenisch with Beatrice Mintz that was reported in 
1974, revolved around inserting viral DNA into mouse embryos. Second, I focus on the circulation 
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Fig. 2-1: The “New E.coli”, an adver-
tisement for human lymphoid cells 
from Associated Biomedic Systems, 
Ltd. The extensive detail visible on the 
cell micrograph compared to the E. 
coli image makes the additional visual 
argument for tackling cellular com-
plexity.
Science 174(4007), 1971.
of techniques and plasmids between institutions that attracted unexpected users beyond the core 
molecular biology community. Unusually, these networks were highly decentralised and had to 
function in a diﬃcult regulatory environment. One inadvertent outcome of the post-Asilomar 
NIH guidelines was the exclusion of certain institutions from the networks of exchange due to 
financial constrains that prevented them from building proper containment facilities and were 
influenced by the local regulation context. Still, through contingent moves of individuals, recom-
binant molecules could often make it to unexpected sites. The exchange patterns thus concen-
trated the transitions of recombinant DNA across disciplines to elite institutions, but also allowed 
and set the stage for unexpected collaborations.
I will first discuss the state of gene transfer in higher organisms circa 1970, and move on to focus 
on the Jaenisch-Mintz collaboration in section 2. Section 3 examines the circulation patterns in 
the light of recombinant DNA guidelines, and the role of sharing and credit in the moral economy 
of this expanding enterprise. Finally, section 4 will discuss the articulation of gene transfer into 
mammalian cells as a coherent programme with its own set of conferences, tools and expecta-
tions.  
§1. Gene transfer and somatic cell genetics
The success of research on the molecular biology of viruses and bacteria in the 1960s seeded sev-
eral research programmes that focused on investigating the eﬀects of DNA on multicellular or-
ganisms. In the late 1940s and early 50s, the use of bacteriophages (viruses infecting bacteria), 
labelled with the newly available radioisotopes, was key in several experiments that established 
the nucleic acid component as the carrier of genetic information.4 The phrase “gene transfer” 
originated from bacterial genetics around the same time, to describe the exchange of genes be-
tween bacterial cells, often from diverse strains. This phenomenon was cited widely in the de-
bates about recombinant DNA in the 1970s to normalise the experimental insertion of foreign 
genes into E. coli as an extension of a natural process. However, before the controversy broke, 
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gene transfer was discussed in relation to mammalian cells and experimental interventions took 
place in the 1960s and the early 1970s. 
As early as 1962, a paper by the microbiologist Wacław Szybalski and his wife Elizabeth Hunter 
Szybalska in the Proceedings of the National Academy of Sciences of the USA (PNAS) claimed a suc-
cessful incorporation of whole genomic DNA from one human cell line into another characterised 
by its lack of a specific enzyme, HPRT. Crucial to the work, done at the McArdle Laboratory at the 
University of Wisconsin, Madison, was the ability to select the cells that had taken up foreign 
DNA. To achieve this, the Szybalskis developed a tissue culture medium they named HAT after its 
components (hypoxanthine, aminopterin and thymidine). Only the cells that had taken up the 
normal HPRT gene could grow in HAT. This was one of several similar studies published around 
the time. At Allen Fox’s laboratory, also at Madison, scientists treated Drosophila embryos with 
DNA extracts from diﬀerent strains seeking to observe phenotypic eﬀects.5  Again, while there 
was some evidence that DNA could change phenotype, it appeared to be merely associated with 
the fly genome without integration – reversal of the eﬀect was frequent.6  Such work was t was not 
received with much enthusiasm. The majority of molecular biology was done in bacteria and the 
λ phage, with the genetic code being a major publicised problem at the time. The Szybalskis fol-
lowed the trend and returned to E. coli.7 
This return to bacterial cells was understandable given the availability of instruments, techniques 
and communication networks to support such work, but a small community of biologists working 
on transfer of DNA into eukaryotes did persist on the margins. Thus, Lucien Ledoux, based in 
Mol, Belgium, claimed transformation of plants with bacterial DNA as early as 1966.8  In his ex-
periments with tomatoes, barley and Arabidopsis, Ledoux treated seeds from the strains deficient 
for the synthesis of thymidine (one of the four DNA components) with radioactively-labelled bac-
terial DNA. By separating the plant DNA on caesium chloride gradient – a laborious process in-
55
5 E.g. Fox, et al. 1970, Fox, et al. 1971.
6 Willison 1980.
7 See Wolff & Lederberg 1994, 472–73.
8 Stroun, et al. 1966.
vented by Meshelsohn and Stahl for their experiments that demonstrated the semi-conservative 
replication of DNA9 – Ledoux detected peaks that indicated that the modified plants not only took 
up the bacterial DNA and broke it up it to make their own, but could also eventually produce un-
labelled nucleotides, suggesting gene transfer from bacteria. Yet this work could not be straight-
forwardly replicated and remained a citation oddity.10 
Some of the eﬀorts were collated at a 1970 NATO-sponsored conference on Informative [sic] Mole-
cules in Biological Systems in Mol, organised by Ledoux.11 The conference brought together bacte-
rial, plant and mammalian workers, and presented many claims for transformation of mammals. 
The introduction acknowledged the lack of solid knowledge about the behaviour of DNA in 
mammalian cells, while expressing cautious enthusiasm. The concluding remarks were also am-
bivalent. Written by Hubert Chantrenne, a Belgian molecular biology pioneer based in Brussels, 
they divided the experimental work into two categories: classical and emergent. The latter in-
cluded experiments with higher organisms, which were rather backhandedly likened to “black 
magic”: “controls were inadequate... It took a lot of courage and faith to continue to work along 
such disreputable lines”.12 By contrast, the work on animal viruses and on the genetics of somatic 
cells were elevated as worthwhile pursuits due to their practicality. 
The reviews of the published proceedings were also mixed, often treating the results in eukary-
otic cells as suspect. As one reviewer noted, the interesting questions – whether the foreign genes 
were expressed and integrated into the host genome – were rarely answered in these studies.13 
Moreover, as some of the convenors agreed, the results were not certain and artefact could not be 
ruled out, for instance contamination. The black magic metaphor persisted around gene transfer 
into mammalian cells even as it became acceptable. While viral and somatic cell genetic work 
drew on older traditions and had some eminent names attached to it, the injection of naked DNA 
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remained disreputable, and results uncertain. Its status is a reminder that while multiple claims 
about scientific works were routinely made their survival relied on instruments of credibility, 
best conferred by nurturing further work that could then also function as evidence of replication. 
Unlike the work on using isolated genomic DNA to modify tissues in vitro, cell hybridisation and 
viral experiments were part of established and well-funded research programmes. Since the late 
1950s, several geneticists looked to mammalian – and especially human – cell culture to map genes 
onto specific parts of chromosomes. The field, labelled ‘somatic cell genetics’, sought to override 
the limitations of tracing human genes through family trees and the goal of these experiments 
was to make animal cells more like bacteria, by focusing on cells that could be easily cultured, 
controlled and manipulated. Envisioned and developed in the early 1960s in the laboratories of 
Boris Ephrussi (Gif-sur-Yvette), Guido Pontecorvo (University of Glasgow) and Henry Harris (Ox-
ford University), among others, techniques to make cell hybrids between diﬀerent strains and 
species allowed gene mapping based on the few markers, mostly associated with the ability to 
grow in diﬀerent media. As these hybrids were genetically unstable and lost chromosomes in the 
process of cell division, the correlation between the remaining chromosomes and their parts and 
the cells’ new phenotype could suggest the position of specific genes.14
The early experiments on somatic cell fusion were received with much controversy. When Henry 
Harris first reported his human-mouse cell hybrids in 1965, dramatic reactions followed from the 
British and American press. The press seized upon the experiments as another manifestation of 
the biological revolution and a new frontier that could one day lead to human-animal chimeras. 
Harris’s reaction courted controversy, even as he attempted to distance himself from the press. 
The choice of human and mouse cells in the experiment was deliberate to make a more dramatic 
impression on his colleagues, and when confronted by interviewers, Harris would not dismiss 
future applications to humans and even went as far as entertaining the possibility of a human-ape 
hybrid (a ‘mape’) on television. The late 1960s were a time of dramatic concern over the new bio-
logical research, with bold statements from scientists that would become extremely rare post-
Asilomar. Harris’s insistence on framing his work in terms of species did much to shape the re-
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sponse, even as he subsequently tried to minimise the fallout by pointing out that cells were not 
whole organisms. His work featured in The Biological Time Bomb alongside many others, as part of 
the “new eugenics” narrative in Rattray Taylor’s pessimistic account.15 
Work on gene transfer into mammalian cells was becoming visible in scientific publications, and 
several reviews appeared in the news section of journals and science magazines. In 1971, a Science 
article reviewed Harris’ latest cell-fusion research, alongside work on using a virus to modify 
mouse cells. Noting that the ability to insert foreign DNA, either through viruses or in cell hy-
brids, was going to help with mapping eﬀorts and understanding gene expression, it concluded by 
addressing concerns about genetic engineering and argued that the tools were coming together to 
deliver gene therapy before society was ready. A 1972 piece in New Scientist, the British popular 
science journal with a balanced approach to the new biology, oﬀered another opinion.16 It was 
authored by Benjamin Lewin, a former editor of Nature New Biology 17  and NIH cancer researcher. 
The opening sentence claimed, “‘Genetic engineering’ is already a cliché whose very existence 
obscures reality. Claims to have cured genetic defects in cells by the addition of foreign genetic 
information are as controversial as the arguments about the morality of applying genetic therapy 
to man.”18 Framed as a critical survey, the article covered cell hybridisation, using viruses as vec-
tors, “which ha[d] been in the minds of molecular biologists for some time”, and “just adding 
DNA”. Lewin concluded that genetic engineering was too premature to warrant ethical guidelines 
that would inevitably become outdated, a rhetorical strategy that became common as dramatic 
new experiments were being published. But he also articulated criteria for successful genetic 
modification: stable integration of the gene, use of clear selectable markers and genetic analyses 
to confirm gene transfer, and the presence of the new genetic material in the germ line and there-
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Published over a year before the start of the recombinant DNA controversy, these pieces highlight 
continuities in the debates over genetic engineering. They also indicate a divided biological opin-
ion that the controversy would expose. However, by the early 1970s, media interest in cell fusion 
faded as embryo culture and artificial fertilisation became icons of the new biology, while somatic 
genetic research was in full swing.19 In pursuit of a higher resolution of mapping, specific chro-
mosomes were being isolated. In 1973, a paper by Wesley McBride and Harvey Ozer at the National 
Cancer Institute in Bethesda detailed a new means of allocating genes by what they called 
“chromosome-mediated gene transfer”.20The technique was a means of making cross-species hy-
brids by incubating cells with chromosomes purified by centrifugation, and observing the 
changes that took place in the cells. 
In order for these experiments to be meaningful, a series of cell lines, markers and mutations had 
to be developed. The few known mutants relied on metabolic characteristics, such as the ability of 
cells to grow in specific media such as Szybalskis’ HAT. This remained the simplest system, and 
lack of enzymes such as thymidine kinase (tk) and HRPT could be detected. In the 1960s and 
1970s, the standard biochemical technique of gel electrophoresis was adapted to expand the rep-
ertoire of phenotypes, as diﬀerent forms of enzymes would migrate diﬀerently on a two-
dimensional gel.21 Moreover, by the 1960s animal cells were widely standardised and accessible 
though centralised facilities. In 1964, the American Type Culture Collection, established for stor-
age of microbial samples, began accepting animal cells that could be frozen in liquid nitrogen and 
samples then sent to researchers.22 In the 1970s, these activities expanded and new cell banks 
emerged. One at the MIT was sponsored by the National Science Foundation, while a human cell 
culture bank was established in Camden, New Jersey in 1972.
One geneticist was heavily involved with the expansion of somatic cell genetics in the USA was 
Frank Ruddle, a former postdoc of Pontecorvo. Chairman of the Department of Biology at Yale, 
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Ruddle managed to secure an uncharacteristically long-term grant for his laboratory from the 
newly established National Institute for the General Medical Sciences (NIGMS) for his research 
into the “genetics of somatic cells”.23 At Yale, Ruddle established multiple networks of collabora-
tions within and outside the institution, overseeing and working on several projects associated 
with murine cell genetics, as well as human population genetics. He was also involved in building 
genetic networks. Thus, Ruddle helped the Camden tissue bank secure NIGMS contracts and ac-
tively encouraged his colleagues to contribute cells to the bank, oﬀering them to put a “hold” on 
the material for up to a year so that it could be exploited further before sharing.24 With Victor 
McKusick, he initiated the series of Human Gene Mapping Workshops in 1973, which became the 
major vehicle for communication within the human genetics community. Subsequent meetings 
standardised the nomenclature of human genes and established communication and logistical 
networks that were important in initiating the Human Genome Project.
Ruddle actively promoted somatic cell genetics, for instance by introducing the approach as a way 
to study development. In 1972, he chaired the annual Symposium of the Society for Developmental 
Biology dedicated to the Genetic Mechanisms of Development at the Wesleyan University, Con-
necticut. The meeting brought together topics seemingly distant from embryology. Its first third 
was devoted to bacteria and viruses, envisioned as “as paradigms for the genetic analysis of dif-
ferentiation and morphogenesis in the complex eukaryotes.”25 Another panel was devoted to us-
ing Mendelian analysis for interpreting development, with the usual animal suspects – Drosophila, 
Xenopus and the mouse – and the third part discussing how somatic cells could be “a new tool for 
the developmental biologist”. According to Ruddle, 
In these experimental systems, parasexuality in somatic cell populations is used to ex-
tract genetic information pertinent to developmental control mechanisms. In a sense, 
this approach permits the concepts and methodologies inherent in microbial genetics to 
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be applied directly to the study of differentiated soma of higher eukaryotes explanted in 
vitro. 26
Another unusual aspect of the symposium was a public launch of a film about the impact of scien-
tific research on social problems. Responding to the recent debates, its topic was genetic engineer-
ing. Some argued for oversight from the scientific community, including new committees on eth-
ics and safety. These approaches echoed the sentiment of the 1973 Gordon research conference 
that is usually taken as the starting point of the recombinant DNA controversies, where the con-
cerned scientists voiced public health concerns through open letters to the scientific community.27 
While these debates ultimately focused on the containment of E. coli, a potential human pathogen, 
it was the inserted DNA that caused most concern. In the original experiments from the Berg 
laboratory at Stanford, these genes came from the tumour virus SV40. Virus research had played 
a key role in developing techniques to insert foreign DNA into cells – an approach developed in 
mammalian cells.
§2. Viruses and embryos: The Jaenisch-Mintz collaboration
As Chapter 1 showed, in the 1960s molecular biologists were eager to expand into higher organ-
isms, and embryologists were increasingly attracted to molecular tools and questions. Several 
candidate species attracted big names, the mouse among them. For Sydney Brenner and Francois 
Jacob, working with C. elegans and mouse teratocarcinoma cells, there was no sharp transition 
between molecular and developmental practices – the techniques and instruments were a part of 
locally-elaborated sets of questions.28  Yet such synthesis was not the rule. Success stories in mo-
lecularising the mouse embryo typically relied on collaboration between molecular biologists and 
embryologists, often carried out through the extensive circulation of young postdoctoral fellows 
between institutions. Divisions between expertise were significant and parts of the projects were 
often performed in diﬀerent locations best suited for specific techniques. Here, I discuss one of 
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the earliest collaborations that resulted in the first announcement of inserting foreign genetic 
material – a virus – into the mouse embryo. 
In 1971, the Princeton molecular virologist Rudolf Jaenisch approached Beatrice Mintz with an 
ambitious project – to insert a virus into the mouse embryo. Jaenisch had just moved to Arnold 
Levine’s Princeton laboratory from the University of Munich, where he had completed a medical 
degree combined with a PhD in the molecular biology of bacteriophages. Levine had secured his 
assistant professorship at Princeton in 1968, having studied the replication and control of host 
metabolism by bacteriophage ΦX174 and SV40. The latter virus was to become a major project for 
his laboratory in the early 1970s, and Jaenisch was one of his first postdocs who helped establish 
the system.29
Study of tumour viruses had flourished since the 1960s, when they were successfully promoted as 
a major experimental system to study cancer causation. In the USA, funding for tumour virus 
studies ranked second in National Cancer Institute expenses, topped only by chemotherapy.30 The 
role of viruses as causative agents of all cancers remained controversial, but arguments had been 
made for their use as an experimental system. Before the war, work in fowl and mice showed 
some tumours could be induced by viral particles, even though these kinds of infectious heredi-
tary causes went in and out of fashion.31 In postwar America, the complex “policy-making com-
munity” encompassing politicians, cancer charities, pharmaceutical companies and healthcare 
bureaucracies was compelled to invest major funds into the study of tumour viruses.32 This was in 
response to the political agendas of the war on cancer, the widespread use of molecular biological 
approaches and instruments such as ultracentrifuges to purify viruses, and the major success of 
polio research that led to the unveiling of the Salk vaccine in 1955.  
Leukemia viruses received much initial funding, but other tumour viruses soon became key re-
search objects. Building on the success of mapping bacteriophages, prominent molecular biolo-
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gists and virologists turned to new systems such as the polyoma virus and SV40.33 Jaenisch was 
one of many participants in this migration. In 1971, Levine took sabbatical leave to Europe, and 
Jaenisch was eﬀectively in charge of the lab. As a recent convert to animal viruses, Jaenisch was 
eager to explore the more ambitious questions of tumour causation that went beyond the monkey 
cell system in which SV40 was cultured. He was attracted to the problem of tissue specificity, or 
viral tropism. Why did SV40 give rise to skin cancer but did not aﬀect the liver? Was it unable to 
infect the liver cells, or unable to make them grow uncontrollably, that is, to transform them?34  He 
had come across Mintz’ work on allophenic mice and was attracted by her use of genetics to an-
swer developmental questions. If a virus could infect the early embryo, the expectation was that 
its DNA would infect the majority of cells and tissues. Jaenisch called Mintz to tell her about his 
ideas, and she invited him to visit her lab – a short drive from Princeton. Jaenisch recalls her as 
polite, but skeptical, to the extent that he began reaching out to other mouse labs. However, after 
some time Mintz called him back and suggested they work together. 
The collaboration was negotiated with the absent Levine, and relied on Jaenisch driving between 
Princeton and Fox Chase. In Mintz’s lab, he would learn to deal with mouse embryos – a prime 
location for the task. At Levine’s lab, he would purify SV40 DNA after growing it in monkey cells 
by isolation in alkaline sucrose gradient and further purification. Jaenisch would then take the 
isolated viral DNA to Fox Chase, where he would attempt to inject the isolated viral DNA into the 
blastocyst, following Mintz’s guidance. This technique was based on Teh-Ping Lin’s microinjection 
method and Richard Gardner’s work on microinjecting inner cell mass into the blastocyst, with 
which Mintz was familiar.
Mintz may have thought Jaenisch’s project risky, but several other laboratories were pursuing 
similar research. Lin’s was one: as Jaenisch recalls, he went for a brief visit to UCSF that he did not 
find particularly helpful, and he was perplexed by Lin’s attempts to inject ribosomal RNA into 
mouse eggs that remained unpublished. At the Rockefeller University in New York, Elaine Diacu-
makos, a student of Edward Tatum and an expert in microinjection of somatic cells, was trying to 
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work with mouse eggs slightly later, in 1973–1974, again with little success.35 In the UK, Anne 
McLaren was experimenting with the eﬀects of nucleotides on the developing mouse embryo, by 
culturing them in a solution of DNA.36 McLaren’s interest in rodent DNA can be traced to her late 
1960s experiments on repetitive sequences in mice and rats, studies that generated some interest 
among the molecular biologist experts on the issue.37 In 1973, McLaren co-authored a paper on the 
eﬀect of DNA on the growth on the mouse embryo with her student Michael Snow. Snow and 
McLaren’s report showed little eﬀect of external DNA on the embryo – it suggested that freshly-
prepared DNA enhanced growth, while if it had been stored for a while, the eﬀect was deleterious. 
There was, however, no evidence of genetic modification. 
The early experiments on gene transfer mostly relied on phenotypic markers to detect genetic 
modification. While Snow and McLaren used radioactively-labelled nucleotides to follow them 
into the embryo, their conclusions also relied on the lack of phenotypic change. Jaenisch hoped to 
see phenotypic eﬀects – tumours in adult mice, but he was also interested in the fate of the virus 
in tissues where it was suppressed. For this, he was seeking a tool to detect the viral DNA regard-
less of its function, a nontrivial task. Specific DNA could be detected by measuring rates of hy-
bridisation of radioactively-labelled molecules. A DNA solution was heated to just below boiling 
point, and the double strands would unzip and separate. As the temperature was lowered, the sin-
gle strands hybridised again into double-stranded molecules, and the rate of the process could be 
measured through radiation detectors. The hybridisation rate was assumed to be proportional to 
the sequence similarity between the molecules – if it was rapid, it could be assumed many identi-
cal sequences were present in solution. The measurements were inscribed as C0t curves (or “cot 
curves”), and were a means of confirming presence of specific DNA as well as being useful in early 
studies of genome complexity and repetitive DNA (Fig. 2-2). 
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For Jaenisch’s experiment to work, the SV40 probe had to be identifiable in the mix of mouse DNA 
that had been sheared with a non-specific restriction enzyme. He achieved this by preparing a 
highly radioactive (“hot”) probe from the purified SV40 DNA, a solution that presented itself in 
1973, when, having completed his postdoc at Princeton, Jaenisch moved to the Salk Institute. Lo-
cated in La Jolla, San Diego, the Salk had been pioneering small laboratories for new faculty.38 It 
was also attracting prominent molecular biologists as non-resident fellows. Among them was Paul 
Berg, who joined the institute just as the recombinant controversy began to unfold. With a British 
postdoc Peter Rigby, Berg was developing “nick translation”, a method to make specific DNA mole-
cules highly radioactive.39 
At the Salk, Berg passed the protocol for the technique to Jaenisch as early as 1973, though it re-
mained unpublished until 1977. Such circulation of methods was not uncommon among molecu-
lar biologists, given long delays in publication, but Jaenisch certainly benefited from access to 
Berg that his position at Salk allowed. Another crucial technique for DNA detection that super-
seded cot curves, Southern blotting, was developed in 1973 at the University of Edinburgh by Ed-
win Southern, but was only published in 1975. In Southern’s case, the Journal of Molecular Biology 
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Fig. 2-2: A C0t curve from Jaenisch and Mintz’s 
1974 paper, showing extracts from the brain tissue 
in several mice (numbered). The relative rate of 
reannealment between single stranded DNA mole-
cules [c0/(c0– ca)] is plotted against incubation 
time. The high rate for mice #1 and #15 indicates 
presence of SV40 sequences. C.T. stands for calf 
thymus DNA, used as a control on its own and 
with a sample of SV40 DNA (“C.T. + SV40”) to rule 
out contamination.   
© PNAS
rejected his “methods” manuscript until a significant biological application could be included, in 
line with its policy. However, Southern liberally shared his protocols with fellow biologists, and 
they soon spread to the USA via his transatlantic visits.40  Berg went even further, allowing Jaen-
isch to announce and briefly describe nick translation in the paper with Mintz. This generosity 
was not restricted to Jaenisch – Berg’s 1977 method paper on nick translation lists nine further 
publications that had relied on the technique in 1973–77, most of them from Stanford. Berg was 
duly acknowledged as a donor of the technique, and its emerging use enabled him to garner evi-
dence for future publications and demonstrate a clear biological significance of his method. 
Jaenisch and Mintz published their results in the Proceedings of the National Academy of Sciences 
(PNAS) in 1974. Mintz had been elected to the Academy in 1973, which made it easy for her to sub-
mit papers without looking for another fellow to “communicate” the manuscript, and the publica-
tion was fast. Their data strongly suggested that SV40 DNA was present in the tissues of the em-
bryo, in various concentrations, and they speculated that the virus had probably integrated into 
the mouse genome, even though alternative possibilities could not be entirely dismissed. Other-
wise, the framing of the paper was in terms of tumour virus biology – tissue specificity, the eﬀect 
of the embryo on viral activity and tumour formation. Remarkably, the experiment was not posi-
tioned as an attempt at genetic intervention, nor was the possibility suggested in the rather fo-
cused language of the paper. It is unlikely that it had not been entertained, but perhaps the 
authors felt it was too fanciful – and potentially controversial – to express in print. While the ex-
periment did not use recombinant DNA, SV40 was a source of anxiety that fuelled the recombi-
nant controversy in the first place. While the 1974 paper suggested that viral DNA might integrate 
into an embryo, this was not entirely unexpected, since this is what viral DNA is supposed to do. 
Whatever the reason for refraining from genetic speculation, the Jaenisch-Mintz SV40 work went 
unnoticed beyond the expert community, although it was well-received within. In the following 
years, Mintz shifted her agenda to work on teratocarcinoma cells, but Jaenisch continued viral 
work with mouse embryos. 
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§3. Recombinant exchanges 
Methods to isolate DNA and analyse it predated 1970s and, while laborious and sometimes yield-
ing ambiguous data, as in the case of Ledoux, they could be used successfully and to much ac-
claim. However, with the ability to cut and paste DNA using restriction enzymes and DNA ligase, 
insert it into a circular bacterial molecule called a plasmid that could then be taken up by other 
cells, and then detect and map fragments through radiolabelling methods. These techniques, com-
ing together in 1974, rapidly expanded the scope and scale of research with DNA. In a complex 
political climax in the USA, with severe concern over the safety of such experiments, new net-
works formed through which plasmids travelled. This section will examine the circulation of re-
combinant DNA in the second half of the 1970s, stressing the concerns about access, sharing and 
communication that were part of the moral economy of recombinant DNA research. This context 
is crucial to place the subsequent invention and communication of transgenic animals, as the 
laboratories that made these mice partially adopted the new style of doing molecular biology with 
the plasmids and tools that they received from these networks. 
For Jaenisch, SV40 was convenient because he had much expertise in handling it, and it was avail-
able in Levine’s Princeton lab. It was also a major instrument of molecular virology, and the tim-
ing of the PNAS publication was opportune. In 1973, John Tooze authored the first textbook on the 
subject.41 Moreover, shortly after the paper appeared in the April 1974 issue of PNAS, the Cold 
Spring Harbor Symposium on Quantitative Biology, an eminent annual meeting at the core of mo-
lecular biology in the USA and globally, was dedicated to tumour viruses (Fig. 2-3). The topic was 
chosen by James Watson, still combining his position at Harvard with directorship of Cold Spring 
Harbor, and it brought together leading researchers. Jaenisch’s paper was received as further evi-
dence for the transforming activity of SV40 and its ability to integrate into embryonic cells and it 
was mentioned in David Baltimore’s symposium summary.42 
Back at the Salk, Jaenisch’s attempts to detect tumours in injected mice, or at least SV40 proteins 




lines established from the manipulated embryos germline transmission. The embryos appeared 
extremely mosaic and the germ tissues did not appear to have taken up SV40. While Jaenisch kept 
breeding the SV40 mice, he was also looking for other systems that might have at least some of the 
molecular knowledge oﬀered by SV40. Luckily, in the dynamic environment of the Salk Institute, 
such a system came with new postdocs in 1975. Arriving from David Balimore’s MIT laboratory, 
they brought Moloney murine leukemia virus (M-MuLV) with them, another virus that had been 
used extensively in mouse cancer research.43
Postdoctoral fellowships were established in the interwar USA, as research was becoming an in-
creasingly important part of academic work but universities remained reluctant to hire full-time 
research staﬀ. The funding came from philanthropic foundations such as the Rockefeller and was 
intended to encourage transatlantic exchange as European research institutions were 
blossoming.44 With the major expansion of American biomedical funding after World War II, the 
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Fig. 2-3: Rudolf Jaenisch at the June 1974 
Cold Spring Harbor Symposium on 
Quantitative Biology.
© Cold Spring Harbor Laboratory.  
trajectory frequently turned the other way as many European scientists, especially molecular bi-
ologists, went to the USA for brief periods.45  As funding for biomedical research grew steadily 
through the 1950s and 1960s, postdoctoral positions became increasingly common, with the ex-
pectation that young scientists who had just completed their graduate studies would spend be-
tween 9 months and 3 years in several laboratories before getting a permanent position and, if 
successful, starting their own group. Perhaps the most famous postdoc, James Watson, spent sev-
eral years in Copenhagen and Cambridge, before returning to the USA and taking up a position at 
Harvard.  
The senior scientists running the labs – the principal investigators, or PIs – performed increas-
ingly managerial duties. In universities, they were hiring, teaching and sitting on university 
boards as well as running their laboratories. However, even in research institutions like the Salk, 
PIs had to submit multiple grant applications to attract funds and prestige to their laboratory; 
they would travel the conference circuit, presenting their results and help articulate the ‘state of 
the art’ in their field. Some continued to do bench work – this was often important to their reputa-
tion as good scientists uninterested in institutional ‘politics’ – but running a successful laboratory 
was usually very time-consuming. Thus, while the circulation of postdocs was supposed to expose 
young scientists to diverse techniques and let them publish as many experiments as possible to be 
in position to start their own group, postdocs and graduate students also performed the vast ma-
jority of experimental labour.
Moreover, they served as immediate vehicles of disciplinary exchanges and cross-fertilisations of 
techniques, ideas and experimental systems. While Jaenisch was not a formal postdoc in Mintz’s 
laboratory, the combination of expertise and access to resources between Princeton and Fox 
Chase were crucial to their experiments. Many stories of resource circulation feature DNA sam-
ples, enzymes and cells that postdocs brought with them. Thus, the celebrated Cohen-Boyer-Berg 
collaboration used Xenopus DNA that Berg’s postdoc John Morrow brought from Don Brown’s lab at 
the Carnegie Institution, and plasmids were then ferried between UCSF and Stanford by a re-
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search assistant in a Volkswagen Beetle.46 Similarly, restriction enzymes required for these ex-
periments arrived in a thermos flask from Holland with Boyer’s postdoc. As Sally Smith Hughes 
points out, “these enzymes were not then available commercially and had to be begged for or bor-
rowed through a network of material exchange or tediously synthesized and purified from 
scratch.”47
The free exchange of materials was the basic premise in the moral economy of molecular biology, 
and it thrived through the 1970s. However, it was perceived to be under attack by the attempts to 
regulate and to commercialise recombinant DNA. Even the earliest attempts to control the use of 
the plasmids that Cohen, Boyer and Berg shared met resistance. The requests as innocuous as not 
inserting tumour virus DNA onto plasmids for safety reasons could be resisted, and the insistence 
on not sharing the DNA further was met with suspicion. In 1971, Andrew Lewis, a young virologist 
at the National Institute of Allergy and Infectious Diseases developed a hybrid between SV40 and 
a common cold adenovirus, he drew up a memorandum of understanding that asked recipients of 
the new construct to take safety precautions and not to share it further unless they could receive 
similar assurance. Heads of major molecular labs, including Paul Berg, James Watson and Daniel 
Nathans (Johns Hopkins), refused to sign. Lewis was breaking the code of sharing and his implicit 
doubts about the competence of senior molecular biologists were a major faux pas.48   
Later in the 1970s, when limitations on recombinant research were grudgingly accepted by some 
biologists (and eagerly promoted by others), the problem of sharing did not diminish. Despite the 
culture of sharing resources, credit had to be allocated properly and it was expected that the in-
ventor would ‘capitalise’ on his or her technique. The field was highly competitive, between indi-
viduals and institutions. The moratorium on this research, as well as the further NIH guidelines 
and public hearings had real eﬀects on some careers, and several scientists concerned about their 
future went as far as moving institutions. Thus, after public debates in Cambridge, MA led to a 
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Maniatis had just received an assistant professorship at Harvard and was working on techniques 
for cloning DNA using mRNA molecules as templates (complementary DNA or ‘cDNA’). The lab 
that was being built for recombinant work at Harvard, which would include the Maniatis group, 
was one of the focal points of the criticism. Through an encounter with James Watson, he was 
oﬀered to move to the more peaceful environment at Cold Spring Harbor, and subsequently set-
tled at the California Institute of Technology (CalTech) in Pasadena, where he moved on to work 
on inserting cDNA fragments into mammalian cells.49   
Maniatis was recruited to CalTech by Robert Sinsheimer, one of the most vocal opponents of re-
combinant DNA research in scientific circles. Despite his political commitments, he believed that 
it was his responsibility as chair of the biology division to attract the best talent at the cutting 
edge of research. Less prominent and endowed departments, by contrast, were less likely to invest 
in required facilities. Thus, Richard Palmiter, a biochemist at the University of Washington in 
Seattle who was then working on chicken ovalbumin gene spent much time in Pierre Chambon’s 
laboratory in Paris after his home institution was reluctant to build containment facilities.50  
My goal here is not to criticise the NIH guidelines, which were a result of complex negotiations 
with great scientific input and in many ways a success story of the scientific lobby that avoided 
federal regulation. It is rather to note the eﬀect they had on the dynamics of circulation and ex-
perimental work and access to novel techniques before their standardisation. Despite the con-
straints that the guidelines imposed on research, recombinant molecules could circulate with 
relative ease. Even though it was recognised that molecular biologists had limited awareness of 
how to work with potential pathogens, the exchange of reagents was defended. At Asilomar, a 
group of delegates voiced concerns about the eﬀects regulation could have on sharing, and argued 
that the dangers were limited to the primary stage of inventing new recombinants and were best 
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left to ‘quality’ labs.51 Isolated DNA could be posted through courier services within a secondary 
container in case of spillage.52  The space in the large dry ice boxes used to ship samples could even 
be optimised by packing in some ice-cream and occasionally lobsters.53 It was the escape of modi-
fied organisms that was most strongly policed, even though these could also be shipped with 
proper requirements. 
Circulation of molecules and information were also important concerns in the patenting debates 
surrounding the basic “cut and paste” methods. As Boyer and Cohen published their work on in-
serting a Xenopus gene into E.coli in 1974, Stanford’s patenting oﬃcer learned about it from the 
front page of the New York Times and set oﬀ to file a patent application within the remits of the 
university’s institutional patent agreement with the US Department of Health, Education and 
Welfare (DHEW). The move caused severe debates both within Stanford and in the scientific 
community at large.54 In these early discussions, Cohen and Boyer agreed that their experiments 
were made possible by multiple existing tools and innovations. The challenge to the distribution 
of credit within the moral economy of recombinant research was negotiated through the late 
1970s, partly by making the case for patents being in public interest, and by the great interest of 
the US government in biotechnology as the industry to reinvigorate flailing US economy.55   
In 1976, under the leadership of NIH director Donald Fredrickson, DHEW consulted scientists, 
scientific associations, industry representatives, patent lawyers and a few consumer organisa-
tions on patenting recombinant methods.56 University scientists’ responses were diverse, ranging 
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from reluctance to comment to outright opposition. Some, like Szybalski, assumed commerciali-
sation was inevitable and resigned to it. Others were more positive about industrial applications, 
but felt recombinant DNA was too controversial a field, both in public arena and in terms of dis-
tributing credit among the inventors. However, while scientists were uncomfortable with secrecy, 
administrators and patent lawyers believed that patents would not delay communication. Even 
though both academic and industrial correspondents were worried about trade secrets (compa-
nies wanted to be able to keep them, scientists were concerned they would arrest the progress in 
the field), the feeling was that publications were too important for academic researchers, espe-
cially in such a dominant and novel area, to be significantly delayed by patent concerns, and peer 
review and journal back-logs would likely be a much more significant obstacle to speedy circula-
tion of data.57
The exchange of information was thus another key concern. It occurred through specialised pub-
lications, conferences and the scientific grapevine. New journals appeared continuously in the 
1970s, despite the steady growth in price and the declining resources of scientific libraries. Some 
of them were responding to the growing publication lags between submission and appearing in 
print – something that could take between 6 and nine months, according to a Nature comment in 
1972. Cell, a new journal of “exciting biology” as claimed in its first editorial, was founded in 1974 
by Benjamin Lewin and promised a rapid publication of comprehensively research and argued 
papers using an international board of editors who could deal with manuscripts on a more local 
basis. In the same year, Nucleic Acid Research was founded, also promising rapid publication. Jour-
nals more specific to recombinant research appeared in the late 1970s. Gene, dedicated largely to 
gene mapping with restriction enzyme but in practice publishing an array of recombinant re-
search, was founded in 1977, and was flooded with manuscripts. It was edited by Szybalski who 
used his journal’s editorials as a platform to comment on the current state of knowledge and regu-
lation.
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Despite the emphasis on speeding up publication, they were never fast enough for the key sites of 
molecular research, and much personal exchange of information occurred before publication. 
Preprints of papers and conference talks circulated between collaborators without the pressure of 
formal publication. Conversations and personal correspondence often involved data and images 
sent as courtesy. Again, expectations on sharing existed, even though they had to be counterbal-
anced by interest in securing priority and developing one’s own work. James Watson’s essay in the 
1973 Cold Spring Harbor annual report summarised this paradoxical situation. It emphasised the 
importance of priority as not a mere matter of pride, but a career requirement for securing posi-
tions and research funds (“There is little enthusiasm for those who always come in second”).58 
How one learned about a competitor’s results was an important consideration in adopting some-
one else’s method or experimental system: if there had been a publication, the problem was “up 
for grabs”, but if one learned about it informally, an expectation existed that one should let the 
author publish. Publications lags were thus not only frustrating to the author, but to those waiting 
to reap the benefits of the paper. However, most manuscripts circulated as preprints, given to 
students, collaborators and selected colleagues – the writing up moment, Watson argued, was the 
more useful timing of discovery. While the author may have requested that a colleague refrain 
from sharing the data, news and secrets were impossible to keep once they began circulating be-
yond the author. Watson concluded with a call to persevere with science, to the best of one’s abil-
ity, despite the inevitable “the rat-race aspects of much of the high-power science” that was not 
going to disappear.59   
With the rapid pace of recombinant DNA research and political uncertainties around it, its scale 
expanded dramatically. Unlike earlier stories of animals or isotopes, there were many hubs of 
sharing DNA. While they were attempt to centralise plasmid supply and catalogue isolated genes – 
most notably by GenBank, but it collected sequence data60  – plasmids moved contingently before 
74
58 Reprinted as Watson 2000. Quote on p.103. Watson, himself notoriously benefitting from being shown Rosalind 
Franklin’s unpublished DNA X-ray crystallography images without her knowledge – an episode that The Double 
Helix recounts in vivid and nonchalant detail – had a case to make.
59 Ibid.:103. Latour and Woolgar’s influential Laboratory Life reflects a similar take on publications and credibility. 
While they may have presented their book as a study of contemporary science in general, it is no accident that 
their fieldwork was conducted in a high-profile molecular biology lab. Latour & Woolgar 1986: 187–233. 
60 Strasser 2011, Stevens 2013: 137–62.
the courses and handbooks on recombinant DNA techniques were available. In these years, jump-
ing on the “molecular bandwagon” relied on alliances that were likelier to succeed at prestigious 
and well-funded institutions. With the growing interest in eukaryotic genes that were now mo-
bile and subject to analysis, scientists working with animal cells and even embryos were increas-
ingly securing access to these networks. 
§4. “DNA-mediated gene transfer”: Expanding the networks
While Jaenisch benefited greatly from his position at the Salk, his work remained within the 
bounds of animal virus research. With M-MuLV, Jaenisch was able to trace the virus through the 
cell and subsequent generations of mice, establishing Mendelian transmission of the virus. He 
had developed a more straightforward method to detect specific DNA, using viral cDNA after the 
methods pioneered by Tom Maniatis spread through the elite networks of molecular research. 
Moreover, he found that embryos could be infected with M-MuLV at 4–8 cell stages, avoiding the 
need for microinjection that made the procedure much easier to perform.61 There were no sugges-
tions in the papers that viruses could be used to introduce new genes via recombinant experi-
ments. Given the central role of tumour viruses in inspiring such work, it is hardly the case that 
the idea hadn’t occurred to him or his readers. However, such an emphasis allowed Jaenisch to 
avoid participating in unsavoury debates and to focus on the important questions of cancer ori-
gins and the regulation of viral DNA. However, other labs were increasingly looking to use plas-
mids to answer questions about mammalian gene expression. The success of this programme 
drew on aligning research from somatic cell genetics, tumour virus work and recombinant ex-
periments to articulate a new agenda for genetic modification of mammalian cells.
In 1976, gene splicing delivered on the promise of isolating eukaryotic genes; the first plasmids 
carrying interesting genes were reported and shared. Genes for various globins and immuno-
globulins were isolated among others. Combined with the array of other techniques mentioned 
above, but not yet in wide use, the researchers working on eukaryotic DNA were in optimistic 
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mood. The new work was brought together in the 1977 Cold Spring Harbor symposium on ‘Chro-
matin’, the structural element of eukaryotic chromosomes that combines DNA and proteins. The 
symposium on ‘Chromosome Structure and Function’ had been held as recently as 1973, so the re-
turn to the topic – and the subsequent 1978 symposium on DNA replication – signalled enthusiasm 
about eukaryotic genomes. In his forward to the published proceedings of the Chromatin sympo-
sium, James Watson noted that “at the end we were both overwhelmed and dazzled, and many 
participants left feeling they had been part of an historic occasion”.62  Pierre Chambon’s summary 
reviewed recent research on eukaryotic cells to claim that the previously ‘dirty’ field that had 
looked up to bacterial genetics for its clarity and elegance was now more than capable of being 
understood in similar terms. It also brought together the molecular techniques of gene splicing 
and nascent DNA sequencing with the more nuanced appreciation of eukaryotic genes in cellular 
context. All the advances, Chambon suggested, “marked the beginning of a new phase where we 
can foresee the day when eukaryotic developmental problems will be elucidated at the molecular 
level.”63
While gene transfer in mammalian cells was still seen as ‘black magic’,64  experiments that aimed 
to adapt bacterial transformation protocols to tissue culture were gaining traction. In 1973, the 
Canadian microbiologist Frank Graham had published a paper with Alex van der Eb, whose lab in 
Leiden he was visiting, in which they developed a method of transferring purified herpes simplex 
virus (HSV) DNA using calcium phosphate and salmon sperm DNA. In April 1977, Graham pub-
lished further work on inserting isolated fragments of the herpes virus with the thymidine kinase 
(tk) gene into human cells in PNAS.65 A month later, a similar paper from Richard Axel’s group at 
Columbia University appeared in Cell, refining the method somewhat.66  As a brief review in Na-
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ture suggested in 1977, “it may eventually become feasible to use the HSV model for DNA-mediated 
gene transfer.”67 In the late 1970s plasmid carrying the tk gene became a vector of choice.
The use of HSV tk relied on the older work on gene transfer from the early 1970s, as it was one of 
the first genes whose phenotype could be easily detected in cell culture by the ability to grow on 
specific media such as HAT. The transition of HSV tk from a sign of viral infection was represen-
tative of a broader instrumental shift towards using plasmids made with restriction enzymes to 
ask questions previously addressed by infection research. Similarly, SV40 DNA was being rou-
tinely isolated and inserted into plasmids, as one of the first materials of interest to recombinant 
researchers. New means of detecting and assaying for the tk gene were being developed,68 and it 
was shared widely. Moreover, as purified DNA was increasingly accessible, a new network of dis-
cussions was constructed around its use in higher organisms.
Designed to foster communication between diﬀerent fields, conferences on gene transfer helped 
elaborate new questions, and their proceedings, increasingly published through rapid photo-
printing, document the attempts to give some coherence to the ‘cutting edge’. A major meeting 
dedicated to ‘Genetic interaction and gene transfer’ took place in 1977 at the Brookhaven National 
Laboratory. Its convenors claimed the objective was to “collect information, scattered in diﬀerent 
disciplines in biology, pertaining to how functional genetic material could be eﬃciently trans-
ferred to a eukaryotic cell, maintained in a stable state and expressed in a regular manner.”69 The 
audience was diverse: Beatrice Mintz talked about using teratocarcinoma cells as vehicles for for-
eign genes; Frank Ruddle about chromosome-mediated gene transfer; John Gurdon about nuclear 
transfer as a way of introducing new genes into frogs. Plasmids, viruses, gene expression of 
eukaryotic genes in bacteria and bacterial genes in cultured mammalian cells were all discussed. 
The diversity of agendas was not easy to organise. The final talk by the respondent, Charles Tho-
mas from Harvard, was instead devoted to the public discussion of genetic engineering.70  Titled 
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‘The fanciful future of gene transfer experiments’, it attacked the confused discussion of ‘genetic 
engineering’ in the press, claiming its perceived hazards were “totally conjectural”. In practice, 
however, Thomas’ piece engaged heavily with the scientist-critics of genetic engineering such as 
Salvador Luria or Robert Sinsheimer, as well as some science journalists. The message was to 
avoid exciting public distrust through conjectures and science fiction and focus on pressing con-
cerns. Thomas believed gene therapy, a major theme in these earlier debates, was not feasible for 
the majority of hereditary disease. Instead, he emphasised the practical concerns of economic 
advance and the growth of knowledge: producing useful proteins in cells and understanding the 
developing organism, and by extension cancer that he argued was a developmental programme 
gone awry.  
Even though the scientists involved had expressed diverse views about regulating recombinant 
molecules, the pressures of compliance and a sense of urgency contributed to constructing a 
community that was often made up from diverse research programmes. The emphasis on com-
munication was repeatedly used to create new spaces for exchange. In 1977, a Gordon research 
conference on ‘Introducing macromolecules into eukaryotic cells’ was proposed, with the first 
meeting held in 1980.71 The Gordon Research Conferences were a series of elite scientific meetings 
in New Hampshire started in 1932 by the chemist Neil Gordon under the aegis of the American 
Association for the Advancement of Science. By 1970, they had turned into a wide web of special-
ised events spanning the academic summer. These meetings became prestigious, a networking 
space where the trends in biology could be discussed and created.72 Each conference was limited 
to about 100 delegates, no records were published and note-taking was discouraged.73  Prominent 
scientists, including Berg and Ruddle, backed the proposal to have a dedicated meeting on intro-
ducing macromolecules into eukaryotic cells. Its author, Martin Rechsteiner, associate professor 
of biology at the University of Utah, stressed the need for wider communication and argued that 
“the conference [would] draw individuals from the diverse disciplines of lipid biochemistry, 
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genetics, cell biology, and nucleic acid chemistry. At present, there is simply no forum in which 
these individuals can meet and exchange ideas.”74 
In May 1979, a major Wistar Institute workshop on ‘Introducing Macromolecules into Viable 
Mammalian Cells’ took place in Philadelphia, a few months after the NIH significantly relaxed its 
recombinant DNA guidelines. Representing the state of the art, the focus was on the new ap-
proaches to gene transfer in mammals, especially recombinant techniques. The papers encom-
passed several approaches. The established calcium phosphate method was presented by its in-
ventor Frank Graham. Microinjection of molecules was discussed by several scientists whose 
laboratories were experimenting with the technique. Attempts to use membrane components to 
deliver DNA were also communicated.  
Despite the concerns expressed in the Gordon conference application, the extent of existing col-
laboration between researchers at the cutting edge was evident in the Wistar papers. Cell lines, 
virus fragments and increasingly plasmids were being shared and acknowledged in publications. 
Richard Axel, Saul Silverstein and Michael Wigler were especially generous with their material, 
sharing the herpes virus fragments with the tk gene and the cells widely among the Wistar pre-
senters. Moreover, with Tom Maniatis, Axel’s group was advertising a new means of introducing 
any gene into mammalian cells, based on the tk selection. If a plasmid could be made that carried 
the gene of interest and HSV tk, the transformed cells could be selected straightforwardly on HAT 
medium or with drugs that specifically targeted the viral protein.75  
Alongside this wide sharing, Columbia was also filing a patent on the co-transformation tech-
nique developed by Axel’s group. The Columbia patent proved to be extremely lucrative, bringing 
around $790 million in over through its lifetime.76 The first of what came to be known as the ‘Axel 
patents’ were filed on the cusp of a major transformation in the debates on patenting federally-
funded research, just after the Bayh-Dole Act was passed in 1980 but before it came into force in 
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1981. The Bayh-Dole Act, initiated during Jimmy Carter's administration but seen to eﬀect by Rea-
gan's, was a product of the US government's anxieties about the future of US economy and the 
decline in traditional manufacturing. It was hoped that it would encourage the rise of a 
knowledge-intensive economy and so reinforce the US position in the global marketplace – a hope 
for which the nascent biotech industry was a poster-child.77
The wide sharing and promotion of the cotransformation technique in the academic community 
was not in immediate conflict with the patenting attempts and indeed was generating a market 
for them. Even if the application was controversial in some circles, it was much less so than the 
Cohen-Boyer application, and the commercial viability was uncertain, at least according to the 
scientists' recollections. In fact, by the time the patent was granted in 1983, the technique was 
widely used both in industry and university research, which enabled Columbia to charge royalties 
retroactively. This ability to use mammalian cells brought recombinant methods further in line 
with the growing interest in eukaryotic genes and their products, including potential drugs like 
insulin and interferon, as well as molecules implicated in genetic disease, most notably haemo-
globin. 
With the expansion of recombinant DNA techniques to mammalian cells, the amount of research-
ers who could benefit from the rapid techniques and circulating genes moved beyond the ex-
panded laboratories. New experiments could be envisioned, and several high-profile reports of 
modifying mouse and human somatic cells were made in 1980. As the next section will demon-
strate, this expanded circulation and communication also included scientists who were consider-
ing transferring genes into mouse embryos. While Jaenisch and Mintz’s work had shown that mo-
lecular intervention into the mouse embryo was feasible, it was the growing circulation of plas-
mids, easier methods for detecting foreign DNA and assaying expression, success with somatic 
cells and new communication arenas that encouraged several groups to attempt genetic engineer-
ing in the mouse. 
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Conclusion  
The story of “genetic engineering” in the 1970s – both as a controversy and as a loose set of scien-
tific research programmes – goes far beyond the now ‘classic’ experiments in bacteria or debates 
over public safety and regulation. Activities at the margins drew many high-profile followers, and 
integrated older research traditions with new techniques. Thus, the work of Beatrice Mintz and 
Rudolf Jaenisch that would become a common reference point for the actors’ histories and citation 
pattern on transgenic mice, predated recombinant technology. However, such research projects 
benefited greatly from the emergence of simpler, adaptable and dramatically mobile techniques 
that allowed the experiments to become more eﬃcient. 
One of the crucial eﬀects of recombinant research was the making of exchange networks and the 
expanded communication between institutions. Access to these networks was not necessarily ex-
clusive – the likes of Berg or Axel shared with colleagues from unestablished laboratories. Yet it 
was limited by both the proximity to the key sites where recombinant work was done, and by the 
economic and political costs of proceeding with such experiments in a safe manner. As Rudolf 
Jaenisch’s 1970s career shows, a location at the crossroads of people, techniques and information 
could be extremely productive for someone eager to engage with cutting-edge methods and per-
form experiments that aimed to answer ambitious questions. 
In the emergent field of recombinant research, sharing was a paramount impetus that allowed 
specific methods to disseminate widely, and their inventor to receive credit. However, these ex-
changes happened in a competitive field and an extremely unstable climate for experimentation. 
The possibility of federal regulation was successfully avoided by the scientific lobby, and was in 
many ways transitory. Other longer-term changes were more pertinent to the practices of circula-
tion. First, the standards of what counted as a legitimate means of circulating knowledge were 
relaxed somewhat, as experimental results were discussed widely before formal publication (see 
alsoChapter 4), and journalists became heavily engaged with recombinant debates and received 
easy access to most regulatory and scientific meetings. Second, the rise of the commercial prom-
ise of genetic engineering introduced a new form of distributing credit: the patent application. 
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While patenting university research had not been unheard of before the 1970s, it was largely ab-
sent from molecular biology. With the slow growth of federal funding in the 1970s, coupled with 
institutional and government impetus to secure private patronage for biomedicine, intellectual 
property was being firmly introduced on campus. 
As I have shown, intellectual property concerns did not necessarily aﬀect the circulation of mate-
rials between academic sites in the early days, but they did introduce a whole other series of con-
siderations when conducting research, as well as opening up new opportunities for molecular 
biologists. In this context, ideas and methods for gene transfer into eukaryotic cells were becom-
ing articulated more readily, and new alliances were being made across disciplines and subdisci-
plines, increasingly defined in terms of experimental methods and held together by distinct shar-
ing networks. Such alliances enabled ambitious the experiments that ultimately yielded trans-
genic mice.  
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Chapter 3. Putting genes into mice: Promises, experimental trajectories and expertise
Between 1980 and 1981, six groups published articles claiming that foreign DNA could be injected 
into a mouse embryo and persist through development. The papers relied on similar methods: 
direct microinjection of DNA solution into a fertilised mouse egg at the one-cell stage. However, as 
all participants have agreed, the results were achieved independently, with one exception in 
which techniques were learned directly from another group. These mice were thus a multiple in-
vention – something Robert Merton believed to be routine in scientific research and a prime site 
for investigating the functioning of scientific norms.1 With the decline of the Mertonian norm-
centred programme of sociology and the constructionist and practical “turns” in history of sci-
ence, multiple discoveries have mostly slipped out of focus. The social mechanisms behind set-
tling priority received some attention in the 1980s,2 and I will address the assignment of credit in 
Chapter 4. Here, I am interested in the practical worlds of the multiple laboratories that worked 
on introducing DNA into mouse embryos, their traditions and diverse experimental expertise. 
While multiple inventions are assigned as such retrospectively, the question remains: how did 
very similar scientific programmes come to be pursued at multiple locations? What explains the 
scientific Zeitgeist?
As late as 1979 it was not at all clear that introducing DNA into a mouse would work in the near 
future, or indeed that it was necessarily a productive avenue to pursue. While the idea of a geneti-
cally modified mammal – or rather, various ideas – were floated in keynote lectures and discus-
sions, other ways of combining mammalian development with the techniques of molecular biol-
ogy received more attention. Despite the apparent homogeneity of methods and goals in the dry 
published accounts, the successful laboratories represented a diverse set of research traditions 
and experimental programmes. 
To some extent, the locations and timings of these experimental results were historical accidents. 
Yet there were certain ways of organising research and DNA exchange that were essential for 
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gene transfer into mice to work. Others pursued similar lines of research but did not generate 
comparable results – a useful point of comparison for conditions that made collaborations suc-
cessful. For the work to succeed, considerable expertise in working with mice and their embryos 
was essential. Some groups fulfilled these criteria by complementing their laboratory expertise by 
hiring postdocs; others managed to establish productive collaborations through well-managed 
divisions of labour. Moreover, plasmid exchanges and growing access to molecular tools made 
risky experiments with mouse embryos a possibility for those laboratories that could aﬀord 
speculative research. 
In addition, I will argue that a system of partial communication of unpublished results and specu-
lation about what was happening in other laboratories promised high rewards due to a sense of 
competition and the lack of a clear leader. Distance between sites played a doubly productive role. 
Rumours that others were attempting this kind of experiment pulled the cutting-edge project into 
the realm of the possible and made it an attractive avenue. At the same time, limited and uncon-
firmed knowledge about whether competitor laboratories had been successful meant that credit 
for modifying a mouse was up for grabs.
I begin by examining the discussions about making a genetically modified animal in the late 
1970s, which shared little consensus as to the right experiments to pursue. I will then examine the 
research programmes in laboratories that ended up reporting gene transfer into mouse eggs. In 
the second half of the chapter, I will focus on the experimental work that was done in these labo-
ratories, especially microinjection and the interaction between embryological and molecular 
work at the bench.
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§1. “Possibilities and realities”
The interest in... monsters is that they show how 
a culture handles the possible and marks its limits.3
François Jacob
A discussion of monsters and their role in delineating the future opened François Jacob’s lecture 
at the University of California, Berkeley in 1977. In a sweeping overview of recent biological  sci-
ences Jacob touched on the diﬀerent modes of inquiry and explanation, from magic to science; the 
hierarchy of scientific objects and therefore disciplines, from ‘hard’ physics to ‘complex’ social 
sciences; and the metaphors of evolution, at the heart of his argument that one best think about 
natural change as “tinkering” rather than design. At no point was genetic engineering mentioned, 
but the omission was rhetorical: the subject was constantly alluded to and flirted with, from the 
introduction devoted to monsters to a section on ‘molecular tinkering’. This lecture fit well within 
Jacob’s writing, known for its elegance and philosophical ambition, but it also resonated with the 
wider contemporary narratives of naturalising gene splicing, giving these experiments a long 
genealogy rooted not only in established human activities such as breeding, but also in the way 
nature itself worked. For Jacob, naturalising genetic tinkering meant that the scientific approach 
– which he couched as a mode of human understanding – was the best way of delineating the pos-
sible. 
The idea of introducing genetic changes into animals (including humans) had been at the fore-
front of ‘new biology’ discussions in the 1960s. Despite the focus on bacteria in the recombinant 
DNA controversy of the 1970s, the interest in using the new methods to manipulate animals and 
plants was strong. As I have shown in Chapter 2, in the 1970s the ability to manipulate eukaryotic 
genes in bacteria and eukaryotic cells attracted many scientists to recombinant DNA. The molecu-
lar promise also captivated a number of laboratories that sought to apply the power of genetics to 
diﬀerentiating embryos. These latter programmes often predated the expansion of recombinant 
DNA and relied on the burgeoning research into animal viruses, somatic cell genetics and the bio-
chemistry of proteins and nucleic acid.
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Given the political diﬃculties around genetic engineering, suggestions for potentially controver-
sial future research tended to no longer be aired in public. Scientific papers were rarely a place for 
speculation. However, writing that addressed expert audiences without a firm commitment to 
presenting experimental results – review articles, “trends” pieces, lectures and talks – did and 
discuss future experiments. These sources hint at multiple plans to harness recombinant DNA to 
modify animals in the late 1970s, even though the most promising routes were by no means set-
tled. By adopting the rhetoric of future directions, senior scientists shared their awareness of ex-
perimental work that was being pursued before publication, highlighted what they saw as 
worthwhile projects and made links between the possible and the real.
With the new techniques of somatic cell genetics and recombinant DNA, genes themselves be-
came instruments as well as subjects of molecular analysis. Early attempts to introduce nucleic 
acids into embryos, such as the Jaenisch-Mintz experiment, focused on viruses as a subject of in-
vestigation. Concurrently, John Gurdon was turning another kind of germ cell, the frog oocyte, 
into a powerhouse of molecular analysis. Celebrated for cloning Xenopus by transferring a nucleus 
from a tadpole cell into an enucleated egg in 1958, Gurdon articulated the need to understand gene 
regulation to decipher the mechanics of development.4  In the early 1970s, his Oxford group col-
laborated with Donald Brown at the Carnegie Department of Embryology to inject RNA molecules 
into oocytes – large egg cell precursors, around 1 mm in diameter, that could be easily cultured. In 
1971, Gurdon moved to the Laboratory of Molecular Biology (LMB) in Cambridge, where he ex-
tended his system to analyse DNA. 
With a strong emphasis on molecular thinking as a way to understand eukaryotic biology, Gurdon 
and his followers were representing the Xenopus oocyte as a simple system that resembled E.coli 
and could become attractive to molecular workers. Moving away from the discussions of embry-
onic complexity and determination common in developmental discourses, Gurdon repeatedly 
employed the metaphor of a test-tube to describe the oocyte (Fig. 3-1). In reviews and forward-
looking pieces, such as a 1977 “Future Trends” article in Trends in Biochemical Sciences, Gurdon and 
colleagues argued for the advantages that oocytes oﬀered over cell-free systems and bacteria, 
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claiming that the “crudest” system such as the living eukaryotic cell might also be best for detailed 
biochemical analyses.5 With the spread of DNA cloning, Xenopus oocytes were envisioned as a 
promising system to track the elusive promoters – DNA sequences upstream of a gene that control 
its expression: “One way of overcoming these problems [lack of promoter mutations and ade-
quate transcription assays] would be to combine methods of DNA cloning with the injection of 
DNA into oocyte nuclei.... The injection of these DNAs into oocytes should make it possible to 
identify which segment contains the promoter.”6 
Frog oocytes oﬀered a well-established system with large cells. By contrast, mammalian embryos 
had been notorious for their relative scarcity and small size that made detection of minute con-
centrations of molecules a challenge. Several mammalian embryologists with an interest in mo-
lecular questions, such as Mintz, Brinster and Gardner, experimented with teratocarcinoma cells, 
an alternative system that combined elements of cell culture and embryo-like behaviour.7 They 
were incorporated into existing practices of manipulating mouse embryos. In 1974, Ralph Brinster 
announced successful microinjection and subsequent incorporation of such cells into a mouse 
embryo, which he recently called the hardest experiment he had ever done.8 In 1975, Mintz’s and 
Gardner’s groups also reported incorporation of teratocarcinomas into a developing blastocyst 
and showed their contribution to adult tissues and reversal from a cancer-inducing phenotype.9 
The younger scientists who were involved with these experiments went on to become key names 
in mammalian development: Mintz’s postdoc Karl Illmensee, Gardner’s student Virginia Papaio-
annou as well as Martin Evans and Gail Martin, then at UCL, who went on to culture embryonic 
stem cells in 1981. Between 1975 and 1981, teratocarcinomas were promoted as a means of inte-
grating cellular approaches (such as somatic cell genetics) with embryology, by nobody as 
strongly as Mintz. 
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Mintz was receiving wider recognition in American biology, having been elected to the National 
Academy of Sciences in 1973. Her work on mosaic mouse embryos had been occasionally reported 
in the New York Times since the mid-1960s, and in 1976 it was included in a magnificently-
illustrated three-part feature on the ‘New Biology’ by the National Geographic.10  Like the other 
prominent scientists, however, Mintz balanced speculation with reality checks in her public ap-
pearances. She delivered a series of high-profile lectures in the late 1970s, many of them devoted 
to the problems of cancer, development and genetics. Thus, in 1976 she was among the Harvey 
lecturers at the New York Academy of Science and argued for the need to “seek ways of analyzing 
some of the most complex, and least understood, aspects of [cancer and diﬀerentiation] where 
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Fig. 3-1. “Xenopus oocyte Cadillac assembly line” – a drawing from Gurdon’s programmatic review in 
Trends in Biochemistry.
De Robertis et al 1977
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they actually occur: in vivo.”11 She suggested two wide ranging experimental programmes. One 
was to focus on the problem of malignancy, which she approached in decidedly developmental 
terms – whether tumours arose from one cell or many, which factors aﬀect their growth and dif-
ferentiation, and whether the key changes were genetic. The other approach sought to interrogate 
diﬀerentiation more generally by looking for new informative mutations:
Through mutagenesis and selection in vitro, followed by differentiation in vivo, experi-
mentally useful genes could be introduced into mice. There, the full developmental con-
sequences of specific gene mutations coding for biochemically identified changes could 
be brought to light.12
A year later, when addressing a specialist audience at the 1977 Brookhaven meeting on gene trans-
fer, Mintz made the point even more strongly: she referred to teratocarcinomas as “surrogate 
eggs”, cells that could integrate the whole-organism approach of classical genetics with the selec-
tion advantages oﬀered by somatic cell genetics. She specifically discouraged the use of mouse 
eggs as they were too few in number and impossible to select in culture, while other kinds of so-
matic cells could not contribute to the embryo since they were already diﬀerentiated and their 
genetic status was “usually uncertain”.13  By contrast, teratocarcinoma cells had the potential to 
fulfil these criteria, even though their genetic status, as cancerous cells that accumulated muta-
tions, was not exactly certain. Mintz’s talk at the Brookhaven meeting provoked many questions, 
including from Ruddle, and in the following years her lab focused on developing a teratocarci-
noma line that would be seen as genetically stable and could contribute to the germline in allo-
phenic mice.
Beyond these important meetings, Mintz’s growing clout exposed her to new audiences. In 1978, 
she was a go-to source for scientific comment in the aﬀair that unravelled around David Rorvik’s 
book In His Image that claimed a Californian millionaire had himself cloned in a remote jungle 
clinic on a South American island. Rorvik’s established medical publisher, J. B. Lippincott, mar-
keted the book as non-fiction based on Rorvik’s word and his supposed role as negotiator in the 
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murky process. The book was dismissed as a hoax by the scientific community, but it stirred a 
heated media debate about the possibility and ethics of human cloning.14  Mintz, alongside Clem-
ent Markert, Peter Hoppe and Derek Bromhall, was quoted in multiple sources commenting on 
inconsistencies in book and the state of the art in mammalian development, delivering some 
choice quotations to journalists, for instance when she described Rorvik as “a fraud and a 
jackass”.15 In May 1978 congressional hearings before the Subcommittee for Health and Environ-
ment of the US House of Representatives ensued. Designed to interrogate Rorvik, who failed to 
show up, they ended up focusing on the state of research and funding in cell biology. Testifying 
alongside such scientists as Markert, cloning pioneers and Fox Chase colleagues Thomas King and 
Robert Briggs, NIH oﬃcials and the omnipresent lobbyist and genetic engineering opponent Jer-
emy Rifkin, Mintz used the hearings as an opportunity to outline her work and to express anxiety 
about eﬀects of unsavoury public exposure on future funding.16  
Several conferences with ambitious titles encouraged their speakers to go beyond presenting the 
latest experiments. The 1978 Ciba Foundation London symposium on “Genetics and Human Biol-
ogy: Possibilities and Realities” was one such event. Sydney Brenner’s introductory remarks 
picked up Jacob’s 1977 lecture on monsters and tinkering. Referring to contemporary debates, 
Brenner argued that genetic engineering in the sense of designing an organism had not been de-
veloped. “All we can do is a little ‘tinkering’, but that, as François Jacob... has pointed out is na-
ture’s way and not ours.”17 Jacob was in the audience, alongside other luminaries of molecular bi-
ology, developmental biology and genetics, including Walter Bodmer, Francis Crick, Richard 
Gardner, John Gurdon, Henry Harris, Hilary Koprowski, James Neel, Guido Pontecorvo and Rud-
dle (Fig. 3-2). In the speculative atmosphere of the symposium, participants discussed papers on 
recent advances and possible futures in genetics, from cultural evolution to cancer. The sympo-
sium was dedicated to the retirement of Sir Gordon Wolstenholme, the Ciba Foundation’s director 
and chairman of the Genetic Manipulation Advisory Group (the British equivalent of RAC), which 
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explains its ambitious scope. Given the Ciba Foundation’s policy of publishing edited discussions 
as well as presented papers, the proceedings oﬀer a rare glimpse into the informal process of de-
lineating future possibilities by some of the biggest names in the field.18 
Charles Weissmann, a molecular biologist at the University of Zurich, presented a programme of 
what he called “reversed genetics”, a new way of asking questions by manipulating the DNA mole-
cules to introduce mutations and assess their eﬀects. The phrase was novel, even though discus-
sions about doing ‘genetics in reverse’ had been already aired.19 With the expanding availability of 
eukaryotic genes, ways to induce specific DNA mutations, DNA synthesis and new sequencing 
techniques, “reversed genetics” oﬀered an alternative to the workflow of classical genetics, which 
started from a mutation phenotype and then mapped the relevant genes. A lively discussion arose 
as to which experimental systems would be best suited for such an approach, as the attendees 
worked on a diverse group of laboratory species and cell-free systems. It is helpful to quote at 
length:
Gurdon: Professor Pontecorvo, do you prefer the use of a true in vitro system (test tubes) 
to the alternative in vivo cells (injected living cells)?  
Pontecorvo: Yes. It is a lot simpler. 
Crick: He is a reductionist! The thing is surely clear: one tries the simplest system first; it 
may be slightly artifactual so one checks it against different stages of in vivo or in vitro 
systems. There is no real conflict here. 
Brenner: This is simple molecular biology, but there is also the problem of assessing the 
value of genes that may have to work in entire organisms to produce their effects. Could 
you comment on the very long-term idea of putting genes back into organisms? 
Weissmann: I think that John Gurdon’s [oocyte and egg injection] system will eventually 
lend itself to this approach. It should be possible to do the injections in such a way that 
one ultimately gets development of the embryo and takes the inserted DNA through the 
complete cycle.20 
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Brenner described the idea of putting a gene into an organism as ‘long-term’, but Weissmann sug-
gested he was attempting just this kind of work with Hilary Koprowski at the Wistar institute, 
following the lines of the Jaenisch-Mintz experiment:
The other approach we are discussing with Dr. Koprowski is the injection of cloned DNA 
into mouse blastocysts... By introducing appropriate mutations at predetermined sites 
the functions of control and other regions of the DNA can be explored. It may be possi-
ble to get mice which are thymidine kinase-minus, add some selective pressure by 
dampening the in vivo synthesis of thymidine, and give the cells which carry the vector 
certain advantages. Thus, one might get most of the embryo populated with the DNA 
hybrid. Those are dreams at present. 
Henry Harris: I don’t really think they are dreams. People have got quite a long way with 
this kind of thing. David Martin has used mutant teratocarcinomas that are deficient in 
the gene for [HPRT]. The animal can be populated with the mutant HRPT— cells. It is not 
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Fig. 3-2. Frank Ruddle (centre) with Guido Pontecorvo (left) and Francis Crick (right) at the 1978 Ciba 
symposium on Genetics and Human Biology.
Guido Pontecorvo Archives, Glasgow University. Available through the Wellcome Library Codebreakers website. 
at all difficult to put a chromosome fragment bearing a good HRPT gene into such cells 
by cell fusion technique.21
The language of dreams and possibilities highlighted the interest in introducing genes into an 
animal, but stressed the diﬃculty of this scenario as an experimental programme. The tension 
between the possible and the existing reflected the perceived pace of change in biology, with 
hopes placed on new techniques, but also left open the exact way this might be pursued. It was 
revisited by Frank Ruddle after John Gurdon’s talk:
Ruddle: Your experimental system might be well-suited to studying the integration of for-
eign DNA into chromosomes and the propagation of integrated sequences through the 
developing organism. There is also the possibility of recovering integrated sequences in 
the germ plasm. Are you looking into this?
Gurdon: We are starting experiments on that but most of these things have technical 
difficulties.22 
The experiments with teratocarcinoma cells that Henry Harris referred to were a collaboration 
between Gail Martin and David Martin at UCSF, and Beatrice Mintz’s laboratory.23 Mintz hoped 
that once a mouse could be produced from the teratocarcinoma line in the mosaic “the animal 
would literally be the model of the human disease”, but her lab was still having problems making 
teratocarcinomas contribute to the germline. 24 Mintz was not at the Ciba symposium, and her 
work came from a diﬀerent research trajectory. If the questions among the geneticists at Ciba fo-
cused on the way to trace a gene through the developing embryo, Mintz was concerned much 
more with development and cancer, using genes as markers to track diﬀerentiation rather than a 
primary subject of investigation. 
While Mintz’s lab was a key site of teratocarcinoma research, others pursued this experimental 
system. Teratocarcinomas as a vehicle for genetic modification were being explored by Karl Ill-
mensee, who moved out of Mintz’s lab to work with Carlo Croce at the Wistar and subsequently 
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secured a permanent position at the University of Geneva in 1977. Today, Illmensee is most fa-
mous, or notorious, for the allegations of fraud surrounding his claims to have cloned three mice 
in 1981, but this controversy did not break until 1983.25  In the late 1970s, he was a rising star in 
developmental biology, garnering a reputation as a virtuoso experimentalist and a charismatic 
public speaker.26 With Croce, Illmensee hybridised teratocarcinoma cells with diﬀerent somatic 
lines, hoping to make a hybrid that would contribute to the developing embryo and perhaps in-
troduce novel mutations from somatic cell lines into the whole mouse. Moreover, Illmensee estab-
lished a collaboration with Peter Hoppe, a mouse embryologist at the Jackson lab, with whom he 
attempted making parthenogenetic eggs (eggs induced to begin development without fertilisa-
tion) and nuclear transfer – a programme of cloning in mammals. After a series of high-profile 
publications, mostly in PNAS, Illmensee was writing programmatic review papers and gave sev-
eral keynote lectures in 1980.27  These were devoted to genetic modification of the embryo – yet 
the methods he proposed were diverse, covering his cell hybrid work, parthenogenesis and nu-
clear transfer, and diﬀered significantly from those that proved successful.
In these discussions, recombinant DNA was not the primary tool for the job, nor had it always 
been entertained as relevant, even though it was being used in several locations. The extent of 
these attempts is hard to assess as few led to publication, but some can be traced. Howard Good-
man – famous for a conflict with Genentech over work on the insulin gene – applied to RAC in 
early 1980 to insert rat insulin DNA into a two-cell mouse embryo, even though no results came 
out of this project.28  Illmensee attempted to inject a plasmid containing the mouse beta globin 
gene into a mouse egg, in an experiment designed to distinguish between the native and foreign 
versions of the protein. However, such work was seen as a long shot, the protein from the plasmid 
could not be detected and the work was therefore never published, surviving only as a “personal 
communication” in a PhD thesis.29 
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Recombinant techniques were still novel and inaccessible to most developmental biologists but 
were met with interest as a promising new tool. A review in Developmental Biology published in 
1979 gives a good idea of the more obvious applications. The focus was decidedly on the new in-
formation about eukaryotic genomes and on isolating specific genes known to be involved in de-
velopmental phenomena. It also thematised gene regulation and its possible role in diﬀerentiation 
– a well-established molecular take on development by then – as well as the two families that were 
receiving much attention for their roles in disease and immune response: globins and immuno-
globulins. Even in its more speculative parts, however, the review did not raise the prospect of 
using isolated genes to modify an embryo. 
The overall focus was on understanding eukaryotic gene regulation in simpler systems: cultured 
cells or even as isolated molecules in vitro – practices much more consistent with the triumphant 
model of microbial molecular biology. As Tim Stewart, Mintz’s postdoc who ended up succeeding 
at injecting DNA into mouse eggs and then tracing those sequences in an adult mouse, pointed 
out,
Most of the DNA... transfectional work going on... was primarily focused on understand-
ing the relationship between gene structure and expression, as opposed to: what is the 
gene product doing in the context of the whole animal? And so when you think about, if 
that’s your motivation, trying to understand gene expression, it seemed like a hell of a lot 
of work for pretty modest pay-offs.
Despite conflicting ideas as to what genetic manipulation of the the mammalian embryo might 
look like, several laboratories simultaneously pursued experiments that involved microinjecting 
DNA into mouse egg. Discussions of possible uses crystallised around existing laboratory prac-
tices and agendas of individual researchers to become biological reality and a new entity. In the 
following section, I discuss the research programmes of the successful laboratories.    
§2. Research agendas
Genetic modification of a whole mouse, while entertained in increasing detail, was not a clearly 
articulated agenda in 1980, and prominent biologists relegated it into the realm of distant possi-
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bilities. However, in 1979–80, at least eight groups worked on introducing various forms of DNA 
into cultured mouse embryos at the one or two-cell stage, with six of them eventually reporting 
successful results. As I will show, these were mostly speculative projects pursued by postdocs or 
graduate students in well-funded laboratories that were integrating new molecular tools into 
their everyday practice. Most of these had secure funding, a certain level of prestige and access to 
the exchange networks of plasmids discussed in Chapter 2. These laboratories, mapped on Fig. 3-
3, pursued experimental programmes over a considerable disciplinary range. Here, I will review 
their agendas and focus on what made these local and collaborative enterprises the places where 
mice would be genetically modified. 
The NIH recombinant DNA regulations were relaxed in late 1978 and allowed wide-ranging work 
with eukaryotic DNA and cells, with even further scope permitted in 1980. Yet while the promise 
of genetic modification of mammals was being discussed, converting this into a research agenda 
was not straightforward. Various audiences had to be convinced that these experiments were 
worthwhile and fundable pursuits – a challenge given their speculative status. These projects 
therefore tended to be spin-oﬀs from already established grants on the more fundable strands of 
research– a practice known as ‘bootlegging’.30 Thus, Ralph Brinster at the University of Pennsyl-
vania felt that DNA injections into mouse embryos was ‘unfundable’, and instead built his success-
ful grant applications to both the NIH and the NSF around replicating John Gurdon’s experiments 
with mRNA in Xenopus. These RNA grants then bankrolled the DNA injection work.31 In Beatrice 
Mintz’s lab, the DNA injection was a sideline in the teratocarcinoma project. At Yale, Frank Ruddle 
relied on his generous somatic cell genetics grant from the National Institute of General Medical 
Sciences, and his large laboratory to assign first a graduate student and then a postdoc to the 
project.32 
While perfectly aware of the recombinant turn, Rudolf Jaenisch continued to work with viruses. 




32 Ruddle interview, McKusick 1984, Anon. 2013.
partment at the Heinrich Pette Institute, University of Hamburg, in 1977. There, he spent several 
years setting up a mouse facility and continued working on introducing viral DNA into the em-
bryo. Using the Moloney virus, Jaenisch and his students injected it into embryos at various 
stages: blastocyst, four-cell embryo and eventually a fertilised one-cell egg. Their questions cen-
tred on preferential viral gene expression in specific tissues and the eﬀect of an embryonic envi-
ronment on viral replication and activity. Despite reports from Hilary Koprowski at the Wistar 
that SV40 and the Moloney virus could be active in the embryo, Jaenisch could not replicate these 
results. Experimenting with infection at various stages in mouse development, Jaenisch adapted 
microinjection techniques to work on the newly-fertilised egg.33 Yet, despite powerful pro-
grammes focusing on animal viruses, with the expansion of DNA cloning viruses were becoming 
less attractive as a means of delivering genetic information into cells.
Not all experiments took place in established mouse labs. John Gurdon’s injection work on Xenopus 
continued in Cambridge, and one of his PhD students, Keith Willison, decided to pursue mouse 
embryos. Willison attempted to inject SV40 DNA into two-cell embryos and into blastocysts, with 
some results suggesting he could detect injected DNA in adult mice.34 Expertise in manipulating 
mouse embryos – not an animal used at the LMB – came from elsewhere: the Cambridge Anatomy 
and Genetics departments (notably from Martin Johnson and Martin Evans), as well as Willison’s 
relationship with Oxford embryologists. The overall inspiration and guidance came from Gurdon, 
but Willison obtained SV40 DNA and learned the latest methods of detecting and analysing it 
from Janet Mertz, who had moved to the LMB from Stanford. Mertz had been a graduate student 
of Paul Berg – her proposed experiments with SV40 genes had started the recombinant DNA con-
troversy in 1973. When she moved to Cambridge, she brought expertise from the cradle of recom-
binant research as well as the SV40 molecules that Gurdon’s group would use.35 
Towards the end of his PhD, an institutional contingency severely damaged Willison’s research – 
with no mouse facility at the LMB, he kept his animals at Addenbrooke’s Hospital, where the 
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whole colony was culled without any warning after a viral infection. Salvaging some results that 
he had collected and collating them into a thesis, Willison submitted in late 1978, with final cor-
rections approved in December 1979. By then, he had moved on to a postdoc at Cold Spring Harbor 
to learn the recombinant techniques and had set his mouse work aside.36  Rudolf Jaenisch cited his 
thesis in a 1981 paper (misattributing both the submission year and the institution where it was 
undertaken) but overall it was not easily available and any hints of results would only spread 
through word of mouth.37  While the culling of Willison’s mice was unpredictable and unfortu-
nate, it highlights the importance of solid infrastructure for speculative work. An institutional 
commitment to using the mouse as a laboratory organism, combined with local expertise from 
animal technicians and scientists was common to those laboratories that ended up publishing 
such experiments. 
Gurdon’s experiments on nucleic acid injections in Xenopus were an inspiration for mouse embry-
ologists beyond his laboratory. Since 1979, Ralph Brinster’s laboratory in the University of Penn-
sylvania Veterinary School in West Philadelphia was abuzz with work on manipulating mouse 
eggs, including injecting RNA and DNA. In a 1998 interview, Brinster recalled that the ultimate 
goal was to use purified DNA, readily available with the new gene cloning techniques, but that he 
started with RNAs as a more fundable project with precedent in other species.38  Like Mintz, Brin-
ster had adopted microinjection in the early 1970s to inject cells into blastocysts – another side-
project that he funded by using his embryo culture grants to purchase microinjection 
equipment.39  With postdocs Mary Avarbock, Howard Chen and Myrna Trumbauer, he developed 
the technique to work with the even smaller mouse eggs. 
While Brinster was an experienced embryologist with the capacity for honing micromanipulation 
techniques in his own laboratory, the purified nucleic acids came mostly from Gurdon’s collabora-
tors. Thus, the rabbit beta globin RNA came from Jerry Lingrel, a molecular biologist at the Uni-
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versity of Cincinnati.40 The second RNA was for a Xenopus 5S gene from another Gurdon collabo-
rator, Donald Brown.41  The HSV tk gene was a gift from Carlo Croce of the Wistar institute down 
the road. In 1979, after reading Paul Berg’s published a paper in Nature that described a viral con-
struct with the rabbit beta globin gene, Brinster requested a sample, which was provided in Sep-
tember 1979.42 
Finally, in autumn 1979, Brinster contacted Richard Palmiter, a biochemist at the University of 
Washington in Seattle, to secure ovalbumin RNA. This connection resulted in a long-term collabo-
ration, in which Palmiter supplied plasmids for the future gene transfer work.43 Brinster’s con-
nections and institutional position at a major university enabled him to benefit from the networks 
of exchange with molecular biologists, who had provided samples of nucleic acids that could be 
expanded into new systems. In January 1980, Brinster published a brief communication in Nature 
showing the successful translation of rabbit beta globin RNA in mouse eggs, while his group was 
working on injecting DNA and trying to trace its presence in adult mice at the same time.44
Only a short train ride from the University of Pennsylvania, in the suburb of Fox Chase, Mintz’s 
group carried on working with teratocarcinoma cells, although not in communication with Brin-
ster. In 1979, Mintz started a collaboration with Richard Axel’s laboratory at Columbia.45 Their 
work brought together expertise in culturing teratocarcinomas and gene transfer into mammal-
ian cells. Using a teratocarcinoma mutant line that lacked functional thymidine kinase, the re-
searchers inserted a plasmid containing the HSV tk gene combined with the human beta globin 
gene that had been purified by Maniatis, Axel’s collaborator and friend. The plasmid remained in 
Mintz’s laboratory and was used in new experiments.
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Quite how much anyone knew about what was going on in Mintz’s lab is an open question. Her 
teratocarcinoma research certainly put Mintz’s lab on the radar as a place where a genetically 
modified animal could soon be born. Her postdocs’ recollections refer to multiple conversations 
about possibilities and research plans.46 Apart from the sense of expectation from scientists in 
other labs that they recalled in interviews, this is evidenced by a letter from Paul Berg to the RAC 
that inquired about whole animals as hosts for recombinant experiments – something that had 
seemed like a fantastic possibility only a few years earlier. In the letter, Berg stressed the “tre-
mendous scientific and medical importance of such experiments”, and wrote: 
As you know the experimental ground work for [introducing recombinant DNA into 
whole animals] has already been provided by Dr. Beatrice Mintz's experiments. She has 
shown that teratocarcinoma cells grown in culture can be incorporated into mouse blas-
tocysts which ultimately can yield mice containing a variety of cell types derived from the 
teratocarcinoma cells. Using appropriate selections it is feasible to introduce exogenous 
DNAs (be they derived by recombinant techniques or otherwise) into such teratocarci-
noma cells and hence into animals.47
It was not just developmental biologists who pursued genetic modification of the mouse embryo. 
Two final research programmes I will discuss came from less expected trjectories. One was Frank 
Ruddle’s lab at Yale with a catholic focus on somatic cell genetics. The other was the result of a 
partnership between Peter Hoppe – a mouse embryologist at the Jackson Lab and Illmensee’s col-
laborator – and Thomas Wagner, a biochemist at Ohio University. 
Ruddle’s approach to somatic cell genetics went beyond traditional disciplinary divides that were 
increasingly irrelevant in the world of biomedicine. He ran a large laboratory of about 30 people 
and made eﬀorts to connect to diverse communities of practicing biologists. Ruddle’s extensive 
participation in academic networks combined with his secure institutional position allowed him 
to start multiple collaborations, and his eclectic approach brought many techniques to his lab. 
Ruddle’s laboratory was exploring chromosome-mediated gene transfer, and in pursuit of higher 
eﬃciency, he sought new means of incorporating genes into somatic cells. Learning of microin-
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jection from Elaine Diacumakos at Rockefeller University, who had worked extensively on honing 
the technique, Ruddle eagerly adopted the apparatus and introduced a microinjection room in his 
laboratory, with a NSF instrumentation grant and help from Clement Markert. The first publica-
tion from Ruddle’s laboratory that relied on the technique appeared in 1979.48
Despite multiple scientific commitments and co-authored papers, Ruddle’s main focus was on 
mapping human genes in somatic cells. Experiments with recombinant plasmids that he labelled 
DNA-mediated gene transfer oﬀered an even higher degree of resolution, as transferred genes 
could be radioactively detected on specific parts of the chromosomes. The injection of DNA into 
embryos, on the other hand, was a speculative experiment that Ruddle hoped could be useful for 
developmental studies. He applied to inject recombinant DNA into mouse embryos to the univer-
sity’s Biohazard Committee and received approval in March 1978.49 Initially, Ruddle assigned a 
graduate student to the project, with little success, and then decided to recruit a postdoc.50 This 
was Jon Gordon,51 a medical student in the MD-PhD programme at Yale who had just completed a 
thesis with Markert that relied on making chimeric mice. With much experience in microma-
nipulation and dealing with mice, Gordon was assigned to the embryo project and given much 
autonomy. 
The final group that worked with mouse eggs was the collaboration between Thomas Wagner at 
Ohio University (Fig. 3–4) and Peter Hoppe, a Jackson Lab-based developmental biologist. Wagner 
was a molecular biologist with a background in the physical chemistry of DNA who had set up 
Ohio’s Department of Molecular and Cell Biology in 1970. Wagner struggled to secure large-scale 
federal funding for his department, and despite the administration’s interest in building up its 
research programme, the university was at the periphery of molecular research. Wagner’s ex-
perimental focus was largely structural, but through friendship with Azim Surani, a developmen-
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tal biologist at the Animal Research Station in Cambridge, Wagner became interested in how DNA 
was regulated during development. In the late 1970s, he worked on mouse sperm DNA, and pub-
lished a series of papers on its structure. The sperm nucleus is extremely small and it had been 
recognised that sperm DNA was packaged much more tightly compared to other cells, and that it 
had a diﬀerent kind of protein in its chromatin. Through structural calculations and experimen-
tal analysis of sperm DNA, Wagner hypothesised that it had to contain breaks to fit the sperm nu-
cleus.
The notion of broken-up sperm DNA was unorthodox, and Wagner published his results in Ar-
chives of Andrology, an obscure journal unlikely to be read by molecular biologists.52  However, for 
Wagner, these results implied that sperm DNA had to undergo a series of repairs after fertilisa-
tion. At this point, he suggested it might be possible to introduce foreign DNA into the host ge-
nome. Wagner shared his thoughts with Hoppe on a taxi ride to the airport at a conference in 
Washington, D. C. By then, Hoppe had already been collaborating with Illmensee, and said he 
could carry out an injection into the male pronucleus. On his return, Wagner sent a rabbit beta 
globin plasmid that he had obtained from Richard Flavell in London via a postdoc and sent it to 
Jackson Lab for injection.53 
Most of the key participants above agree that their work was independent. A few expressed their 
suspicions about premature familiarity with unpublished data in interviews, but quickly pointed 
out they had no certain knowledge either way. The exact chronology of these projects thus poses a 
challenge. While the record of publications is clear, it is by no means a straightforward way to 
establish the timing of the work (see also Chapter 4). Without access to laboratory notebooks, it 
can only be extrapolated from ephemeral and circumstantial evidence. Ruddle initiated the ex-
periment after the NIH guidelines were relaxed in December 1978, and commented on the pre-
liminary results to Yale Daily News in April 1979, and had his research programme clearly adver-
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tised in the 1980 issue of GEIS.54 However, not all groups were as open about their research in 
progress. Recruitment of postdocs who performed the experimental work at Yale and Fox Chase 
oﬀers another bookend – most of them joined in 1978–79. The sequence of Fox Chase scientific 
reports shows that Mintz had not listed the egg project as of September 1980, and whether it had 
been attempted before is unclear. Brinster reported some preliminary success with DNA injection 
in a note added in proof to one of his RNA papers that appeared in print in January 1981, a few 
months after Ruddle announced his group’s success.55
However, it is worth remembering that uncertainty about the exact experiments in progress was 
a condition that other scientists faced. The idea that such work was happening elsewhere, while 
the credit was yet to be allocated, was a motivation to go forward and it created a sense of compe-
tition. Rumours circulated about what other labs were doing. As Tim Stewart, then Mintz’s post-
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Fig. 3-4. Thomas Wagner at Ohio University, circa 1985. 
Courtesy of Thomas Wagner.
doc, noted, “it’s always been very hard to keep secrets, people talk about what they’re doing, peo-
ple are excited about what they’re doing and they don’t want to keep it a secret”.56 On the other 
hand, no oﬃcially published claims had been made and the experiments remained a prize worth 
pursuing, even if the risk was high for junior scientists. The experimental procedures were time-
consuming and uncertain to yield results and therefore publications. The next two sections will 
focus on the laboratory practices of microinjection and molecular analysis, and how they were 
brought together and synchronised in these diverse laboratories. 
§3. Mastering microinjection
The expansion of developmental biology as a coherent supra-disciplinary identity has been asso-
ciated with the expansion of communication between embryology and molecular biology in con-
ferences, textbooks and courses. But synthesis of experimental practices was less straightfor-
ward. In a few labs, a hybrid way of practicing developmental biology emerged in the 1960s and 
1970s. The most famous hybrid practices were devised by molecular biologists moving to work 
with embryos, such as Sydney Brenner with C. elegans or François Jacob and mouse teratocarci-
noma cells.57 John Gurdon, a molecularly inclined zoologist, was another notable example whose 
move to the LMB further embedded his work in a molecular context. However, such synthetic ap-
proaches to what Gurdon called “molecular embryology” were not the rule. In all laboratories that 
worked on gene transfer into mouse embryos, there was a division of labour between molecular 
biologists and embryologists, and the latter disciplinary identity was consistently used in inter-
views rather than the cumbersome “developmental biologist”. In this section, I will focus on the 
key embryological technique that made mouse transformation possible, microinjection of DNA 
into a fertilised egg, and then in the next section compare it with the techniques of molecular 
analysis. 
Microinjection is a form of microsurgery or ‘micrurgy’, an instrumental tradition established in 
biological research since the turn of the twentieth century. First widely employed in bacteriology 
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to isolate single cells, microsurgical procedures relied on micromanipulators – instruments that 
converted the manipulation of screws, knobs or joy-sticks into minute three-dimensional move-
ments of capillary needles or pipettes.58 The first commercially available micromanipulators were 
devised in the 1930s. By the 1960s Leitz models dominated the biological market.59  Embryologists 
had been using micromanipulators since their early days, as did cell biologists. If much early mi-
croscopic work in experimental embryology, notably in Spemann’s laboratory, was done by un-
aided hand, nuclear transfer experiments relied on careful micromanipulation, as did the new 
methods of producing mouse chimeras by blastocyst injection.60 Teh-Ping Lin’s work on microin-
jecting mouse eggs made it into key handbooks, but had little productive use in the 1970s. Scien-
tists at the key sites of making chimeric mice were adept at microinjecting blastocysts: Mintz’s, 
Brinster’s and Gardner’s laboratories had integrated the technique into their everyday practices. 
Beyond the embryological tradition, micromanipulation was used by cell biologists mostly to 
study the eﬀects of removing specific organelles and even chromosomes. Thus, Elaine Diacu-
makos at Rockefeller University and Adolf Graessman’s group at the Free University in West Ber-
lin pursued the technique with limited communication beyond their immediate colleagues. How-
ever, through growing interest in cell manipulation – encouraged by the expansion of somatic cell 
genetics – these techniques attracted several geneticists. Thus, both Frank Ruddle and the gene 
therapy pioneer French Anderson approached Diacumakos to learn her methods, and microinjec-
tion became a potential tool for gene transfer into eukaryotic cells in the late 1970s.61 
Microinjection experts emphasised its attractiveness from two angles. On the one hand, they 
highlighted simplicity and utility for molecular biology, arguing that the procedure could turn a 
cell into a test-tube. The cell-as-test-tube metaphor was used in reviews from the Gurdon and 
Graessman groups.62 At the same time, the virtues of working with “natural” cells, free of arte-
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facts, were extolled, with implication that the method could conquer eukaryotic complexity.63  
Thus, when addressing a mixed scientific audience interested in gene transfer, Diacumakos 
moved away from the test-tube metaphor and suggested instead that:
Another disadvantage [of microinjection], which is only superficial, is that “quick and 
dirty experiments” are not doable. The design of experiments using this approach must 
therefore be defined and clear-cut... This is not the type of activity that someone with no 
knowledge of cell biology can perform and interpret accurately...
[T]his is an approach that should be considered seriously, for the cell is not merely a test 
tube, in the hands of a good cell biologist; the cell itself can become a laboratory.64
The craft-like nature of micromanipulation was stressed routinely in contemporary accounts and 
in recollections. Karl Illmensee’s remarkable experiments and his growing reputation in devel-
opmental circles relied on his perceived “golden hands”. In 1979, the eminent geneticist James 
Crow was quoted saying “Karl Illmensee has the embryological equivalent of a green thumb. He 
actually does the experiments everyone else talks about.”65 
In the labs that decided to microinject plasmid DNA into mouse eggs in-house, this practical ex-
pertise was carried by the postdocs who performed the experiments. The experimental design 
appeared straightforward enough: DNA was to be injected into a pronucleus, with the egg subse-
quently implanted into the oviduct of a surrogate mouse. Yet for both Gordon and Stewart, at-
tempting such a speculative project was a career risk. As postdocs without secure prospects, de-
spite being placed in highly-respected laboratories, they required publications of impressive re-
sults to secure a permanent position. As Gordon recalls, 
In Frank [Ruddle]’s lab, the atmosphere was that this was more or less a speculative ef-
fort. A lot of big-time labs were unable to do it, I mean, Beatrice Mintz, it’s a big time 
lab... so I don’t think a lot of people felt that it was very likely I would do it, and I told 
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63 See e.g. McKinnel 1978: 118: “Certainly, one of the virtues of the [Xenopus oocyte] test system is that it is natu-
ral. A nucleus is asked how it will perform in a milieu of normal and unmutilated cytoplasm.”
64 Diacumakos 1979: 97–8.
65 Anon. 1979. On the other hand, Mintz was reportedly rather critical of Illmensee in private conversations once 
he had left Fox Chase. The golden hands argument later was pivotal to Illmensee’s defence in the face of fraud 
allegations about his nuclear transfer work – Kolata 1998. On micromanipulation and mammalian embryology, 
see also Franklin 2007a, 2013.
Frank that, I said ‘Hey, look, I need a back-up project. I’m on a postdoc here, what if this 
isn’t possible? Can I map a gene?’66
Similarly, Stewart said: 
When I got there I knew that Bea [Mintz] had been writing grants, talking about this. 
There was a lot of scepticism and I remember talking to one of the postdocs at Fox 
Chase and I think there might have been scepticism outside the institution. Can you ac-
tually do it? – and even if you could, how much value are you really going to get out of 
this? [...] getting [DNA] into an embryo and then having that embryo survive the trauma 
of this manipulation and to get a whole animal out of it was considered a long shot.67
The decision to work with a one-cell fertilised egg was not obvious. The mouse egg had been seen 
as diﬃcult. Much like the rabbit embryo was once elevated over other mammals as a ‘robust’ sub-
ject of manipulation, stages in egg development were not created equal. Thus, in John Gurdon’s 
Xenopus work, the oocyte – precursor of egg – was characterised as the robust cell, whereas the 
freshly fertilised egg was seen as extremely fragile until it approached its first division.68 Though 
Elaine Diacumakos stressed that her work showed the somatic nucleus to be much more robust 
than previously thought and able to withstand injection, it was a diﬀerent matter to make the ex-
periments work in another lab and with a diﬀerent type of cell.69 
Moreover, for mammalian development, the two-cell block was an important concern: whereas 
eggs at the two-cell stage could be forced to develop to blastocyst and then implanted into the 
uterus, eggs extracted just after fertilisation would only divide once in vitro and degrade. Methods 
had been developed to overcome the two-cell block, particularly by Biggers, Whitten and David 
Whittingham, either by adding oviduct extracts or by changing the culture medium.70  Still, the 
phenomenon itself remained somewhat mysterious, with suggestions that it was aﬀected by the 




68 “In general, oocytes are very much more tolerant to injection than fertilized eggs, which are best injected at the 
2-cell stage”, Willison 1980.
69 Diacumakos, et al. 1970; stressed in Diacumakos 1979.
70 Whittingham & Biggers 1967, Whitten & Biggers 1968. See also Biggers 1987, Biggers 1998.
bryological experiments did not require complete culture. This concern about the two-cell block 
led Keith Willison to inject mouse eggs at the two-cell stage, as well as at the blastocyst. Gordon 
also attempted two-cell injections, with little success. 
Existing techniques were being reinvented from scratch, and many avenues led nowhere. Part of 
the problem was that the criteria of a successful experiment were by no means agreed, because 
nobody expected that most injected eggs would survive the process and indeed have detectable 
DNA in the end. Contamination could not be ruled out straightforwardly, even with control ex-
periments. Issues of eﬃciency were also at stake because selection was not an option, in contrast 
to cells culture experiments. Thus, multiple eggs had to be injected in one go, which required 
making the procedure routine and keeping the timeframe of embryo transfer as brief as possible 
to avoid the two-cell block – a technique Gordon and Stewart both settled on independently. They 
cultured multiple eggs and injected them in series, sucking each egg with a holding pipette. Willi-
son came up with a technical innovation, adapting a Nylon grid to keep the eggs in order – a 
method that never spread, probably because his thesis remained largely unread.   
Microinjection was thus a fraught procedure that relied on embodied skill. Adapting local instru-
ments, developing ways of focusing the optics and arranging the pipettes to achieve best results, 
as well as training the eye to tell when a pronucleus was pierced and successfully filled with the 
DNA solution all took time and eﬀort, and the skill set was not easily portable (Fig. 3-5). It is un-
certain how many other labs attempted similar experiments, beyond Illmensee, Lin and Diacu-
makos. However, success in the enterprise did not rely solely on injection skills or the persever-
ance of dedicated postdocs working long hours. It was also crucial that experimenters had access 
to DNA to inject as well as means of tracing it once the embryos were transferred into surrogate 
mothers. This relied on a synthesis of molecular and developmental practices, for which there 
were many possible arrangements. In the next section, I will focus on these means of combining 
embryological and molecular skills.
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§4. Recruiting molecular expertise 
Many people were thinking about development in molecular terms and envisioning experiments 
that could help interpret gene expression, but combining molecular and developmental practices 
was diﬃcult. While some molecular laboratories had embraced a synthesis of both approaches in 
the late 1960s, there was still a sharp division of labour and identities, even in spaces that encour-
aged interdisciplinary research. The laboratories that developed microinjection into mouse eggs 
combined these kinds of expertise in several distinct ways, which were crucial to their success. 
First, getting hold of genes that could be injected and detected in the mouse embryo was still not 
entirely straightforward in 1980. A lab either had to have a recombinant DNA research pro-
gramme in its vicinity, furnished with appropriate containment facilities, or it had to access the 
plasmids exchange networks discussed in Chapter 2 (Fig. 3-6). Second, once the DNA was injected, 
it had to be followed through in the adult embryo and tested for expression. The techniques for 
these procedures were established and increasingly routine in molecular laboratories, but not yet 
standardised or widely disseminated beyond the core molecular community. Finally, to be certain 
of the potential positive results, proper methods of visualising and publishing the data had to be 
followed.  
For Mintz and Ruddle, access to plasmids was straightforward. Both had collaborated with Rich-
ard Axel and Saul Silverstein at Columbia – Mintz working on teratocarcinomas and Ruddle on 
chromosome-mediated gene transfer.71  Mintz’s laboratory used the dual HSV-tk/beta globin con-
struct. In Ruddle’s laboratory, Diane Plotkin and Jim Barbosa were working on culturing and 
modifying the Columbia HSV-tk plasmid. Moreover, Ruddle’s Yale colleague Bill Summers had es-
tablished tests for the expression of HSV tk. The gene had been used widely in selection experi-
ments, while the globin genes were among the first to be cloned for their relevance to heritable 
blood diseases. These DNA constructs were chosen not for their value in answering developmen-
tal questions, but simply because they were available and readily detectable.
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Brinster had been securing DNAs and RNAs from a variety of high-profile American scientists for 
his experiments, from Donald Brown to Paul Berg. However, as his programme of microinjection 
was expanding, he first collaborated with Carlo Croce at the Wistar, and eventually settled on a 
long-term relationship with Richard Palmiter at the University of Washington in Seattle, who had 
been sending him ovalbumin, metallothionein and HSV tk DNA. Even though Palmiter had to go to 
Strasbourg to perform his first recombinant experiments with ovalbumin, by 1980 the University 
of Washington established proper containment facilities and Palmiter could produce enough DNA 
to ship. Thomas Wagner’s access to a plasmid was less straightforward. His laboratory was not at 
the time pursuing gene splicing and plasmids could not be easily obtained on the margins of the 
East and West Coast exchange networks. Luckily, one of Wagner’s students, Christine Schuma-
cher, was moving on to a postdoc with Richard A. Flavell at the National Institute for Medical Re-
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Fig. 3-5. Photomicrograph of an egg being microinjected. The egg is kept in place by a holding pipette 
on the left, with the smaller micropipette piercing a pronucleus on the right. 
T. Wagner et al 1981. 
© PNAS
search in the London suburb of Mill Hill. Flavell was one of the first biologists to clone the rabbit 
beta globin gene, which circulated alongside the Maniatis construct. On Wagner’s request, Chris-
tine Schumacher sent the DNA to Ohio in the post, and Wagner started a collaboration with Joseph 
Jollick, a biochemist at Ohio University with expertise in recombinant methods.  
Analysis of the experiments required a more committed interaction. Collaborations that com-
bined expertise of diﬀerent laboratories were a common strategy, but both Ruddle and Mintz 
sought to expand on using molecular techniques that fitted their research agendas. As primary 
investigators in highly regarded laboratories, the most straightforward way to gain practical ex-
pertise was to recruit expert associates. In 1979, Ruddle hired George Scangos, a microbiologist 
trained in E. coli genetics at the University of Massachusetts. In Ruddle’s lab, Scangos worked on 
DNA-mediated gene transfer into somatic cells, as well as doing some work on analysing the mole-
cules in experiments. In June 1979, Erwin Wagner (no relation of Thomas Wagner) joined Mintz’s 
lab. A molecular biologist with some experience in researching development, Wagner had been 
trained in animal virus genetics in Munich. During his doctoral work, he visited Francois Jacob’s 
lab at the Institut Pasteur were he encountered teratocarcinomas. As Wagner recalls, a strict divi-
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Fig. 3-6. Molecular networks: sources of recombinant DNA in 
the mouse gene transfer experiments
sion of labour was imposed in Mintz’s laboratory, and his collaboration with Stewart’s oocyte in-
jections (and learning the associated embryological techniques) had to happen on the side.72  
By contrast, both Brinster and Thomas Wagner established long-distance collaborations. Wagner 
worked with Jollick on molecular analyses and immunological tests in attempts to detect rabbit 
beta globin, using the mice made by Peter Hoppe at the Jackson Lab. Brinster’s collaboration was 
more long-term: Palmiter was attracted by the new project and once the results turned promising, 
abandoned most of his earlier work on ovalbumin. In 1981, a two-way postal relationship emerged 
between Seattle and Philadelphia. Brinster would receive the DNA, inject it in his laboratory and 
send the samples back to Seattle for analysis – an arrangement that persisted throughout the 
1980s and was made routine. Coordinating the molecular and developmental aspects of the work 
was carried out in regular Saturday phone conversations. In fact, Brinster and Palmiter had not 
met in person until just before the publication of their first paper in November 1981 (Fig. 3-7). 
Once the relationship was stable, Brinster’s lab would conduct the injections, take liver, spleen or 
tail samples from the resulting mice and send them to Seattle in SDS, a chemical that denatured 
the tissues for analysis. Palmiter would then post the DNA analysis results back. FedEx thus be-
came an extension of the laboratory.73 
The first products of these analyses were usually Southern or dot-hybridisation blots (Fig. 3-8). 
The former allowed to determine the size of cut DNA fragments to further confirm identity, the 
latter gave a yes-or-no answer to the presence of the tested DNA. Since their early dissemination, 
Southern blots had become the standard in analysing specific DNA, replacing the cumbersome cot 
curves, and were becoming a publication standard in molecular biology. These images were also 
the first indication that microinjection worked and the foreign genes could be detected in the 
newborn mice. They did not provide any certainty as to whether the genes integrated into the 
mouse genome or persisted as extra-chromosomal elements. Unlike cot curves, these analyses 
could also be straightforwardly applied to a large number of samples, in line with overcoming the 
problems of eﬃciency in microinjection. Scangos and Gordon analysed 78 newborn mice, born 
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73 Brinster & Arechaga 1998, Brinster 2013, Palmiter interview, Hanahan, Wagner & Palmiter 2007.
after several hundred embryos had been injected and transplanted into surrogate mothers. The 
newborn mice were killed and homogenised and the resulting blended mix analysed. Of these, 
only two (no. 48 and 73) showed the foreign HSV tk sequences on Southern blots – luckily, since 
after a beer to celebrate the first positive result, Ruddle sent the pair to look at more blots to see if 
they could confirm the result. Similarly, Stewart and Erwin Wagner analysed 33 surviving foe-
tuses, of which five responded positively to the test.
In the accounts of the technique and actors’ recollections about this work, microinjection re-
ceived the greatest focus as the diﬃcult technique that had to be figured out. By contrast, molecu-
lar methods are often taken for granted and were seen as straightforward. They had been settled 
to some extent. Southern blotting, DNA cloning and purification were becoming common, but the 
techniques had not been codified yet. These molecular tools, however, became routine during the 
1980s, while microinjection remained a laborious process, and it is likely that these accounts re-
sponded to this configuration. Yet much local variation and personal knowledge were involved in 
114
Fig. 3-7. Richard Palmiter (left) and Ralph Brinster, meeting in person for the first time in
November 1981.
From Hanahan, Wagner & Palmiter 2007.
making molecular methods work, too.74 But the emphasis on the diﬃculty of the embryo re-
mained an important story in the field, one that had to be actively challenged as transgenic mice 
propagated through courses (see chapter 5). In these experiments, molecules circulated between 
sites of injection, and molecular representations such as Southern blot photographs were key evi-
dence. With molecular techniques outsourced to either expert postdocs or outside institutions, 
molecular analysis received a stable image.
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Fig. 3-8: Visualising DNA. Above, Southern blots images from Gordon and Scangos’ analyses of two 
mice that carried the injected DNA after birth. Below, Tim Stewart and Erwin Wagner’s dot-blot hy-
brids for fetuses (F) and placentas (P) (their Southern blots were also published). These images were 
pasted together from multiple photographs. 
From Gordon et al 1980 and E. Wagner, Stewart & Mintz 1981. 
© PNAS
Conclusion
A genetically modified mouse had been envisioned and discussed for a long time, drawing on both 
existing experiments such as the Jaenisch-Mintz work and applications of new techniques. Het-
erogeneous approaches were pursued to integrate foreign genes into an animal, in laboratories on 
a broad disciplinary spectrum. The early success with microinjection happened in the few labora-
tories that combined specific molecular and developmental expertise, had the infrastructure to 
support large-scale mouse work and suﬃcient financial means to pursue a highly speculative and 
potentially “unfundable” endeavour. Multiple divisions of labour – between molecular and em-
bryological skills, between PIs and postdocs, occasionally geographically separated – were a com-
mon criterion of success.  
In the social studies of science, much has been made of the importance of proximity in making 
experiments travel and be replicated and the need for direct contact to transfer tacit knowledge 
that comes with experimental practice.75  However, distance was not necessarily an obstacle to be 
overcome, but could in itself be a productive resource. As Mario Biagioli points out in his study of 
Galileo’s strategies of securing credit, knowledge at large is “constituted through a range of 
distance-based partial perceptions”.76  In this case, the limited communication between laborato-
ries, the “grapevine” and speculations about what was going on in competing laboratories sus-
tained an interest in pursuing gene transfer into embryos as a promising and cutting-edge line of 
research. However, the partiality of communication maintained a diversity of local practices and 
fostered the attempts to keep trying. The few “failed” experiments that can be gleaned from the 
records, and the many more that one can only speculate about, never achieved the status of secure 
knowledge and remained rumours, leaving the horizon of possibility open and not discouraging 
scientists who also had to worry about advancing their academic positions. Thinking about multi-
ple discoveries therefore needs to involve the productive power of partial perceptions as a means 
of keeping the field open. 
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76 “I do not look at how a knowledge claim travels from A to B, but at how the transactions made possible by the 
fact that A and B are distant from each other allow for the production at such a knowledge claim.” Biagioli 2006: 
26. I thank Robin Scheffler for pointing me in this direction. 
Moreover, distance was recruited as a way of negotiating the distinct practices of molecular 
analysis and embryo manipulation. These laboratories avoided the synthetic programmes focus-
ing on compromise experimental objects, for instance the ultimately unproductive teratocarci-
noma system in Jacob’s lab.77  By maintaining the division of molecular and embryological labour 
in the early stages, either within the same laboratory or through postal contact, local problems 
and minute details involved in manipulation or DNA analysis could be resolved by the expert, 
whereas material objects were produced at the border with exchange in mind: plasmids, biopsies 
from resulting mice and molecular inscriptions, whether in the form of Southern blot images or 
otherwise. Though such arrangements had to be reconfigured to make transgenic mice a technol-
ogy that could be easily taught and disseminated, at the time of emergence of a new and as-yet 
untested set of methods the division of labour was a pragmatic way to legitimise these mice 
among distinct communities, as I will discuss in the next chapter.
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Chapter 4. Negotiating new mice: News, journals and priority
In 1980, several groups were pursuing similar strategies that relied on microinjection to intro-
duce new genes into mouse embryos, and they announced their successes within a short space of 
time (Table 4-1). There is still little consensus as to which experiment was first, with diﬀerent 
participants and commentators variously emphasising the achievement of one or another team. 
While none of the participants have publicly contested the succession of events and publications, 
and the key players I interviewed unanimously confirmed the independence of their work to the 
best of their knowledge, there is still no clear answer to the apparently innocent question, who 
invented transgenic mice?
Rudolf Jaenisch had refined the techniques for inserting viral DNA into later-stage mouse em-
bryos at the Salk Institute as early as 1976 and claimed that Moloney Murine Leukemia Virus (M-
MuLV) integrated into the mouse germline. His major interest, however, was not in inserting new 
genes into mice but in studying the activity of animal viruses and the eﬀects of embryonic devel-
opment on their function. The first announcement of inserting recombinant DNA into mouse em-
bryos came from Frank Ruddle’s lab at Yale in 1980, though the results were not immediately em-
braced by all of his colleagues. Many claims to dramatic biological experiments had been made 
and unmade before, so one lone announcement, even from a very prestigious group, was not 
enough to establish animal modification. 
Credit for multiple discoveries, or any discovery for that matter, is necessarily allocated after the 
event. In the historiography of science, the focus on social and retrospective allocation of credit 
was emphasised by the sociologist Augustine Brannigan in 1981, in line with the Strong Pro-
gramme in sociology of scientific knowledge.1  Many studies have followed in that key. Thus, des-
ignation of Gregor Mendel as the ‘unnoticed father’ of genetics has been analysed as a strategy to 
settle a potential priority dispute between the ‘rediscoverers’ of genetics in 1900.2  Similarly, the 




post-factum negotiations and allocation of credit in defining disciplines and making their origin 
stories, and the variety of publications, images and perspectives that are recruited in the process.3 
Many discovery accounts that have drawn historical attention were at various points controver-
sial, since controversies can force scientists to articulate tacit assumptions. Two prominent ex-
amples around the time when transgenic mice were being made are the discovery of HIV and the 
controversy over the patenting of monoclonal antibodies in the US.4  In both cases, there were 
highly public tensions between two camps with stakes beyond academic credit – the former dealt 
with a terrible pandemic, the latter pushed painful issues over the changing ways of benefitting 
from scientific work. The discussion over transgenic mice never reached comparable levels of 
animosity. None of the dissenting opinions that interviewees expressed 30 years after the events 
had appeared in print at the time. This was, in fact, a successful resolution of priority that was no 
resolution at all, leaving fluid allocation between laboratories with diﬀerent research agendas 
that were mostly secure in their funding and not in immediate competition in other areas.  
Still, work was done to register and communicate the experimental results. Some of this hap-
pened through the traditional medium of the peer-reviewed scientific paper, and a citation pat-
tern was established to reflect a consensus genealogy. Discussions of discovery narratives for 
monoclonal antibodies,5  citation analysis of the HIV debate or the controversy over lizard sex 
have focused almost exclusively on scientific papers. While informative, this focus conceals the 
variety of arenas where a discovery or invention may be negotiated. Case studies from Louis Pas-
teur’s public performances of vaccination to the media frenzy surrounding the first heart trans-
plants all highlight the utility of recruiting broad audiences in building successful careers and 
registering scientific or medical events as significant.6
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6 Bucchi 1998, Nathoo 2009. 
This chapter addresses the making of a new kind of laboratory animal in 1980–81, at a time when 
science-media relations in biomedical research were unstable and new avenues of communica-
tion became increasingly common and acceptable. The first section will focus on the announce-
ment of the Yale experiments and the media adaptations of the story. Rather than treating it as a 
narrative of genetic monsters, as would have been the case circa 1976, most reporters instead rep-
resented these mice as new wonders that carried medical promises. I then move to consider the 
interests and constraints that scientists had in promoting their work in the media alongside, and 
often before, journal publication, and what this meant for assigning priority. In the third section, I 
analyse the diﬀerent categories that the groups who followed Ruddle elaborated and sought to 
elevate in journal publications. Finally, in the fourth section I discuss the labelling of these new 
mice as ‘transgenic’, and the establishment of a set citation pattern that contained a narrative of 
the invention, though this could be used flexibly to emphasise some agendas over others. This 
fluid resolution of priority united the eﬀorts from diverse laboratories that had not been in im-
mediate competition into a new field, but it also excluded or downplayed other projects. The in-
clusions and exclusions were multi-sited, distributed across multiple locations and media, and 




Table 4-1. Major papers on gene transfer into mice, 1974–1981.
Authors Jour-nal Published Submitted Revised Announced Major claims
Jaenisch & 
Mintz 
(Salk Inst. & 
Fox Chase)
PNAS April 1974 13 Dec 1973 — —
SV40 virus injected into 
mouse embryo at blastocyst 
stage can be found in several 
tissues of resulting mice. No 
expression or germline trans-
mission. 
Jaenisch
(Salk Inst.) PNAS April 1976 26 Jan 1976 — —




Ruddle et al. 
(Yale)
PNAS Dec 1980 23 Sept 
1980
—
3 Sept 1980, 
New York 
Times
HSV tk gene detected in 2 
microinjected mice out of 79. 






Nature 15 Oct 
1981
13 Jul 1981 28 Aug 
1981
3 Sept 1980, 
New York 
Times







PNAS Aug 1981 13 May 1981 — 28 Aug 1980, 
Science
Human β-globin injected as 
well as HSV tk. Integration 
indicated. tk expressed. 
T. Wagner, 
Hoppe et al.










Rabbit β-globin successfully 







1981 20 Jul 1981
11 Sept 
1981
15 Nov 1981, 
Nature com-
ment




al. (U Penn 
& U Wash-
ington)
Cell 5 Nov 1981 4 Sept 1981
25 Sept 
1981 —
HSV tk strongly expressed 

















synthesis of existing papers. 
Germline transmission of HSV 
tk gene and human 
interferon. Integration 
strongly indicated. 
* Paper returned for extensive revisions after peer review – Marx 1981b, T. Wagner interview.
§1. Breaking the news
When Jon Gordon and George Scangos told Frank Ruddle about the results with mice, Ruddle was 
on his way to attend the Second International Congress on Cell Biology in West Berlin that ran 
through the first week of September 1980. He was scheduled to give a plenary lecture on the vari-
ous methods of gene transfer into cultured animal cells. The congress may have been described by 
the New Scientist as a ‘prosaic meeting on cell biology’, but was in fact a major event bringing to-
gether key scientists working in cytology, molecular biology and development.7 The sheer number 
of participants (almost 1800 abstracts were submitted) and the variety of topics covered by pres-
entations and workshops oﬀered a large-scale opportunity to communicate new research and 
capture cutting-edge work. According to the president’s address, such a meeting was “desirable in 
order to broaden our outlook and make us aware of stimulating and exciting new developments in 
neighbouring fields.” He expressed the hope that “the younger generation will have had their ho-
rizons extended, and that the older generation will appreciate that we all benefit far more than we 
sometimes tend to admit from personal contacts.”8  
Despite the wide scope of the talks, which ranged from chromosome structure to cell membrane 
components, the plenary lectures were devoted exclusively to molecular genetics and gene ma-
nipulation, preempting the focus on ‘molecular cell biology’ that would become the dominant way 
of conceptualising the field in the 1980s.9 Illmensee’s presentation focused on genetic manipula-
tion of the embryo via nuclear transfer or artificial parthenogenesis, while others gave talks on 
expressing eukaryotic genes in bacteria or the organisation of immunoglobulin genes. On 3 Sep-
tember, Ruddle gave his lecture on gene mapping by gene transfer in mammalian cells that mostly 
addressed the utility of cross-species cell hybrids and gene transfer into cultured mammalian 
cells. At the end, Ruddle briefly mentioned the new results on gene transfer into fertilised eggs. 
Yet this was the highlight of the talk, received with both excitement and doubt, as he recalls.10  
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10 Ruddle interview.
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Fig. 4-1. Front page, New York Times, 3 September 1980, A1. 
© New York Times
Image removed from the digital copy for copyright reasons. 
Ruddle did not limit his audience to the congress attendees. Before making the announcement, he 
phoned Harold Schmeck at The New York Times, who had covered scientific news for the paper 
since the 1960s. Ruddle had met Schmeck at the Jackson Lab course on mouse genetics, where 
journalists had been regularly invited for extended press conference sessions. Schmeck, who had 
been covering genetic engineering and cloning in the previous years, was eager to pursue the 
story. On 3 September, the same day Ruddle delivered his lecture in West Berlin, readers of The 
New York Times learned about the experiment from the front page.11  
The prominent position may be explained by the somewhat slow news day, as it sat next to the 
settlement of a Polish coal miner strike, an update on the senatorial race and a piece on the new 
police academy recruits being sworn in (Fig 4-1). In the following week, the news about the Yale 
experiment was picked up by major newspapers, magazines and science periodicals in the United 
States. Footage of mice – ordinary lab mice, not the genetically modified ones – appeared on na-
tional television alongside interviews with Ruddle and footage of Gordon performing microinjec-
tion. While Ruddle was in Berlin, Yale organised a press conference, putting the bemused Gordon 
and Scangos in a room full of journalists.12 A report of he press conference, distributed globally by 
Associated Press, seeded further news stories. 
As Gordon recalls in his 2003 book on the ethics of genetic modification and testing, 
When we first introduced genes into the mouse germline in 1980, much of the scientific 
community, as well as the popular press, were thunderstruck. Major articles announcing 
this development as a gigantic leap forward appeared on the front pages of leading 
newspapers and nationally circulated news magazines. Suddenly, as if out of nowhere, 
we stood at the threshold of a new era in genetics.13 
By contrast, in her account of early IVF in the United states, the science writer Robin Marantz 
Henig oﬀers an apparently contradictory view:
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Opponents of gene swapping at the 1975 Asilomar conference had said it might lead to 
exactly the kind of research that Gordon and Ruddle were doing five years later. Ironically, 
however, by the time the Yale investigators proved the critics right, nobody seemed to 
notice. Had their work received wider publicity, there might have been newspaper col-
umns in which career Cassandras warned that cross-species experimentation would lead 
to the creation of bizarre man-beasts reminiscent of H.G. Wells’ Island of Dr. Moreau.14 
In fact, both accounts shed some light on the events that took place. Gordon’s recollection is justi-
fied – their press conference did result in major coverage. Yet, even though Henig missed these 
stories, she does have a point in that the response to the Yale results was brief and largely framed 
as a breakthrough, even though they clearly subverted the often-aired claims that significant ap-
plications of recombinant DNA to animals (and therefore humans) were too fantastic and remote 
to entertain. The harsh debates about genetic engineering, so prominent in the mid-1970s when 
the tension between opposing viewpoints was often amplified by the press, were almost absent in 
this case, and certainly did not come anywhere near the contemporaneous discussions surround-
ing IVF, gene therapy or cloning. Nor did they recreate the earlier dramatic controversy about 
cross-species hybrids that followed Harris’s work on somatic cells. How, then, did media outlets 
report gene transfer into mice, and why was the reaction so mild? As the remainder of the chapter 
will argue, it was a combination of fortuitous timing, with a change in the way journalists were 
approaching genetic engineering stories, engagement with the press on the scientists’ part, and 
the apparent lack of other dubious elements such as commercial interests to fuel the story. 
§2. “A one-way trip to the Brave New World”?
In 1978, The New York Times established a pioneering dedicated Science Times section that coincided 
with the foundation of new glossy popular science magazines across the country.15 Partly driven 
by publishers’ increased interest in dramatic scientific stories as a potential source of revenue, 
and partly, as one editor put it, by “the Sputnik generation [being] now of magazine-buying age”.16  
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Schmeck had worked as the paper’s science writer since 1957, and wrote extensively on medical 
and biological research, including the recombinant DNA controversy.17 While he had mostly main-
tained the neutral tone characteristic of the paper’s editorial policy, there had been critical arti-
cles. Thus, in 1979, Schmeck voiced concern about the rushed and hyped-up clinical trials of inter-
feron, without solid clinical evidence for its eﬃciency, and then faced criticism from some scien-
tists and new biotech entrepreneurs who accused him of misleading the public and standing in 
the way of progress.18 
Despite this, Schmeck took a rather positive view of the Yale news. He described the work as “ex-
periments with profound implications for genetic research”, distinguished by their “success at 
altering an animal’s fundamental genetic composition”. The article hinted at the possible implica-
tions of the technique of transplanting genes: creating animals with new characteristics, and cur-
ing genetic disease. At the same time, while noting that genetic engineering was controversial and 
opposed by some groups, it firmly placed Ruddle group’s research within the realm of basic sci-
ence. Mapping mouse genes was stressed as the main purpose, and the article emphasised the 
uncertainty as to whether the foreign genes could have an eﬀect on the mouse, and whether they 
could be transmitted to oﬀspring. The balance between enthusiasm and caution was expressed in 
the two concluding quotations from Gordon and Ruddle. Ruddle said, “This is just the first step in 
a long-term project,” while Gordon emphasised, “The possibilities that this opens are so broad 
that it is hard to know where to begin”.
Other broadsheets and ‘quality’ news magazines largely followed Schmeck’s template. By the end 
of the following week, the Yale experiments had made it to the Medicine section of TIME maga-
zine, with the headline “Moving Towards Designer Genes.”19 The article also associated the devel-
opments with treating human genetic disease, and while voicing Ruddle’s reservations about the 
scientific potential of the technique, focused on potential extensions to humans, and the likely 
rekindling of the recombinant DNA controversy. Newsweek was the only news periodical to give 
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voice to dissenting comments, quoting Jeremy Rifkin, head of the Peoples [sic] Business Commis-
sion20  an activist on a long crusade against genetic engineering, “It’s a one-way trip to the Brave 
New World”.21 Despite this soundbite – not exactly an invitation to debate – the overall coverage 
was favourable. The Los Angeles Times placed the story in the context of a recent breach of NIH 
guidelines elsewhere and went so far as to suggest that “[t]he scientists’ caution about the impli-
cations of DNA work may be spurred in part by a desire to allay public concerns about danger 
from the research.”22
These very concerns likely encouraged Ruddle to engage with the press and attempt to set the 
tone for the news stories. The media frenzy that had accompanied discussions of recombinant 
DNA since Asilomar, and the risk of federal regulation beyond the NIH guidelines made scientists 
appreciate the risks to their day-to-day work more, and take public relations seriously. While 
Ruddle’s laboratory was not immediately involved with recombinant DNA research and only 
started using the methods routinely in 1978–79, as head of the Biology Department and its Biohaz-
ards Committee, he had overseen the local implementation of the guidelines and had been in-
volved in campus debates on genetic engineering at Yale.23
Similarly, the major periodicals that had been perceived to matter, as evidenced by being selected 
by the Yale news-clipping service, were convinced that inserting genes into mice would not make 
monsters.24 Indeed, while Ruddle, Gordon and Scangos were careful to stress the uncertainty of 
any medical applications, the references to gene therapy were prominent. Much like the other 
aspects of ‘new genetics’, gene therapy was moving from the domain of science fiction into tangi-
ble experiments and proposed trials.25 The language used in most publications about the Yale ex-
periments was strongly evocative of medical terms, perhaps echoing ‘microsurgery’ as a common 
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way to describe embryo manipulation. The genes were “transplanted” into mice, the process was 
“gene surgery” and an “operation” and Gordon was compared to a skilful surgeon and television 
footage spotlighted him at his microscope. Reporting medical news was a priority for newspapers, 
as it carried the human interest, and such use of language helped make the scientific narrative 
appealing to broad readership.26
It would be misleading , of course, to limit the analysis to elite periodicals like The New York Times. 
The New York Daily News, an established tabloid whose circulation at the time was only slightly 
below the Times,27 took a diﬀerent view. On 7 September, it ran an opinion piece from its science 
editor, headlined “Gene-Splicing: Will it Create a Monster?”.28 The article echoed the concerns 
about genetic engineering that were prominent in the mid-1970s, discussing the regulation of 
genetic engineering by drawing analogies with nuclear energy. The concern had been expected by 
the Yale scientists, and Gordon and Scangos addressed it in their press conference. A local Con-
necticut paper, The Hour, quoted Gordon as saying “I feel that we will always operate at a level be-
low creating a genetic monster”.29   
However, television evening news reports, reaching much wider audiences, took their cue from 
The New York Times. On 4 September, the day after the announcement, the NBC correspondent, 
Robert Bazell, stressed that it was not clear whether these experiments would lead to new forms 
of life, but hailed them as a “big step” in genetics. The report featured a brief interview with Rud-
dle, who said, “My own feeling is that knowledge is neither good nor evil”, implying that how this 
invention would be used was not a relevant question when pursuing basic research.30  A week 
later, ABC News featured the Yale experiment in their final instalment of an investigative report 
on genetic engineering. Setting the meaning of this work against the concerns about creating new 
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life, the piece ends with the position of the scientists who claimed it would bring new knowledge 
about human genes in an animal – using the mouse as a test-tube, as Ruddle put it.31 
The news seemed to make little impact in Europe. In the UK, it was picked up only by the New Sci-
entist, where science writer Stephanie Yanchinski argued that the Yale mice were anything but 
mundane, in a piece provocatively titled ‘Opening the Pandora’s Box of Biology’ – another common 
metaphor in genetic engineering writing.32  The opening sentence did not disappoint: “Three Yale 
scientists have teased open the lid of the Pandora’s box of assembly-line human beings.” However, 
in what followed Yanchinski oﬀered an eloquent account that described the experiment in a lot 
more detail than other publications had done, particularly emphasising Gordon’s virtuoso skills as 
a microsurgical manipulator. The rest of the article speculated about potential uses of microinjec-
tion in human gene therapy. Yanchinski placed it alongside the iconic IVF advance of Robert Ed-
wards and Patrick Steptoe, and the article was, in fact, illustrated with a photo of Louise Brown, 
the first ‘test-tube baby’ born in July 1978. In the conclusion, Yanchinski argued that combining 
the two techniques could “fundamentally alter human genetics”, and that both experiments might 
be “the start of something big”. 
In contrast to the journalism in science periodicals, editorial opinion often aimed to preserve the 
authority of scientific institutions. A Nature editorial by John Maddox took the opportunity to at-
tack outspoken critics of science: 
One of the hopes, perhaps unrealistic, of this new decade was that the arguments about 
the hazards of this or that new scientific development would be couched in more mod-
erate language than used to be the fashion in the 1970s... Messrs Jeremy Rifkin and Dan 
Smith, described as directors of the [Peoples Business] commission, say that the devel-
opment represents “the greatest potential technological threat to the sanctity of life 
since the beginning of human history”...33
Maddox went on to dismiss Rifkin as a “diligent reader of The New York Times” unfamiliar with the 
scientific literature, and suggested that everyone wait for a publication. Around 1980, the moder-
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ate language that Maddox urged was becoming commonplace for genetic engineering. Since the 
late 1970s, coverage of biotechnology was increasingly couched in the language of progress and 
promise at a time of political and economic uncertainty. This trend was recognised at the time and 
has been documented in retrospective analyses of the US press.34  In her award-winning 1980 arti-
cle, ‘The Gene Craze’, the science studies scholar Rae Goodell observed the shift from debates 
about the possible health risks of recombinant DNA and the moral implications of genetic engi-
neering to a celebration of a new form of enterprise.35 She argued that scientists and the emerg-
ing biotech industry were strongly behind this change, with eminent scientists and bodies includ-
ing the National Academy of Sciences lobbying Congress to prevent federal regulation. Moreover, 
the industry, convinced that there was a new market to explore after announcements about suc-
cessful synthesis of human somatostatin and insulin in bacteria, brought expertise in public rela-
tions into the mix.  
Echoing Maddox, Goodell also argued that science writers were exhausted with the polarised de-
bate framework: 
Tired of the fading, repetitive congressional battle, and plagued by the Three Mile Island, 
test tube babies, and a number of the other complex controversies, science writers were 
ready for a good, clean science story, and industrial announcement of new DNA discov-
eries provided it.36 
As the controversy over the regulation of recombinant DNA was reported as solved, and the vol-
untary moratorium praised as an unprecedented act of social responsibility, the dissenting opin-
ions were disappearing from news reports, with even left-wing American periodicals such as 
Mother Jones, The Progressive and New Times ignoring press releases from the Peoples Business 
Commission. That the change aﬀected most general periodicals can be explained by Sharon Dun-
woody’s concept of an ‘inner club’ of science journalism. Dunwoody argued that most science 
writers routinely discussed topics among themselves and relied on mutual exchange of expertise, 
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leading to a rather uniform landscape of reporting. Scientists formed the vast majority of sources, 
and were rarely criticised or undermined.37
While Goodell’s account seems to pinpoint the key changes in the late 1970s, it is worth noting that 
the landscape was more diverse. First, many senior science journalists were increasingly uncom-
fortable with what they viewed as excessively sensational coverage of the recombinant DNA con-
troversy. This sentiment was expressed at a recorded roundtable organised and published by 
MIT’s Technology Review in March 1980.38  The framing of the conversation suggested that science 
writers had lost the ‘age of innocence’ that supposedly existed in the 1960s, and now had to seek 
balance in a world where science inspired both dramatic interest and strong opposition. ‘Break-
through’ was a dirty word, even if editors liked it, and writers knew that many promising reports 
had failed to deliver in the long run, especially when it came to pharmaceuticals. At the same 
time, most participants refused to see themselves as advocacy journalists and strongly contested 
Mother Jones’s Mark Dowie suggestion that more were needed in science writing. On recombinant 
DNA, the feeling was that the press had emphasised the “public’s right to know” and that the reso-
lution was satisfactory. The San Francisco Chronicle’s David Perlman suggested that the opposition 
between scientific viewpoints had developed to such a passionate degree where “the objective re-
alities that can be discerned in the laboratory have been forgotten,” but that at the end “partici-
pants and spectators finally reached a more rational level of compassion, so to speak.”39
Perhaps ironically, journalists writing for the news sections of scientific periodicals, particularly 
Science and Nature, were likelier to be critical of specific developments, as Yanchinski’s New Scien-
tist piece shows. For instance, Nicholas Wade, the news editor for Science, had maintained a criti-
cal balance over recombinant DNA. With William Broad, he co-authored Betrayers of the Truth, a 
book that unapologetically tackled the uncomfortable subject of scientific fraud when a series of 
high-profile whistle-blowing cases threw this into the limelight in the early 1980s.40  However, by 
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1980 other kinds of stories were drawing the critical attention: the seminal Supreme Court deci-
sion in Diamond v. Chakrabarty that allowed patenting of bacteria in June 1980; breaches of NIH 
guidelines; plans for direct involvement of universities such as Harvard in biotech business. A 
striking example was the backlash against Martin Cline’s attempts to extend his experiments with 
mouse somatic cells when he inserted recombinant globin genes into human blood marrow cells 
that were then transplanted to two patients suﬀering from beta-thalassaemia in Italy and Israel, 
only a month after Ruddle’s announcement.41 By contrast, the Yale experiments were framed as an 
academic advance with clear medical benefits, the mice predominantly described as genetic won-
ders rather than monsters. It is also worth remembering that the story, while receiving a remark-
able amount of coverage for a scientific experiment, lasted for only two weeks. 
Finally, the mice themselves were largely absent from view. Aside from the footage of laboratory 
mice in newsreels, only one image of a mouse featured in printed sources. Newsweek ran a story 
illustrated with a photograph featuring a cropped profile of Gordon at a microscope with micro-
manipulators, and in the centre, a white laboratory mouse (Fig. 4-2).42 This mouse, in the staged 
132
41 Jacobs 1980.
42 Begley & Carey 1980.
Fig. 4-2. “Gordon with subject” 
Newsweek, 22 September 1980. 
Photograph by Maggie Steber. 
Image removed from the digital copy for copyright reasons. 
photograph that was a product of discussion between the photographer, Maggie Steber, and Gor-
don, who wanted to make the mouse a ‘hero’ of the image,43 is atypical. The first batch of trans-
genic mice was homogenised, their DNA extracted and represented as bands on agarose gels. And 
while Newsweek and NBC featured footage of mice in the laboratory, these were not the specific 
‘heroes’ of the experiment but ordinary lab animals in fleeting shots. Instead, the attention was 
focused on the elaborate technique and images of microinjection that appeared on the blurry 
screen attached to the dissecting microscope. This displayed the mysterious process of embryo 
manipulation while hiding the gruesome fate of the animal subjects from public view. 
In December 1981, a New York Times piece by Schmeck suggested that “Biotechnology no longer 
provide[d] intense concern.”44 This observation may have been a reasonable reflection on the cov-
erage in major US newspapers, but according to NSF statistics public support for regulating ge-
netic engineering research remained high. In the 1981 poll, 50% of the respondents ‘attentive’ to 
scientific issues suggested some limits should be imposed on research into “creating new life 
forms”, only a 1% drop from 1979 figures. The same indicator among “potential attentives” in 1981 
was as high as 67%.45  The changes in reporting new experiments, including gene transfer into 
mice, were not following ‘public opinion’. To a large extent, they were a product of the changing 
relationship between science journalists and their sources, and the internal trends in mediating a 
controversy. 
§3. Journals and the politics of priority
Ruddle’s engagement with the press allowed him to keep some control over the coverage. While I 
do not suggest that he controlled publicity religiously – after all, he trusted two inexperienced 
postdocs to handle the media – by being seen as open and ready to comment, his group became the 
sole expert voice in the story. Aware of the work going on in Mintz’s and Brinster’s laboratories, 
Ruddle understandably wanted to secure priority:
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Well those people who were doing mouse work... it was a very big deal for them and, you 
know, we were talking about... Mintz and Brinster, and others. They had put a lot of work 
into doing transformation studies on the mouse and I think it was hard on them, be-
cause they had made such a big investment and to have someone like myself come from 
out of the blue, not having the same kind of experiences that they’ve had in the kind of 
work they were doing, I think... it was really difficult for them, but that’s science. And I’ve 
been in situations where I’ve been scooped and it’s been hard for me.46   
The press conference at Yale not only addressed the possible implications of inserting genes into 
mice, it also stressed that the group was at the cutting edge – as Gordon put it, “We're quite a bit 
ahead of other labs working in this area.”47 Having considered the coverage of the Yale experi-
ment, let us return to the circumstances of the announcement. What did it mean for a scientist to 
talk to the press about an unpublished scientific result in 1980? 
It might appear that in the middle of the twentieth century it was increasingly problematic for 
researchers to engage with the press and address the public directly. However, the sentiment is 
rather mythological, as recent studies show.48  Some respectable activities were beneficial for a 
senior scientist. Thus, Ruddle wrote detailed articles for Scientific American reviewing new fields 
of research for an educated readership interested in science.49  Established researchers often acted 
as experts on controversial matters and advocates of the scientific community, but those roles 
almost required rhetorical distancing from the ‘sensational’ press. This happened with Rorvik’s In 
His Image, discussed in Chapter 3. Derek Bromhall, an Oxford embryologist whose nuclear trans-
fer work had been mentioned in the book’s introduction, went as far as suing for libel.50 At the 
same time, Bromhall was happy to consult for The Boys from Brazil, a 1978 Hollywood film based on 
Ira Levin’s 1976 novel – a story remarkably similar to Rorvik’s, except it was about Joseph Mengele 
cloning Hitler in a jungle laboratory. Finally, advocates of recombinant DNA research were a ma-
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jor influence, and that controversy alerted an increasing number of scientists to the importance 
of engaging with the media.
This, however, was diﬀerent for new work. At the time, announcing scientific results to the press 
before publication could be questionable, and publicity-seeking was being associated with the 
new commercial context of biotechnology and the competition between companies to establish 
priority claims in a potential intellectual property dispute. It also appeared to challenge the estab-
lished system of peer review. Thus, an influential opinion piece in the New England Journal of 
Medicine titled “Gene Cloning by Press Conference”, was published only a few months before the 
Yale press conference. The author, Spyros Andreopoulos of the Stanford Medical Centre’s news 
bureau, highlighted the trend among the new biotech companies to announce the isolation of an 
important and commercially promising gene such as interferon before academic publishing, and 
lamented the circumvention of the traditional peer-review that “[did] not contribute to either 
good science, or good science reporting.”51
Scientific journals deemed themselves the only place where important new science should be an-
nounced, and were eager to discipline their authors and science journalists. Since the 1960s, the 
practice of ‘embargoes’ was established, whereby journals allowed writers early access to papers 
on condition that no coverage appeared before the journal article. Journal editors argued that this 
allowed journalists more time to write quality articles and at the same time enabled experts to 
consult the ‘proper’ publication as soon as the story broke in the news.52  Alternative communica-
tive trajectories were frowned upon. The 1976 guidelines for journal editors, compiled by some of 
the major figures in science publishing, left accepting papers based on experiments that had been 
previously announced elsewhere to the discretion of the editor, but advised against approval if 
“the circumstances suggest that the prior publication in a news medium was actively promoted by 
the author”. For the authors of the guidelines, “premature publications in the scientific or lay 
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news media of research findings that may not be scientifically valid... may therefore mislead and 
be harmful to society.”53 
The reluctance to allow double publication was commonly known as the ‘Ingelfinger rule’, after 
Franz J. Ingelfinger, the editor of the New England Journal of Medicine who had imposed it in 1969 
mainly to avoid double publication of the same findings in multiple journals.54 The rule was ex-
tended to press coverage in the late 1970s, but its application was never straightforward. As Vin-
cent Kiernan suggests, in the 1970s announcement at a conference was usually suﬃcient to con-
firm that the scientific community had learned about an experiment first.55 A February 1979 edi-
torial in OMNI, a lavishly printed new popular science and science fiction periodical co-founded 
by the publisher of Penthouse magazine, lambasted scientific journals’ presumed monopoly on 
disclosure.56  Referring to the allegations by the New York Post that the first IVF baby Louise Brown 
was a hoax, based on the fact that Patrick Steptoe announced the results to National Enquirer 
rather than a journal, OMNI’s Frank Kendig argued that journals were too slow and too specialised 
to announce new work, and while their caution with what they published was justified, they 
should not monopolise technical information.57 Similar opinions were voiced in a 1982 report on 
press coverage of science by the journal BioScience. It cited French Anderson, a public health 
authority and the head of communications for the American Association for the Advancement of 
Science, who all claimed that “the public’s right to know” trumped the danger of reporting shoddy 
or overblown research – a sentiment that made sense after Asilomar and with the growth in popu-
lar science publishing. 
Another dissenting view came from Eugene Garfield, the founder of the Institute of Scientific In-
formation and publisher of Current Contents, a lucrative abstracting and reprint-order service. In 
1973, he incorporated a Press Digest into Current Contents, which traced news stories in “popular 
magazines and newspapers that scientists should know about”. He viewed it as part of a “basic-
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science lobby” that would reverse the major funding cutbacks and sell academic science to the lay 
audience more eﬃciently. The editorial that launched the Digest was to the point: “Too many sci-
entists feel that ‘public relations’ is not only a waste of time, but also a kind of blasphemous mal-
practice alien to professionalism. Nothing could be further from the truth.”58 While Garfield may 
not have been the most popular figure in the scientific mainstream and his promotion of biblio-
metrics to assess scientific output disturbed many critics, his influence was considerable.59  His 
invitation to take the general press seriously in 1973 was vindicated by the recombinant DNA de-
bate that followed. In the light of critical interest directed at molecular biology in the mid-1970s, 
his suggestion at a 1976 conference on plasmids that newspapers were a legitimate way of enhanc-
ing science communication made more sense than even five years before: “While we would hope 
that journals like Science and Nature, and others of a weekly frequency, would make certain to re-
port [new scientific] information promptly, there can be no doubt that, at the present time, the 
only prompt outlet for such information of necessity is the New York Times and comparable publi-
cations elsewhere.”60 While the bold statement appeared at a relatively obscure meeting in 
Czechoslovakia where Garfield was advertising his products, he was backed by Esther Lederberg, 
Joshua Lederberg’s wife and collaborator who was promoting a plasmid repository she established 
at Stanford. 
Ruddle’s decision to communicate in advance of journal publication might have raised eyebrows, 
but it was not necessarily against the grain in an increasingly public world of biomedical re-
search. It could have been dangerous for a younger, less established scientist, but someone of 
Ruddle’s stature and reputation was unlikely to face problems, and a brief announcement at a ma-
jor conference suﬃced. Moreover, ‘cloning by press conference’ was not limited to biotech firms, 
and work with promises for gene therapy was especially public at that time. Thus, before contro-
versy broke over Cline’s clandestine human trials, his results with mice were well-promoted by 
UCLA – something Nicholas Wade and Gina Kolata retrospectively critiqued in Science once the 
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trial story broke.61  Moreover, similar publicity surrounded French Anderson’s work with Diacu-
makos on inserting the HSV tk gene into somatic mouse cells. The news broke after an announce-
ment at a conference in October 1979, before the paper was published in PNAS in September 1980, 
despite Anderson’s professed reluctance to speak to journalists on a deadline after his earlier tha-
lassaemia research had been blown out of proportion in the early 1970s.62
Priority was another major part of the De Bakey journal guidelines. Concerns about priority and 
credit have a long history, and various practices had been used to resolve possible disputes. Scien-
tific societies were often responsible for distributing credit: thus, the French Académie des Sci-
ences had encouraged sending discovery accounts in sealed envelopes that could be opened in 
case of dispute. The invention of the telephone is perhaps the most dramatic example, as Alexan-
der Graham Bell and Elisha Gray filed a patent for very similar devices on the same day, 14 Febru-
ary 1876.63  By the twentieth century, the journals had taken over in that role for university re-
search. The complexities of priority assignment were elaborated in a chapter from the same 1976 
guidelines that considered what dates were appropriate markers to serve “as an index of 
priority”.64 The chapter listed 14 options, ranging from the date of the original idea to the day 
when the journal issue reached its subscribers, via dates of a preprint being sent out, on the letter 
of submission, on the postmark, of firm acceptance, and others. Dates that could be firmly estab-
lished – of receipt of the manuscript, acceptance, receipt of revised version, actual publication – 
were preferred as easy to confirm and safeguarding the editor from getting involved in a dispute.
To safeguard their claim, the Yale group decided to publish the paper as soon as possible in PNAS. 
This was a reputable journal that required a member of the Academy to submit or “communicate” 
a paper, and there are indications that this means of assessing credibility meant the review proc-
ess could be more lax, and publication quicker – not a trivial consideration as waiting times were 
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growing, to universal discontent. As an active member of the Academy, Ruddle could submit the 
paper himself and negotiate speedy publication, so that it appeared in December.65 This timing 
was especially important, since Ruddle’s group was eager for the paper to appear before the end of 
the calendar year, so that the reference in subsequent papers would be “Gordon et al. 1980”, not 
1981.66  The decision was still equivocal among the authors – Diane Plotkin, named as a co-author 
for providing the DNA, was not convinced the results were suﬃciently solid to publish, and felt 
more work could be done. Gordon, on the other hand, was pressing to publish as soon as possible 
and establish priority.67 
An experienced network-builder, Ruddle was promoting the interests of his laboratory and took 
care to distribute the credit and recognition within his laboratory, allowing the postdocs who per-
formed the experiments to take centre stage. It might be tempting to dismiss Ruddle’s media work 
as an odd episode, and it was indeed the most high-profile in his distinguished career. However, 
with the next two papers on gene transfer into mouse embryos – from Mintz’ lab at the Fox Chase 
Institute for Cancer Research and Thomas Wagner’s at Ohio University – newspapers again acted 
as an alternative means of scientific communication.
The Mintz paper was the second published claim to support the possibility of gene transfer into 
mice through microinjection, and from another reputable – if very diﬀerently organised – labora-
tory. It also took the experiments further, showing that the foreign herpes virus tk gene was ex-
pressed and made viral protein, and indicating that the other injected gene – human beta globin – 
could have been making RNA. However, before it appeared in print, another manuscript that 
claimed expression of microinjected beta globin gene, this time from rabbit, had been submitted 
to PNAS. It came from the collaboration between Thomas Wagner’s lab at Ohio University and Pe-
ter Hoppe at the Jackson Lab. The manuscript had been sent to PNAS by the celebrated mouse ge-
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neticist and National Academy member Elizabeth Russell at the Jackson, a former collaborator of 
Mintz. 
The submission date printed on the Ohio/Jackson paper is 9 July 1981. However, at this point one 
might wish to remember the 14 kinds of dates that could be used for establishing priority that the 
informal guidelines for science journal editors mentioned. According to Wagner’s recollections, 
contemporary releases from Ohio University’s news service and a more recent book about its 
then-president, Charles Ping, the publication of Thomas Wagner’s paper was anything but 
straightforward. It was submitted to PNAS in February 1981, but delayed by a referee who, not un-
commonly, insisted further experiments be performed.68  The Ohio sources claim that the paper 
was scheduled to be published in September 1981, but once the editors learned that another 
“better-known lab”69 (i.e. Fox Chase) was about to publish, they decided to bump the Ohio paper to 
the October issue. However, the Mintz paper was published in August 1981, not September, and 
had been submitted to the journal in May.70
During the delay, Wagner learned that The New York Times was about to run an article that fea-
tured the Fox Chase results. This piece, again by Schmeck, appeared on 8 September and tried to 
integrate recent publications about gene transfer in embryos and somatic cells as a next step in 
the development of gene therapy, and involved a large image of microinjection acquired from 
Ruddle’s lab (Fig. 4-3).71 Thomas Wagner had been delaying communicating with the media until 
his paper was published, in line with the standard embargo practices. Crucially, however, Ohio 
University filed a patent application on 12 June that claimed priority over microinjection with 
predictable gene expression.72
The Ohio team was then partially funded by Genetic Engineering, Inc., a biotech start-up based in 
Denver, which would be the exclusive licensee. Patents on basic techniques such as pronuclear 
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microinjection were problematic, as epitomised by the much more controversial patent on mak-
ing recombinant DNA that was awarded to Stanley Cohen and Herbert Boyer in 1980, and caused 
much academic discontent.73 It also went to the core of what David Dickson, a Nature correspon-
dent, would call “the new politics of science”,74  as epitomised by the US Bayh-Dole Act passed in 
1980 to allow universities to patent the products of federally-funded research. While select uni-
versities had used multiple strategies to secure intellectual property since the early twentieth 
century, it normalised and disseminated these practices.75   
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Fig. 4-3. Microinjection in The New York Times. 
From Schmeck 1981b
Image removed from the digital copy for copyright reasons. 
On learning about the PNAS delay, Wagner appealed to Charles Ping, the president of Ohio Uni-
versity who had recruited him to set up the molecular biology department in 1969, in the hope of 
placing his institution on the international map of cutting-edge research. Ping contacted his old 
acquaintance (and former landlord) Philip Handler, then president of the National Academy of 
Science. As head of the academy, Handler had been a major administrative figure and advocate in 
the world of research.76 Handler did not aﬀect the publication date, but he did get in touch with 
The Washington Post’s veteran science writer, Victor Cohn.77  Probably in a competitive race with 
Schmeck, the Post published the piece on Wagner’s work on the same day as the New York Times’ 
Mintz-Ruddle story, 8 September 1981, that was followed by a major press conference in Athens, 
Ohio and follow-up stories in the US dailies (Fig. 4-4).78 
Cohn’s article liberally quoted Wagner, who stressed the potential for agricultural applications of 
the technique to breed farm animals – cattle as well as “goats or sheep or buﬀalo” – that would 
require less feed and be productive on lower diets. The focus was more in line with Genetic Engi-
neering Inc.’s commercial aspirations than Wagner’s scientific ambition, but it defined his re-
search through the 1980s. He also suggested that medical applications might be “further away”, 
and reiterated the value for “knowledge”. As Cohn paraphrased, “Work like this will give biolo-
gists a tool to look into one of nature’s greatest mysteries: how genes act or ‘express themselves’ 
inside cells, and how and when they are ‘turned on’ during an embryo's wondrous development.” 
Beside the discussion of future applications, the article stressed the novelty of the work: “The first 
successful transfer of a gene from one animal species to another – from rabbits to mice and then 
to their oﬀspring – has been achieved by biologists.”79 Cohn’s article mentioned the research done 
in Mintz’s lab, but stressed that their team only managed to insert the viral thymidine kinase gene 
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“at least into the fertilized egg of a female mouse.”80 Wagner’s results were presented as the “first” 
and “quite important”, according to Elizabeth Russell.
It can be seen that the politics of priority, brushed over in scientific journal publications, was be-
ing played out on the pages of important news sources, and that decisions about press releases 
and access to journalists were becoming an integral part of making discoveries public. This was 
especially important for the patent application. But for someone relatively unknown, it was also a 
risky strategy. Peter Hoppe would have nothing to do with his collaborator’s media outreach, and 
requested that the Jackson Lab public relations department ensure that his name was not men-
tioned before journal publication.81 
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Fig. 4-4. Rabbit genes.
Ohio University Archives; Chicago Tribune, 1981.
Image removed from the digital copy for copyright reasons. 
This episode demonstrates the diversity of media that could be recruited to establish priority, and 
shows that scientists could rely on newspapers to advance their causes. Moreover, it highlights 
the interest of science writers in publishing stories and claiming greater authority in the dis-
semination of scientific news, tied to the growing interest and opportunities in popular science 
publishing. It also indicates the roles played by university administrative oﬃces dealing with the 
press and intellectual property played that can only be glimpsed in the available sources. 
§4. Criteria of success
Despite the great interest and competitive spirit that surrounded the announcement of the Yale 
gene transfer, there were many uncertainties in the published paper. It was not clear whether the 
experiments could be replicated, or were even, simply, an artefact. Moreover, their utility to de-
velopmental research and gene mapping was not clear, and many alternative approaches were 
envisioned. This is exemplified by a news article in the December 1980 issue of Science, in which 
the journal’s reporter Jean Marx placed Ruddle’s work as a curious advance alongside many other 
manifestations of gene transfer, a field she had been following for several years. Similarly, French 
Anderson and Elaine Diacumakos placed much more emphasis on gene transfer into cultured so-
matic cells – their own pursuit – in their Scientific American article in the summer of 1981.82 
Yet with the competition and independent experimental work, the pressure to generate new re-
sults beyond what had been published was growing. When Mintz’ two postdocs – Tim Stewart and 
Erwin Wagner – arrived at their results, they pursued further experiments, partly to answer 
specific questions that were interesting to them, and partly to produce more evidence to justify a 
publication after Ruddle. By spring 1981, they had a stable means of injecting DNA into pronuclei, 
and managed to show that the HSV tk gene, which was on the same plasmid as the human beta 
globin, was expressed, and as both RNA and protein. Since Mintz was also a member of the Na-
tional Academy of Sciences, she submitted the paper to PNAS in May 1981. As in Ruddle’s case, ac-
cess to this publication enabled speedy review and the paper was published in August.83 It set up 
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the experiment as a successful part of a larger programme of inserting genes into mice, although 
the modification of teratocarcinoma cells remained her major ambition.
The authors acknowledged the Yale’s group recent success in transferring a foreign gene into a 
whole mouse, the first formal legitimation of this work in the journal circuit as a replication of 
sorts. However, other citation choices also stressed the existing expertise of the group and a long-
running commitment to inserting genes into embryos, starting with the 1974 Jaenisch & Mintz 
paper, and referencing Teh-Ping Lin as the source of the microinjection technique. Finally, the 
discussion section stressed their demonstration of the tk gene expression, implying that this made 
the technique meaningful:
Inasmuch as the ultimate objective of in vivo gene transfer is the study of gene regulation 
during development, it was important to learn whether the foreign genetic material in 
our developing mice could function in its new environment... 
The existence of the alpha-thalassemic mutation in mice presents a unique opportunity 
to extend this experimental system, with alpha-globin gene transfer, for the further analy-
sis in vivo of tissue-specific gene function in a hereditary disease.84
Yet despite clear progress in establishing gene expression, the criteria that many, including Rud-
dle, had raised as key to a useful mouse system remained to be met in full. These were the produc-
tion of proteins from the foreign genes and germline transmission – that is, the inheritance of the 
genes by the following generations.85  Wagner’s paper claimed both and featured a variety of data 
indicating the expression of the rabbit globin gene, but his results were treated with suspicion, 
especially as the other major labs could not demonstrate the presence of the globin protein. While 
a relationship with the press or commercial ties may have played a role, such treatment was more 
to do with the lack of an established reputation.
Another important concern in the early days of microinjection was the fate of the injected DNA. 
Gordon and Ruddle’s paper suggested that the DNA integrated into the mouse genome, yet their 
evidence was ambiguous. Some of the injected DNA was heavily rearranged and appeared to have 
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multiplied; this would become a commonly observed phenomenon. The existence of foreign DNA 
as a separate non-integrated molecule that propagated autonomously, or even contamination of 
samples with the plasmid, remained a possibility. Such concern was expressed explicitly in a pa-
per from Jaenisch’s group.
When Jaenisch secured a tenured position in Hamburg, his laboratory continued working on in-
serting viral DNA into embryos, and he adapted the microinjection techniques used for blasto-
cysts to fertilised mouse eggs. His results on injecting the Moloney virus were published shortly 
after Mintz’ and Thomas Wagner’s reports, in the October 15, 1981 issue of Nature.86  The paper in-
dicated the presence of the viral DNA and suggested its integration into the genome, but ex-
pressed caution as to the meaning of the results:
The data, however, were difficult to interpret with respect to the structure and origin of 
the recombinant DNA found in the newborns. We find a general problem in such ex-
periments – the possibility of plasmid contamination.87
While gene expression was presented by both the scientists and the press as a crucial means of 
demonstrating that gene transfer into whole animals was an eﬃcient and promising technique, 
germline transmission – the presence of the gene in subsequent generations – was a major desid-
eratum. Establishing strains in the lab that could be bred and exchanged was crucial to make pos-
sible all the applications mentioned in the papers, and would enable the novel animals to colonise 
further laboratories and recruit more researchers. Moreover, it had been established as an impor-
tant failure in much previous work. Jaenisch and Mintz’ mice born in 1974 did not transmit the 
SV40 virus to the oﬀspring, nor did the chimeras made from teratocarcinoma cells. Mintz’s work 
on developing a cell line that would contribute to the germline was the group’s parallel project, 
and the laboratory claimed such a line in 1981.88 However, the results could not be replicated and 
the original cells were lost. 
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The concern over the actual integration of foreign DNA in the process was also expressed more 
privately throughout the early days of gene transfer, among both the participating scientists and 
interested observers.89 Looking at conference ephemera shows some doubts about the categories 
firmly postulated in publications. For instance, following their initial announcement, Ruddle and 
Gordon presented at the 9th Congress of the International Society of Developmental Biologists in 
Basel, Switzerland, on 29 August–1 September 1981. Among many established developmental bi-
ologists, the congress was attended by Anne McLaren. Her notes in the margins suggest a less 
than wholehearted reception. Thus, in quotation marks there is a weaker claim that most likely 
came from the presenters: “[the plasmid] has at least interacted w[ith] mouse DNA”. But the notes 
conclude with what appears to be her reflection on the presentation, “Prob[abl]y not integr[ate]d. 
How can non-integr[ate]d material be maintained this long?”90 
Integration thus became an important issue that was resolved when germline transmission could 
be demonstrated. Again, while Thomas Wagner’s paper had claimed germline integration, it was a 
relatively minor point and it was not supported with Southern blot photographs that had become 
the standard method of visualising specific bits of DNA. By contrast, a paper published in Nature 
just over a month later, on 15 November 1981, revolved around the demonstration of germline in-
tegration, and recruited several modes of evidence.91  It was published by two postdoctoral re-
searchers at Oxford, Frank Costantini and Elizabeth Lacy. 
The couple had moved to Oxford from CalTech, where both were exposed to innovative work in 
molecular biology. Lacy had been a PhD student of Tom Maniatis and moved to CalTech with him. 
There, Costantini was working with Eric Davidson, an eminent developmental biologist who was 
elaborating molecular models of sea urchin development. After both completed their graduate 
studies, they were eager to move into developmental biology, and managed to secure a double 
postdoc at Chris Graham’s lab in Oxford’s Zoology Department. There, equipped with the purified 
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rabbit beta globin DNA from Maniatis’s lab, the couple learned the elaborate techniques of mouse 
embryology (Fig. 4-5). 
While trying to come up with a promising project, Lacy and Costantini were immersing them-
selves in the lively network of mammalian development in Oxford and Europe more generally. 
After Graham returned from the Cell Biology Congress in West Berlin where he had heard Rud-
dle’s paper, he encouraged them to pursue pronuclear microinjection. On their visit back to the 
USA for the Christmas holidays of 1980, Lacy and Costantini went to Yale, where Gordon taught 
them the technique, the couple thus becoming the first adopters of an uncertain but promising 
technology. Armed with expertise in molecular biology, their own source of DNA to work with, 
and growing competency in embryology, the two pursued gene transfer experiments.
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Fig. 4-5. Elizabeth Lacy in Chris Graham’s Oxford laboratory, 1982.
Courtesy of Frank Costantini.
Lacy and Costantini went to some length to maintain their genetically modified mice that they 
referred to as founders, and incorporated them into further genetic experiments. From about 100 
mice, 24 showed the rabbit globin DNA in their liver samples – a significant increase in eﬃciency 
of the procedure compared to Gordon’s 2–3 out of 70. However, in order to establish the strains of 
these animals, the couple went on to cross the ‘successful’ males with unmodified female mice of a 
diﬀerent strain. A fraction of the second-generation animals that were born as a result showed 
the rabbit gene, with even more copies than the first-generation parents. 
Lacy and Costantini reported these early results in a letter to Nature, which was submitted in July 
1981 and published in November.92 They invoked the familiar Mendelian ratios (“These fractions 
are: one out of four progeny for mice 4 and 23, two out of four for mouse 7, and two out of six for 
mouse 13.”93), even though the small sample size could not support a statistical analysis. They also 
highlighted the possibility of keeping the lines of animals with large inserts of foreign DNA, that 
could become a permanent resource to be bred and studied. The conclusion foregrounded what 
they saw as the next step in the gene transfer work and its key potential: the spatial and temporal 
exploration of specific gene expression in a living mammal, from conception to death:
With such strains of mice it will be possible to examine the expression of the rabbit beta 
globin gene and to investigate whether expression is restricted to specific tissues and/or 
developmental stages. If the rabbit sequences are integrated into mouse chromosomes, 
presumably different strains will contain the rabbit genes at different chromosomal loca-
tions. This will allow us to investigate how the host chromosomal environment influ-
ences the expression of a foreign gene.94
Finally, also in November 1981, a paper from the Brinster-Palmiter collaboration came out in 
Cell.95  The paper confidently claimed that the HSV tk gene was expressed strongly and predictably 
under the control of the metallothionein-1 promoter – a control DNA element that regulated ex-
pression and could be activated by injecting mice with heavy metal salts. Moreover, it proposed 
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likely underwent a series of duplications before being integrated. This publication marked the 
beginning of a series of highly successful experiments that Brinster and Palmiter would orches-
trate, and it oﬀered a hope of control over foreign genes, especially since Thomas Wagner’s claims 
were not taken seriously.  
This was not exactly the first publication from Brinster’s lab on the subject, though. A 1980 Nature 
paper had described the production of protein from RNA injected into embryo cytoplasm.96 A note 
added in proof to another RNA article in Science, published in January 1981, claimed that DNA in-
jection had been achieved with Carlo Croce at Wistar, without revealing further detail. In a 1998 
interview, Brinster said that his group had succeeded in inserting genes into mice by the end of 
1980, and that “[t]hese were tantalizing and encouraging results but certainly did not warrant 
publication.”97 The comment – rather transparently hinting at Ruddle’s haste – does, however, 
open up a question: what counted as publishable for these diﬀerent groups? 
For Ruddle, the experiment was an extension of a research programme aimed at gene mapping, 
and he expressed hopes that it could be used to study the sites where foreign genes integrate, and 
therefore to map mouse genes further. Expression and transmission were desirable criteria that 
the group went on to pursue, but the focus was mainly at the gene level. For Brinster and Mintz, 
the promise of developmental questions that the system could answer made tracing expression a 
key priority, as well as observing how genes could aﬀect the embryo or be used to trace lineage. 
Similarly, Thomas Wagner’s fascination may have lain in whether a foreign gene could integrate 
into the mouse genome based on his ideas about DNA repair after fertilisation, but his engage-
ment with a biotech company put a stress on demonstrating protein products. 
The need to publish novel results was a bigger pressure, as routine replications would not secure 
much credit. As a result, a range of experimental programmes were pursued to establish these 
unmet criteria. The overall eﬀect of these eﬀorts, and of the independent publications, was to es-
tablish the credibility and eﬃciency of the new technique. The multiple invention of the geneti-
cally modified mice not only reflected the general interest in such a project or the availability of 
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techniques and molecules to perform such work – it was also integral to turning claims into in-
ventions as reports from reputable labs confirmed Ruddle’s initial result. Revisiting Merton’s 
claim as to the ubiquity of multiple discoveries, the confirmation that they confer on experimen-
tal results should be thematised. Especially in a case where credit for such events is negotiated 
amicably, the social process of establishing a claim as a discovery or an invention is much more 
rapid and straightforward. In subsequent years, as a citation pattern was established and more 
dramatic results reported, transgenic mice were embraced by the laboratories who could aﬀord 
the funding, time and expertise to make them. In the process, the name and properties of these 
animals were defined. 
§5. “These mice, that we call transgenic”
Credit for discoveries and inventions is necessarily decided retrospectively, and can result in bit-
ter feuds about priority, but it can also be distributed between diﬀerent actors. I have shown the 
communication strategies employed in making such claims, which routinely involved popular 
science and general-interest media as well as traditional journals. As a result, certain exclusions 
did take place: Thomas Wagner was not a major part of the re-telling of the story either in its im-
mediate aftermath or later, and Jaenisch’s work was less prominent, though his older experiments 
with Mintz remained a common ‘precursor’. This final section will examine the establishment of a 
citation pattern that fortified the distributed priority, and show the diﬀerent reinterpretations 
that were still possible within this framework.   
While other laboratories were announcing their results of microinjection into mouse eggs, the 
Yale group was the first to start assimilating and reviewing the work. In 1981, Ruddle co-authored 
several reviews of gene transfer with his lab colleagues.98  These mainly focused on somatic cell 
manipulation, but also mentioned microinjection into zygotes. But in December 1981, Ruddle and 
Gordon published a high-profile paper in Science that reported their success at breeding second-
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generation oﬀspring that also carried the inserted HSV tk gene.99 While only 3 pages long, the pa-
per also functioned as a summary and programmatic statement for a new field.
The Science paper referenced previous publications from the authors’ laboratory, and the groups 
at Fox Chase, Ohio, Oxford, and even unpublished collaborative work from Kurt Bürki at Illmen-
see’ lab at the University of Geneva with Axel Ullrich at Genentech.100 Gordon and Ruddle did, 
however, ignore the new microinjection work done in Hamburg by Jaenisch and colleagues. This 
Science paper was submitted on 30 September 1981, and revised on 30 October, and the summary 
of Jaenisch’s experiments appeared in Nature on 15 October. However, Gordon and Ruddle’s article 
did cite the Lacy and Costantini paper that was published on 5 November 1981, also in Nature, so 
the editing clearly continued in response to peer review, but given the connection between the 
two laboratories Ruddle must have seen the preprint of the Oxford paper in advance and could 
also have acted as a referee.
In this paper, Gordon and Ruddle coined the word ‘transgenic’ to describe their mice: “The feasi-
bility of producing such genetically transformed mice, which we call ‘transgenic’ mice, depends 
upon several factors.”101 Transgenic is derived from gene, and the prefix trans- indicates otherness 
and crossing boundaries, as opposed to cis-, which indicates the same side. The pair of prefixes 
were in common use in molecular biology, when talking about control of DNA function – thus, 
trans-factors usually meant proteins that interact with DNA, while the cis-factors are bits of the 
sequence that control or enable such interactions. However, the practical etymology was much 
more local and related to the research genealogy of the Yale lab. It was derived from ‘transge-
nome’, a word Frank Ruddle had coined when describing bits of alien chromosomes inserted into 
somatic cells through chromosome-mediated gene transfer.102  The naming was decided internally, 
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after Gordon came up with a list of names for consideration. As he recalls, this included “pecalo-
mice”,103 “transgenomic mice”, even “mighty mice”, by analogy with the cartoon character.104 
Names can be important in biology, and sometimes remain linked to individuals and their re-
search agendas. Many examples are at hand in developmental biology. The tension between Mintz 
and Tarkowski over ‘allophenic’ vs. ‘chimaeric’ mice has been discussed in chapter 1. In 1981, 
Cambridge University-based Martin Evans and Matthew Kaufmann cultured what are now 
known as mouse embryonic stem cell, which they called EK cells (for Evans and Kaufman – the 
name did not stick, however), to parallel ‘EC cells’, a name given to teratocarcinomas that were a 
major reference point for their work.105 Similarly, the coinage of ‘transgenic’ contributed to secur-
ing the Yale group’s authority in the field. Despite competition, the word was quickly adopted by 
other groups working on gene transfer in mice, notably Brinster and Palmiter, became common-
place and was extended to other animals, plants and bacteria, even though it was not used widely 
in the media until 1985. This adaptation was one of the many ways in which a retrospective narra-
tive of invention was accepted, despite early doubts about the utility of the Yale methods and the 
real meaning of their data.  
The parallel work that happened in the laboratories involved working synthetically to establish a 
cumulative narrative of invention, as problems were consecutively ‘resolved’ by serial publica-
tion: gene expression, germline integration and its likely molecular structure. The need to make 
further claims about the microinjection work was a response to the pressure for novelty in jour-
nal articles, and reflected the theoretical commitments of specific groups. I argue that the rapid 
pace of publication, enhanced by the liberal communication with mainstream media, facilitated 
the establishment of the success of the new kind of experiment. Reliance on journals that oﬀered 
rapid publication, such as PNAS, further facilitated the transition from uncertainty that Ruddle 
was keen to emphasise to the press early on, to a perception of a new field and a new means of 
investigating genes in a living animal. 
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The change is traceable through outsider accounts of the field. If early descriptions, both in scien-
tific periodicals and newspapers, placed microinjection alongside many other attempts to insert 
genes into animal cells, increasingly commentators treated transgenic mice as a separate agenda. 
By transforming a group of parallel results into a sequence of successes, a productive set of prom-
ises was elaborated, for instance in the Nature comment piece on the work from Hamburg and 
Oxford, which claimed that genetic engineering had entered a new era: “if it has indeed been pos-
sible to insert a cloned gene sequence into the mammalian genome so that it functions correctly, 
the wider implications are enormous. Leaving aside the controversial question of gene therapy in 
humans, it seems certain that the genetic manipulation of agriculturally important animals will 
quickly follow”.106 
Giving the new object a name helped crystallise a new approach, and the coinage as well as prior-
ity allowed the Yale scientists to define the terms of the game, literally and metaphorically. With 
exchanges between the competing laboratories, their wide and rapid communication, a successful 
new thing – a transgenic mouse – became real, through the discovery narrative of an apparent 
collective. This narrative, however, was unstable and could be revisited in the later years, espe-
cially where questions of property and biotechnological interest came into play. Through the 
1980s, as the focus on microinjection of plasmid DNA into the pronucleus of a fertilised egg per-
sisted, the papers from Jaensich’s group were occasionally omitted in review articles, as was Tho-
mas Wagner’s contribution (Table 4-2).  
Yet, while the Ohio-Jackson work may have been sidelined in the journals, Thomas Wagner and 
Peter Hoppe remain the inventors of transgenic technology from the perspective of the US Patent 
and Trademarks Oﬃce as supported by a highly unusual adjustment to their patent that was 
granted in 2005, after its power had expired, which legitimised most of the original application 
claims107 – unlike the more contained 1989 patent. At the same time, the patent had little impact 
on university research and was not contested from therein, and in public discussions was eclipsed 
by the 1988 Harvard mouse patent, the first to be granted on an animal as a product of an inven-
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Table 4-2: Allocation of credit in the major reviews of transgenic technology, 1983–1990. Papers cited 
as a pioneering contribution are indicated with a tick, and in most cases the exact contributions – 
demonstrating successful microinjection, gene expression or germline transmission – are detailed. 
Review Gordon et al. 1980 
E. Wagner 












Gordon & Ruddle, ‘Gene-
transfer into mouse em-
bryos...’ Methods in Enzy-
mology 1983
Palmiter & Brinster, ‘Germ-
line transformation of 
mice’, Annual Review of 
Genetics, 1986
Hogan, Lacy & Costantini, 





mals’, International Review 
of Cytology, 1989
Hanahan, ‘Transgenic mice 
as probes into complex 
systems’, Science, 1990
E. Wagner, ‘On transferring 
genes into stem cells and 
mice’, EMBO medal review, 
EMBO Journal, 1990. 
✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ — ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ ✓ ✓ ✓ ✓
✓ ✓ — ✓ ✓ ✓
✓ ✓ ❊ — ✓ ✓
✓ ✓ — ✓ ✓ ✓
✓ ✓ ✓ — ✓ ✓
❊ The Wagner-Hoppe paper is not cited with the other pioneering contributions here, but is mentioned as a 
claim of gene expression of rabbit beta globin that others could not replicate.
tion. Even if most of Wagner’s competitors still think his first expression results were most likely 
a curious artefact,108 his priority is registered by the US government. 
The curious thing about this recent Wagner patent is that it was issued two years after it would 
have expired, and has largely symbolic value. At this point, I also wish to emphasise that despite 
active measures to secure priority, it was not the ultimate goal, nor did the scientific decorum ever 
break down. These strategies were mostly acceptable in the climate of the 1980s, and few printed 
records of the story survive beyond ephemeral newspaper publications. The diversity of interests 
and plans for the new animals, as well as the sheer number of pioneer groups, prevented a bitter 
controversy, while opening up space for diverse lines of experimentation and keeping the moral 
economy of research in balance.
Conclusion
Through multiple publications in journals with cross-disciplinary readership, claims were made 
about a new living mammalian system for the study of gene function and further molecularisa-
tion of development, employing the most promising techniques from molecular biology. But the 
work to register the advance went far beyond journals. The scientific paper, especially after World 
War II, is a genre that necessarily conceals irregularities, uncertainty and debate as much as it 
reveals the proposed facts. The mediation of these mice was incorporated into existing narratives 
of genetic engineering and biomedical work more broadly.
The key criteria brought together in the very word ‘transgenic’ – gene expression, germline inte-
gration and insertion into the genome – were articulated early, but also left the future open. Until 
1983 the question of what transgenic mice were for was by no means settled, nor were techniques 
standardised or easy to adapt by labs that did not carry a similar combination of expertise and 
resources. While priority order was not explicitly articulated in journal papers, it mattered at the 
time, and was contested more widely via the general press. While all of the scientists I have inter-
viewed admit independent co-invention, most of them predictably emphasised that they were the 
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ones that did the experiment that really mattered. For Jaenisch, transgenic mice were invented in 
1974 during the Mintz collaboration. For Thomas Wagner, his mice were the first to show gene 
expression that came out of molecular biological considerations about the state of DNA in the 
sperm cell, which had not been fully recognised. Similarly, Erwin Wagner and Timothy Stewart 
suggested that while the Yale mice may have been the first transgenics, theirs were certainly the 
first unambiguous evidence of the technology working. Finally, Brinster’s subsequent high-
throughput collaboration with Richard Palmiter became so defining for the field that the animals 
born out of their 1982 experiment, discussed in the next chapter, are sometimes quoted as the 
first transgenic mice. 
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Chapter 5. Bespoke animals: Adoption of transgenic technology, 1982–1988
Histories of successful laboratory animals have tended to focus on dissemination of an organism 
from a single place, often its key supplier. For example, Drosophila strains from the Columbia Fly 
Room, Jackson mice, the Wistar rat were all promoted, shared or sold by the scientists and other 
actors who domesticated these animals.1  New organisms enter biological research with diﬃculties 
associated with domestication, standardisation, building infrastructure and the establishment of 
experimental credibility. Transitions to new research organisms are only worth the eﬀort when 
new scientific agendas are being articulated. Thus, the switch of some drosophilists to the fungus 
Neurospora allowed them to open up a new agenda in biochemical genetics, but also to move up the 
career ladder more rapidly.2 Importing Xenopus from South Africa started as an experimental 
physiology project, but gained traction when the frogs began to be used routinely for pregnancy 
testing.3 Sydney Brenner’s choice of the nematode worm C. elegans allowed for a molecular take on 
tracing development, which combined multicellularity with simple and predictable 
diﬀerentiation.4 The recent explosion of organisms used in developmental biology is a reflection 
of the evolutionary focus and the rise of evo-devo, enabled through the molecular transforma-
tions of the 1970s and 80s when cross-species comparisons were made more straightforward by 
reduction to the level of DNA sequence.5
Unlike new laboratory species, transgenic mice fitted within existing infrastructures. Moreover, 
their epistemic value relied heavily on the established status of mice as the genetic animals best 
suited to studying human pathology. At the same time, despite the initial publicity and multiple 
claims for the viability of gene transfer into mice, the credibility and utility of that approach were 
not self-evident. A group of users had to become converts to the interdisciplinary procedures for 
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making the new animals. For molecular biologists in particular, using transgenic mice would of-
ten mean transitioning to an unfamiliar organism.  
Historians of technology often employ the diﬀusion metaphor when they talk about how innova-
tions spread. While perhaps more appropriate in a commercial context where mass-produced 
items may be sold and used with subsequent modification, this metaphor tends to place the 
agency firmly in the hands of inventors and designers. The spread of a given technology is thus 
imagined as an ever-expanding contagion, ironing out geographic variation and the historical 
fluctuations in its popularity and credibility.6 Turning the tables and focusing on adoption instead 
restores agency to the users who may or may not find a new technology attractive or aﬀordable. 
Users determine whether or not an innovation is successful and able to replace existing alterna-
tives or create new niches for use. Experimental animals – moving in networks between suppli-
ers, stock centres and laboratories – become legitimate research subjects when a large enough 
fraction of users and external observers can be convinced of their utility and promise.
This chapter addresses the adoption of transgenic technology in the 1980s, considering the major 
events and avenues of their dissemination. I begin by discussing the giant ‘supermice’ produced 
through growth hormone gene injections in 1982. These animals were the first and soon the 
dominant success story, because they displayed the immediately visible eﬀects of gene transfer, 
and their images circulated widely between scientific and lay publications. In section 2, I trace the 
early adoption of transgenic mice in the USA and beyond. Some scientists picked up the tech-
niques independently, building on their experience with related methods, but many were aided 
by courses, conferences and personal contacts with established researchers. Section 3 reflects on 
the strategies of making new knowledge with transgenic mice in 1983–88 and considers the rela-
tionship between mice and other animal systems in the molecular age. I argue that the most dra-
matic utility of transgenic mice was the ability to study gene expression in a whole mammal, and 
show how the perceived limitations of technology could be recruited to pose new questions. Fi-
nally, section 4 considers the relationship between transgenic research and the traditional sites of 
mouse genetics and supply, especially the Jackson Lab. The mouse genetics community was not 
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involved in transgenic work and did not supply transgenic mice until the mid-1990s, because of 
its limited communication with the growing transgenic community, diverging practices of estab-
lishing new stocks and the knowledge that could be made with them. Unlike the large-scale 
crosses and mutagenesis assays, transgenic research was a local, bespoke operation. 
§1. Supermice
As I have shown in chapter 4, the coverage of the 1980–81 gene transfer experiments with mouse 
embryos steered media narratives away from any serious controversy. Yet unlike the daily press, 
longer journalistic investigations continued to take a more critical approach to future possibilities 
stemming from genetic intervention, especially genetic testing in the workplace, prenatal diagno-
sis and gene therapy. Following the tradition of long-form reportage on the new biology, these 
stories reviewed multiple strands in biological research. Transgenic mice were occasionally in-
corporated into the narrative of the genetic revolution. Some pieces were optimistic; when con-
sidering the implications of reproductive and genetic technologies for cattle breeding, Business 
Week envisioned vast progressive changes to agricultural industry, referring to Thomas Wagner 
and Ralph Brinster among other scientists.7  Other articles, while fascinated with the scientific 
advances, raised concerns. In the March 1982 issue of OMNI, Yvonne Baskin combined the stories 
of the Yale gene transfer, Martin Cline’s gene therapy attempts and IVF to raise questions about 
the future of human genetics: 
News articles glibly refer to a future when we will program our cattle to put all their en-
ergy into producing milk and we’ll engineer our crops to survive on salt water. Will we 
use our burgeoning knowledge to enhance the individual? Or will we use it to make indi-
viduals, like cattle and plants, to suit society’s needs?8
After the Cline aﬀair, genetic modification of humans was at the crux of such discussions. “Brave 
New Babies”, a November 1982 episode of the BBC science documentary series Horizon, used the 




by the bioethicist Jonathan Glover, it included eerie discussions with the presenter’s children and 
a sinister vision of a clinic where parents could choose the desired features of their future child.9 
Increasingly ready to engage with the media coverage, eminent biologists were discussing these 
issues. At the 1982 Banbury meeting in Cold Spring Harbor, leading experts on gene transfer met 
to discuss the future of gene therapy. Attendees included Brinster, Costantini, Illmensee, Jaenisch 
and Ruddle as well as the likes of French Anderson, Richard Axel, Paul Berg and Victor McKusick. 
Banbury meetings were initiated post-Asilomar in 1978 as a space to discuss potential biohazards, 
and the published proceedings had been technical and dense. The 1983 publication, Gene Therapy: 
Fact and Fiction, was by contrast a cheap and slim paperback that aimed to address a broader audi-
ence and combined summaries of discussions with transcribed dialogue.10 The overall conclusion 
was that germline gene therapy was an unlikely and impractical outcome of the gene transfer ex-
periments, and the somatic approaches were to be pursued. Similar arguments were presented at 
the congressional hearings on gene therapy in November 1982. Transgenic mice did not feature 
prominently, but were mentioned by Barbara Sanford, director of Jackson lab, as a potential step 
on the path towards germline therapy.11 
When talking to the press, pioneers of transgenesis tried to distance themselves from any applica-
tion to the human germline, but at the more esoteric conferences transgenic animals were all the 
rage when it came to gene function and development. The new mice were the highlight of the 
June 1982 meeting of the Society for Developmental Biology, where Mintz and Palmiter presented 
their most recent work on the HSV tk gene expression. As Nature reported, the general mood was 
that “real progress towards understanding the control of gene expression and development may 
be at hand”.12  
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Among the first groups to insert genes into mice, Brinster and Palmiter were at the forefront of 
controlling foreign gene expression, having used the metallothionein promoter that could be 
switched on in the presence of heavy metal salts. Seeking to continue the collaboration, the two 
scientists were considering other genes to inject into mouse embryos that would have clear eﬀects 
and had potential relevance to human health or agricultural improvement. Other labs were mov-
ing to explore more pertinent genes, too. Thus, Ruddle’s group experimented with interferon 
DNA, while Karl Illmensee and Axel Ullrich worked on the human insulin gene. On his way to 
meet Brinster in person for the first time in late 1981, Palmiter stopped over to give a seminar at 
Roswell Park, Buﬀalo. where he learned of a dwarf strain of mice that could potentially be treated 
by a growth hormone gene. Shortly afterwards, he obtained the recently-cloned rat growth hor-
mone gene from Ron Evans at the Salk Institute, spliced it with the metallothionein promoter and 
sent it oﬀ to Brinster who had started building a colony of the little mice. But even before these 
animals were ready for experiments, Brinster discovered that injection of the growth hormone 
plasmid into normal strains also had the envisioned eﬀect – the modified mice grew much larger 
than normal.13 In Brinster’s recollection, “The giant mouse experiment was a fantastic experi-
ment. That is the experiment that made everybody, including us, stop and say, ‘This is incredibly 
powerful.’ That you could enter the germ line and make a change like that”.14 The experiment be-
came the biggest news story in early transgenic research.
Brinster and Palmiter outlined this work in a letter that appeared in the 16 December 1982 issue of 
Nature, and the front cover carried a photograph of a giant mouse next to its regular kin (Figs. 5-1, 
middle & 5-1a).15 This was not the first time that the group’s work made journal covers. In Novem-
ber 1981, when Brinster and Palmiter’s first gene transfer paper had been published in Cell, two 
transgenic mice had also featured on the cover of the journal (Fig 5-1, left) In November 1983, a 
similar image appeared on the cover of Science, accompanying a paper of theirs on the transfer of 
the human growth hormone gene.16  (Fig. 5-1, right) The use of journal covers to highlight research 
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was a relatively recent development in the early 1980s. Science had first put a photograph on its 
cover in October 1959, with an editorial announcing the redesign and speculating as to the diﬃ-
culties in obtaining images for every issue,17 and through the 1960s, journal covers frequently fea-
tured abstract photographs. Nature used most of its cover as an advertising space until the 28 May 
1971 issue, when a larger black-and-white image took about half of the cover, with issue highlights 
listed underneath. In the 1970s, despite printing on cheaper paper, Nature’s cover images became 
more prominent, and authors were encouraged to submit images as “artwork”.18 Colour photo-
graphs made it to the covers of Science only in 1976, with Nature and Cell following suit in 1978. 
This trend was driven not only by declining colour printing costs, but also by the proliferation of 
popular science periodicals in the late 1970s, which in turn took their aesthetic guidance from 
mainstream weekly magazines. By contrast, more specialised periodicals, as well as PNAS – where 
most of the transgenic papers had appeared at that point – kept the table of contents on their 
front cover. 
Striking visualisation of experimental results in these relatively new spaces conferred an addi-
tional advantage to the scientists attempting to make their research stand out. The images in Fig 




Fig. 5-1. Brinster and Palmiter’s mice on journal covers. 
Left to right, Cell, 15 November 1981; Nature, 16 December 1982; Science, 11 November 1983.
© Cell, Nature Publishing Group, AAAS.
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Fig. 5-1a. “Gigantic mice” on the cover of Nature, 16 December 1982.
© Nature Publishing Group.
framed by a plasmid map in the Science image. They alluded to before-and-after advertising im-
ages and the genre of juxtaposing dwarfs and giants, which had been used in much older work on 
growth hormone injections.19  The giant mouse images spread through the scientific and general 
press to a remarkable degree, and their significance persisted in recollections. Thus in 1989, the 
co-inventor of the OncoMouse Philip Leder said of the result: “It was... this uncanny evidence of 
functional expression, that made us sit up and realize that transgenics was [sic] more than just 
some technological stunt.”20  
A sizeable final section of the Nature paper elaborated the potential applications of growth hor-
mone gene transfer: the production of bigger cattle, the synthesis of valuable protein in farm 
animals, and the development of mouse models for gigantism to study the eﬀects of growth hor-
mone gene expression. In parallel with the Nature paper, Brinster and Palmiter wrote a less tech-
nical piece for Trends in Biochemical Sciences (TIBS), which also appeared in December 1982. Re-
viewing their own work and the research of others, the conclusion summarised an agenda for 
future work and press discussion: “Clearly the introduction of new genes into animals promises 
to have considerable importance in addressing fundamental scientific questions regarding gene 
regulation and may, in addition, be put to practical or commercial use.”21 In a final bit of journal 
publicity, Nature commissioned a companion News & Views piece, titled “Mouse and super-
mouse”. Jeﬀrey Williams, a slime mould researcher at the Imperial Cancer Research Fund labora-
tories in Mill Hill, London, noted that this was “the first time that genetic engineering [had] been 
used to alter the phenotype of an animal in such a profound manner” and the “culmination of a 
series of elegant experiments performed by Palmiter, Brinster and their colleagues over the past 
few years.”22 The article also hinted that the technique might be used to produce strains of com-
mercially valuable farm animals and improve meat yields, as well as placing these ‘supermice’ – a 
name that stuck – within the recent advances that could lead towards gene therapy, with a quali-
fier indicating that human embryo modification was unlikely ever to be considered in the clinic.
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The University of Pennsylvania Press Oﬃce was eager to advertise Brinster’s work as a break-
through. In a press release accompanied by the manuscript of the group’s Nature paper, embar-
goed until publication, the experiments were described as opening a “new era in genetic 
engineering.”23 A United Press International wire, with a photograph of the mice, spread the news 
rapidly through the US and beyond.24 On 16 December, the day the article was published, Brin-
ster’s giant mice made it to the front page of The New York Times and The Washington Post and ap-
peared inside The Wall Street Journal, and the British Guardian and Times (via the Nature-Times 
News Service).25  All articles focused on the agricultural applications of the mice, envisioning the 
potential for giant cattle. As the London Times put it, “The parallel development of an outsized 
breed of cattle could have obvious appeal to both farmers and steak-eaters.”26 On 27 December, the 
giant mice made it to TIME magazine. Dramatising the significance of the experiment (“It was the 
sort of biological alchemy that abounds in science fiction”), the article featured a small photo-
graph from the Nature cover, captioned “Next step: enormous cattle”, and a brief interview with 
Brinster and Palmiter. The two were eager to speculate about the implications of their experi-
ments. They emphasised that any modification to humans was premature and unlikely to be at-
tempted, while suggesting less threatening outcomes. Brinster said, “If we can make bigger mice 
we can make bigger cows,” while Palmiter noted that, “in a sense, the big mice are models of pitui-
tary gigantism in humans.”27
Once again, the major focus of the initial newspaper coverage was on the scientific advance and 
the work that went into making these mice. Often, the animals were taken lightly. Editorials in 
The Washington Post and The New York Times made tongue-in-cheek remarks about the new need 
for bigger mousetraps, or perhaps bigger cats.28 Introducing the report from Philadelphia, the CBS 
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anchor remarked, “however you feel about mice, you probably think they’re big enough.”29 To 
Palmiter’s delight, the story was also picked up by the comedian Johnny Carson on the Tonight 
Show. In Carson’s monologue, full of incredulity over anyone wanting bigger mice, “one mouse 
kicked out the door to the lab and said, 'I want a cheeseburger and I want it now!’”30
Unlike the first stories of gene transfer into mice that received fleeting attention, the supermouse 
persisted in the news, aided by the impressive images. Journalists were able to use the story to 
revisit the recent government report on Splicing Life, published on 16 November 1982. The docu-
ment was authored by the recently-founded (and short-lived) US President’s Commission for the 
Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, which weighted 
the ethical issues of human genetic manipulation against the benefits that biotechnology might 
bring to the ailing economy. While the report explored issues around manipulating life, it came 
short of any recommendations to limit research, except to reject human-animal hybrids.31  
Schmeck’s later opinion piece in the New York Times described the report as raising “thorny ethical 
issues” about extending this work to farm animals or, especially, humans.32 Similarly, the last 
paragraph of an article in Boston’s Christian Science Monitor referred to the continued opposition 
to any human genetic modification from US church leaders and the caution urged by bioethicists. 
Another New York Times editorial, from 29 December 1982, took a more sober tone.33 Using the gi-
ant mice as a segue to the discussion of Splicing Life, it argued that the Commission had tiptoed 
around the pertinent issues such as banning human genetic intervention, while entertaining ex-
periments that no one had been planning to undertake.34 
In November 1983, Brinster and Palmiter published another paper featuring a new batch of su-
permice, this time produced with the human growth hormone gene under the metallothionein 
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promoter. These mice, superimposed on a schematic plasmid map, made the cover of a special 
issue of Science that featured papers from the biological frontier of molecular techniques (Fig. 5-
1a, right). The introduction of the human gene led to renewed coverage of supermice that fol-
lowed the pattern of late 1982 very closely. That the gene was human made some uncomfortable, 
although Mintz’s group had already been inserted the human beta globin gene into mice by in 
1981. An unidentified clipping from the University of Pennsylvania archive, likely from a Seattle 
newspaper just after the Science publication, oﬀers a rare glimpse into private letters that Palmiter 
received as it quoted from one such letter at length:
...when I read this (an article about the experiment), my blood began to boil, my stomach 
turned and my mind cranked up some revolting thoughts!!! To me the marriage of hu-
man tissue – no matter how minute – is an abomination when connected with animal, 
bird, insect or plant life... to read about this at Christmas was a double blow to my 
senses... What kind of MONSTERS do you have working with you? Is nothing sacred??35
The quotation, with its preservation of the idiosyncratic style of the original letter, was clearly 
included as a sympathetic gesture towards the scientists. The other letters cited in the piece were 
much less dramatic – for instance, one suggested gorilla genes should be spliced into sheep to 
make more wool. In the conclusion of the article, Palmiter was given the final word to point out 
that it made little diﬀerence, “chemically”, that the gene was human. In all sorts of news settings, 
Palmiter and Brinster continued to evoke practical uses, implicitly including possible applications 
in medicine, and sought to frame their experiments in safer terms. 
Before anyone seriously proposed that a particular transgenic mouse could be a useful model of 
human pathology, the widespread coverage and the context of debates around genetic engineer-
ing turned supermice into models of the moral and ethical dilemmas to come. Scholars of human-
animal relations have repeatedly pointed at how animals are used to mimic and perform impor-
tant cultural anxieties and ambiguities.36 The light-hearted take on the supermouse drew on a 
long history of using mice in laboratories. The familiar place of the animal in a laboratory allowed 
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journalists and activists to rehearse cultural debates with a ‘safe’ species.37 Yet such safety was not 
inherent in the mouse species but came out of the specifics of the communication process, as sci-
ence reporters emphasised scientists’ perspectives and subsequently used supermice to introduce 
issues about human genetics. The diﬀerence between the mouse – a familiar experimental animal 
ensconced in the laboratory – and other mammals is starkly visible in later debates around the 
first attempts to introduce genes into farm animals, again spearheaded by Brinster, which proved 
significantly more controversial. In 1984, Jeremy Rifkin recruited the US Humane Society to file 
lawsuits against the US Department of Agriculture for collaborating with Brinster, and to raise 
publicity around similar experiments attempted by Thomas Wagner with pigs, sheep and cattle. 
With this renewed media attention, the older images of giant mice were occasionally featured, 
this time with a new ability to become controversial.38
With the circulation of supermouse images, transgenic animals were made visible as they became 
incorporated into diﬀerent narratives about farm animals and humans. Yet these remarkable 
creatures yielded no significant controversy in the context of increasingly positive media cover-
age of biotechnology in the USA. Rather, as I show in the next section, the circulation of the im-
ages played a role in the wider acceptance of transgenic technology among molecular and devel-
opmental biologists and their scientific, regulatory and lay audiences. 
§2. Adopting transgenesis
While the possibility of human genetic intervention occupied many column inches in 1982–3, the 
mouse work continued at full pace. If for certain science journalists the images of supermice 
hinted at the future of human genetic intervention, for molecular biologists they demonstrated 
the success of directed gene expression in mammals: a central criterion for the utility of trans-
genic technology. Expression and germline transmission had already been claimed in 1981. But 
while previous experiments had established the expression of viral genes though mundane as-
says, and evidence for the production of foreign beta globin proteins in mice had been contest-
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ed,39  the growth hormone experiments showed the dramatic eﬀect that a foreign gene could have 
on the physiology of an organism. 
These images were thus a testament to the power of transgenic technology. For a Boston Globe 
piece on the first supermouse paper, several prominent scientists were asked for their opinion on 
the experiment. David Baltimore, a celebrated molecular biologist and head of MIT’s newly-
established Whitehead Institute, remarked, “This demonstrates that you can put a gene into an 
embryo and have it function at a high level in the resulting organism”. Another MIT biologist, 
Philip Sharp, described the work as “the most striking demonstration of success” in animal gene 
transfer. With supermice, Brinster’s lab established a firm place at the forefront of transgenic re-
search, and their giant mice were often picked up as a key breakthrough in transgenesis, and to 
date they are occasionally referred to as the ‘first transgenic mice’.40  
In 1983–85, accounts of gene transfer into mice also began appearing in textbooks dealing with 
genetics and biotechnology, often accompanied by the supermouse images. Fincham’s Genetics 
(1983) mentioned the experiments by Thomas Wagner as well as Lacy and Costantini.41  The first 
edition of Karp’s Cell Biology (1984) featured the supermouse image, as did the second edition of 
Benjamin Lewin’s Genes (1985).42  Moreover, a drawing of the mice made it to the cover of Recombi-
nant DNA: A Short Course (1983) by James Watson, John Tooze and David Kurtz (Fig. 5-3).43  The 
book was published under the Scientific American brand, with illustrations in its characteristic 
style. It targeted a broad audience, primarily undergraduate students, and summarised the key 
developments in recombinant research and their applications to biology. A whole chapter was 
devoted to gene transfer in higher organisms, with a particular focus on Brinster’s experiments 
and Jaenisch’s viral work. 
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The highly-publicised promise of transgenic mice made them an attractive research system for 
those labs that were well-placed to adopt them. The combination of skills, know-how and instru-
ments and infrastructure was unusual and costly, yet between 1982 and 1985, a number of labora-
tories succeeded in adopting the technology, some with relative ease: elite institutions at the 
cross-roads of academic exchanges, with existing animal colonies and developmental biologists 
on hand. A series of courses spread the techniques through direct hands-on teaching from ex-
perts in the field. Other places succeeded in relative isolation, with little or no immediate contact 
with experienced scientists.
The postdocs involved in making the first transgenic mice were in an enviable position career-
wise and some of the leading molecular biologists were eager to recruit them. Philip Leder, who 
had received one of the first major university-industry grants in molecular biology at Harvard 
with money from the chemical giant DuPont, attempted to recruit Gordon, who took up a position 
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Fig. 5-3. Recombinant icons. 
Cover of Watson, Tooze & 
Kurtz 1983, image by Marvin 
Mattelson.
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at the Mount Sinai medical school in New York instead.44  Leder then hired Tim Stewart, who of-
fered the embryological expertise and was eager to learn molecular techniques that he was unable 
to pick up in Mintz’s lab. He began working with the new gene called c-myc at Harvard, a project 
that later gave birth to OncoMouse.45  Yale’s George Scangos secured a permanent position at Johns 
Hopkins, only to move back to Connecticut in 1986, to work in Frank Ruddle’s start-up company, 
Molecular Diagnostics. Erwin Wagner secured a post at the European Molecular Biology Labora-
tory (EMBL) in Heidelberg, a major institution where he set up transgenic facilities. Frank Co-
stantini and Elizabeth Lacy had been approached by James Watson to join Cold Spring Harbor, but 
both ended up securing permanent positions in New York City, at Columbia and the Sloan Ketter-
ing Institute, respectively.
The transit of postdocs was one early and safe way to spread the new techniques. Such direct ex-
change of skill was not, however, essential. Many classic studies in history and sociology of ex-
perimentation stressed the diﬃculty with which experiments travel and become replicated, and 
therefore the importance of personal demonstration and contact to make novel instruments 
work. But such replication challenges were not always insurmountable at a distance.46 While per-
sonal contact aided the adoption of transgenesis in specific labs, pronuclear microinjection relied 
on well-established instruments and procedures that could be honed under the right conditions. 
After all, most transgenic pioneers devised pronuclear microinjection independently. 
Several sites with expertise in mammalian embryo manipulation succeeded at replicating the 
technique from published descriptions. With the country’s considerable tradition of mammalian 
development, British centres were in a particularly strong position. At the Agricultural Research 
Council’s Animal Research Station in Cambridge, a key site for farm-animal genetics and embry-
ology, Azim Surani set up a transgenic mouse project. After working on mouse parthenogenesis, 
Surani’s main interest was the epigenetic diﬀerences between maternal and paternal chromo-
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somes in the embryo, and the techniques for introducing new genes into mice oﬀered the promise 
of exploring their fate and regulation. His lab assistant, Sheila Barton, was crucial to helping Su-
rani make microinjection work. Barton had trained as a historian and entered the world of devel-
opment as a secretary to Bunny Austin, eventually becoming extremely skilled at micromanipula-
tion, recognised for her gold hands. Ironically, she taught one of the transgenic pioneers, Thomas 
Wagner, to actually perform pronuclear microinjection when he visited Surani, an old friend, in 
early 1982. The microinjections for Wagner’s previous work had been done by Peter Hoppe at the 
Jackson Lab, and Wagner was eager to learn the embryological technique, despite Barton’s obser-
vation that he was “ambidextrous – lousy with both hands”.47
At Anne McLaren’s MRC Mammalian Development Unit in London, Robin Lovell-Badge started 
microinjecting genes into mouse eggs after his move from Cambridge in 1982. He had been in-
volved in another pioneering project, the isolation of mouse embryonic stem cells in Martin 
Evans’s lab in Cambridge, and this system occupied the rest of his time in McLaren’s unit.48 
McLaren’s 1983 report to the MRC emphasised that pursuing recombinant DNA was a good strat-
egy, confirmed by “the evident eagerness of molecular biology laboratories to acquire from us the 
methodologies of mammalian development.”49 She also expressed a continued commitment to 
gradually integrating molecular tools throughout her unit. However, the opinions of some refe-
rees of McLaren’s work illustrate the community’s ambivalence about embracing the molecular 
approach wholeheartedly and indicate a skepticism less frequently aired in publications. Jonathan 
Slack stated that “There is no doubt that solutions to the major problems of developmental biol-
ogy will come about through a combination of micromanipulative skills with modern molecular 
biology. It is rare to find both in the same laboratory and I think they are quite right to claim this 
as a major strength.”50 Martin Evans’s report saw the encroachment of molecular tools as both 
illuminating and threatening to the study of mammalian development, and encouraged McLaren 
to maintain a firm footing in traditional embryological and genetic approaches. Along similar 
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lines, Chris Graham commended the unit for a new generation of PhD students who combined 
both molecular and embryological skills, but felt the transgenic project was a risk that “requests 
the Unit to become an injection factory for gene cloners (à la Brinster) or to increase their post-
doctoral investment in the work, or to be very, very lucky.” 
While some embryologists were not convinced, a number of molecular biology laboratories 
showed strong interest in picking up the techniques of mammalian embryology and soon several 
workshops and courses were established to address this demand. The Molecular Embryology of 
the Mouse course at Cold Spring Harbor was the first and most influential. It was initiated by Bri-
gid Hogan, a British molecular biologist working on teratocarcinoma cells at the British NIMR. In 
England, Hogan had been learning the techniques of mammalian development first-hand, and 
remembers her frustration at the lack of clear recipes or handbooks. The mystique of embryology 
with its emphasis on the complexity of embryonic manipulation and manual talent was main-
tained, with pervasive local beliefs about what made experiments succeed. Hogan had envisaged a 
course that could synthesise these techniques, but received negative responses from most embry-
ologists. It took James Watson to broker the arrangement and set up such a course at Cold Spring 
Harbor, after a conversation with Hogan at a 1982 teratocarcinoma symposium there. Cold Spring 
Harbor had an established tradition of running summer courses in biological techniques, from 
phage genetics in the 1950s to the key course on recombinant DNA that had started in 1981 and 
was collated into the very successful 1982 handbook, Molecular Cloning.51
James Watson’s clout helped the course start smoothly within a year. He had a strong interest in 
running a transgenic project at Cold Spring Habror, and persuaded Douglas Hanahan to start one. 
Watson approached Lacy and Costantini to help run the course, got the mouse colony organised, 
and secured sponsorship from Leica and Zeiss, which provided micromanipulators and micro-
scopes. The two-week Molecular Embryology of the Mouse course was launched in summer 1983, 
with Costantini and Lacy on board (Fig. 5-4).52  Lacy and Costantini’s own experience in transi-
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tioning from molecular techniques to embryo manipulation proved helpful. From the early days, 
it attracted major figures in mammalian embryology, including McLaren. Structured around an 
invited lecture followed by hands-on lab demonstrations, with full support from the Cold Spring 
Harbor infrastructure, it was an eﬃcient way to transmit mouse transgenesis techniques. It was 
also an opportunity to raise awareness of other aspects of mammalian development among mo-
lecular biologists. IVF and embryo transfer, isolation of stem cells, making chimeras, nuclear 
transfer and teratocarcinoma work were all included alongside basic introductions to mouse de-
velopment and the routine but crucial advice on animal husbandry and running mouse facilities. 
Much of the demand for learning how to make transgenic mice came from molecular biologists 
eager for a new system to extend their ongoing work on gene expression. According to Costantini, 
“at the beginning, pretty much everyone who came wanted to learn how to make transgenic mice. 
A lot of them weren’t so interested in learning other stuﬀ. They would bring their DNA, and their 
boss said, ‘don’t come [back] without knowing how to make a transgenic mouse.’ And then, over 
time, I think it started to get a more diverse bunch of students.”53 Other institutions followed suit. 
The Jackson Lab included transgenesis in its established ‘Short course’ on mouse and human 
genetics.54 Peter Hoppe did much of the teaching on the new techniques there, though Lacy and 
Costantini participated in the 1985 course. In Europe, EMBL ran an annual workshop on gene ex-
pression in mammalian development, with a stronger focus on newly-available embryonic stem 
cells. These, however, were lecture courses without practical demonstrations.55 In Britain, Brigid 
Hogan attempted to replicate the Cold Spring Harbor course at NIMR in 1985, but without compa-
rable resources and strict requirements that all visitors should have Home Oﬃce licences to work 
with animals, it did not become a recurring event.56  
In 1986 the handouts from the Cold Spring Harbor course were compiled into a handbook, Ma-
nipulating the Mouse Embryo: A Laboratory Manual, authored by Lacy, Hogan and Costantini.57 
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Whereas its hugely influential predecessor, Molecular Cloning, had been routinely referred to as 
the “Bible”, Hogan, Lacy and Costantini’s output was labelled “the Mouse Book”. Beyond detailed 
advice on how to make transgenic mice, it included materials on general mammalian develop-
ment and other techniques such as nuclear transfer and stem cell culture, a brief history of mouse 
embryology, as well as information on setting up a mouse colony. It was intended to be used at the 
bench, as evidenced not only by its clear step-by-step recipes and a wealth of diagrams and pho-
tographs, but also by its comb-binding, which meant it could be laid down flat and photocopied 
more easily – a printing choice increasingly employed by the Cold Spring Harbor Laboratory 
Press. 
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Fig. 5-4. Participants in the first Molecular Embryology of the Mouse course at Cold Spring Harbor, 
1983. 
Back row: Peter Rigby, NIMR • Douglas Hanahan, CSHL • ? • Brigid Hogan, NIMR • ? • ?
Middle row: Kathie Raphael, CSIRO, Australia • Tadatsugu “Tada” Taniguchi, Japanese Foundation for Cancer Research • Anne 
McLaren, UCL • ? • Lee Silver, CSHL • Frank Costantini, Columbia • Minoo Rassoulzadegan, Nice University • Elizabeth Lacy, 
Sloane Kettering
Front row: Denise Barlow, NIMR • ? • Bryan Crenshaw, UCSD • ? • Lisa Stubbs, CalTech.
 © Cold Spring Harbor Laboratory.  
The Mouse Book was favourably reviewed. In Trends in Genetics, the Cambridge embryologist Mar-
tin Johnson noted that “all laboratories that aspire to the genetic manipulation of the mouse 
should buy at least two copies immediately – my single copy is never there when I need it, a sure 
sign of its value.”58 A review in Genetical Research praised the book’s contribution as an introduc-
tion to mammalian development at large: “this book is probably unique in its coverage of mam-
malian developmental biology, and will be welcomed by anyone who has tried to plough through 
embryology texts in search of information relevant to mammals.”59 The handbook also did well 
commercially, even though it never quite matched the success of Molecular Cloning or the Press’s 
monoclonal antibody series.60 
Similar books appeared in 1986–7, embracing a wider focus on molecules and mammalian devel-
opment. Janet Rossant and Roger Pedersen’s Experimental Embryology of the Mouse was a collection 
of chapters from prominent biologists, and it aimed to become a more theoretical introduction for 
any “serious student of mammalian development”, focusing on the state of the art. It recognised 
the role of transgenic mice in raising the status of the field: “For the many molecular biologists 
who have discovered the mouse embryo in their quest for transgenic mice, it will provide an in-
troduction to the wider issues of mammalian embryogenesis.”61 Similarly, Marilyn Monk’s Mam-
malian Development, an instalment in the extensive ‘Practical Approach’ series from IRL Press, was 
a British multi-authored handbook with a broader scope.62 Azim Surani, Sheila Barton and two 
postdocs in Surani lab wrote their contribution on transgenic mice. While these volumes were 
favourably reviewed, they did not become as widely used as the Mouse Book.
The success of the Cold Spring Harbour course was partly owing to its ability to bring in heavy 
sponsorship, and in fact, Watson may have considered extending the laboratory’s own transgenic 
work into a commercial venture.63 The 1980s saw a dramatic expansion of the biotech industry 
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and reorganisation of biomedical research. Beyond the success stories of Genentech and Cetus, 
the 1980s was a decade of hybrid arrangements between universities and industry. Major phar-
maceutical and chemical companies – Pfizer, Monsanto, DuPont – funded high-profile 
collaborations.64 The Whitehead institute, founded with a major donation in 1982 and aﬃliated 
with MIT after protracted faculty debates, became a new site for exciting molecular work, giving 
its first director, David Baltimore, extensive control over hiring and research strategies.65  Trans-
genic technology followed the early success stories of biotech and many institutions were keen to 
introduce it into their routine. A 1985 opinion piece in Nature, tellingly titled ‘DNA makes protein 
makes money,’ listed the various recombinant systems used in biotechnological production, and 
then remarked: “Now that the [transgenic] technique has been established... it oﬀers the possibil-
ity of investigating the mechanism of tissue-specific gene expression and maybe eventually of 
producing useful proteins in the milk of cows or in the eggs of chickens” (Fig. 5-5).66
Some commercial applications for transgenic animals were envisioned, but the bigger biotechnol-
ogy firms also pursued cutting-edge research to build reputations and attract university scien-
tists. Seeking to attract the best scientific talent to a new industry, Genentech built on the collabo-
ration between Axel Ullrich and Karl Illmensee and in 1984 recruited Tim Stewart to set up its 
own transgenic facilities. Following prominent research universities and the NIH intramural pro-
gramme, Baltimore oﬀered Jaenisch a place at the Whitehead institute and invested in building 
proper mouse infrastructure.67 Yet the commercial entities keen to attract transgenic research 
were not limited to the biotech hubs of the Bay and Boston areas. Smaller start-ups emerged, 
some of them led by transgenic pioneers. Frank Ruddle was involved in two related ventures, Mo-
lecular Therapeutics and Molecular Diagnostics in West Haven, Connecticut, where George Scan-
gos moved in 1986 to organise transgenic mouse research, taking a sabbatical from his tenure-
track position at Johns Hopkins, and eventually fully moving into industry. In Ohio, Thomas Wag-
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ner was heavily involved with the foundation of an animal biotechnology research institute and 
Embryogen, a company intended to commercialise its outputs.
The Ohio story showcases heavy state support for the ‘private science‘ of biotechnology, and dem-
onstrates alternative modes of funding and network-building.68  Wagner’s original work on gene 
transfer was partially funded by the Detroit-based Genetic Engineering, Inc. which would have 
held an exclusive licence under the Ohio University/Jackson patent on microinjection filed in June 
1981. From the very start, the Ohio University administration was backing Thomas Wagner’s work 
to put the institution on the map and raise revenues. Charles Ping, the University President, man-
aged to secure an important and lucrative alliance with the state administration, which largely 
relied on Wagner’s research and the promise biotechnology held for employment and economic 
growth in a ‘rust-belt’ state. Ohio University opened the Institute for Animal Biotechnology in 
1984 with a grant from the Thomas Alvaro Edison programme, a fund initiated by the new Demo-
crat governor Dick Celeste to provide seed capital for innovative projects. The same year, the uni-
versity bought out the Genetic Engineering, Inc. claim to the exclusive licence, and established its 
own spin-oﬀ company, Embryogen.
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Fig. 5-5. The golden eggs of biotechnology. 
Drawing in Nature that accompanied Emtage 
1985. 
© Nature Publishing Group.
The agricultural promise of transgenic technology loomed large in corporate strategy. It was 
made feasible by Brinster’s collaboration with USDA researchers in Beltsville, Maryland that 
started in 1984 and resulted in transgenic sheep and pigs.69 In 1985, Azim Surani reported the 
production of transgenic sheep at the Animal Research Station in Cambridge, a project enthusias-
tically promoted by its funder, the recently renamed UK Agricultural and Food Research 
Council.70  Sheep transgenesis was also pursued the Edinburgh site of the Institute for Animal 
Physiology and Genetic Research (IAPGR),71 and a spin-oﬀ company, Caledonian Transgenics, was 
founded to commercialise this work in 1986. The global reach and the promise of real applications 
encouraged agricultural institutions to build up their molecular portfolios. Thus, in the Soviet 
Union, a collaborative project focusing on transgenesis and embryo transfer in farm animals was 
established at the All-Union Institute for Animal Husbandry in the Moscow satellite town of Du-
brovitsy. Led by Lev Ernst, the project relied on the infrastructure of Soviet research institutes.72  
With one microinjection facility available and limited molecular expertise on site, Ernst followed 
the Brinster example and secured DNA supply from a molecular biology laboratory at the Moscow 
State University.73   
Biotech companies and universities interested in agricultural applications of animal transgenesis 
created alternative networks through which individuals, skills, DNA and animals travelled. While 
Wagner was being delicately excluded from the citation history of transgenic mice (see Chapter 4 
§5), the fledging patent application ended up creating a new legitimacy – and controversy – for his 
claims when it was granted in 1989. Furthermore, despite Embryogen’s struggle to attract inves-
tors willing to pour money into the Ohio facilities, and the company’s ultimate merger with an-
other start-up and move to New Jersey, Wagner’s involvement in a state-private enterprise opened 
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other doors. Thus, Ohio built connections with emerging Asian institutions, for instance Beijing 
Agricultural University and provincial biotechnology centres in China, as well as universities in 
Japan and Malaysia. Finally, Wagner’s position as scientist-entrepreneur, a new identity forged by 
the rise of biotech, secured him an invitation to the US Congress’s Oﬃce of Technology Assess-
ment (OTA) Committee on Biotechnology in 1986, and he was a prominent voice in congressional 
investigations and media debates on transgenic research and animal patenting.
The success of transgenic experiments was constructed in the early 1980s in a highly visible fash-
ion. A number of laboratories invested in the new technique, hoping to capitalise on a new ex-
perimental system through publications, expanding knowledge and, in some cases, by attracting 
funding and building hope of future profits. A network of courses and personal contacts, with 
active engagement from several pioneers, helped with the transmission of elaborate techniques, 
though a number of laboratories picked the skills up independently. Through diﬀerent strategies, 
new laboratories embraced transgenesis and adapted it to their infrastructure and research pro-
grammes. Moreover, with the expansion of commercial interest in genetic engineering and en-
couragement of private funding for biomedical research, new networks were being built around 
the commercial exploitation of transgenic technology. In the early days, these connections were 
driven by the agricultural promise.  
§3. Making knowledge with transgenic mice 
Unusually, the mouse was the first animal for which a novel molecular technology had been im-
plemented, while other laboratory animals lagged behind. This state of aﬀairs did not last. Be-
tween 1982 and 1985, gene transfer was achieved in other animals key to developmental biology. 
The use of P-elements (transposable genetic elements that ‘jumped’ in the genome) to transfer 
genes into Drosophila was reported in 1982 by Gary Rubin with Allan Spradling, both molecular 
biologists working with the fly at the Carnegie Department of Embryology.74  Gene transfer at-
tempts were also performed with the nematode C. elegans, with genome integration and germline 
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transmission announced in 1986.75 These experiments did not receive attention comparable to 
mice outside of the embryological community, but their profile was high within. With the prolif-
eration of eukaryotic experimental systems suitable for molecular intervention, these species 
were being used to elaborate new knowledge about gene action in higher organisms. The empha-
sis on molecular genes as a unifying focus of research, aided by the ability to splice and hybridise 
genes between species, made comparisons between diﬀerent experimental organisms more 
straightforward. 
In 1985, the Cold Spring Harbor Symposium on Quantitative Biology celebrated its 50th anniver-
sary with a meeting on ‘The Molecular Biology of Development’. It was organised by Joe Sam-
brook, a molecular biologist at Cold Spring and co-author of the Molecular Cloning handbook. In 
his foreword to the published proceedings, Sambrook explained the choice of topic:
In recent years... developmental biology has undergone a dramatic change and has ma-
tured from a descriptive to an analytical science. There is no doubt in my mind that this 
change stems almost entirely from two technical advances – the ability to use molecular 
cloning to isolate and characterize wild-type and mutant versions of genes that control 
or are expressed at specific developmental stages and, second, the ability to generate 
transgenic organisms in which the expression of the introduced gene(s) is correct both 
spatially and temporally.76
Such emphasis could be expected from a molecular biologist and a Cold Spring Harbor event, and 
the programme reflected such excitement. Yet the opening and closing remarks at the sympo-
sium, by John Gurdon and Gerry Rubin, respectively, presented two contrasting perspectives.77  
Rubin’s concluding lecture celebrated the newly available methods such as gene transfer, in vitro 
mutagenesis and antisense RNA – which he characterised as  ‘non-classical’ or ‘surrogate’ genetics 
– and highlighted the variety of species with which new molecular knowledge of development 
was being produced: mice, but also Drosophila (his organism of choice), C. elegans, yeast and 
Xenopus. Gurdon’s introductory lecture emphasised the historical achievements of experimental 
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the ambitious developmental questions of determination, axis formation and patterning. Recog-
nising the promise of gene transfer, to which he himself had greatly contributed, he reminded the 
audience that the traﬃc between molecular biology and embryologists had been two-directional, 
and suggested that to answer the big developmental questions, studies of protein interactions and 
using cell-free systems had to be taken seriously alongside transgenic organisms.
Transgenic mice were certainly a highlight of the symposium, with leading researchers reporting 
their latest work. However, it was a consensus of the meeting that their utility left something to 
be desired. In Drosophila, a single gene integrated into the genome on a P-element showed rea-
sonably predictable levels of expression – something emphasised in discussions around the fly 
publications.78 In mice, integration of foreign genes happened at random into unknown genomic 
positions. The DNA itself did not insert as a single copy, but replicated into tandem repeats 
through a mystifying mechanism. The levels of expression could vary widely and seemed to cor-
relate poorly with the number of gene copies that ended up in the mouse genome.79 Jaenisch’s ap-
proach, which relied on retroviruses with a single copy integration, circumvented that problem, 
but it involved the extra step of purifying the viruses and was more likely to give rise to mosaic 
animals with genes in only some tissues. 
Transgenic researchers were aware of this lack of control and emphasised it in talks (Fig. 5-6). At 
the same time, it did not remain merely a limitation. Unpredictable integration and the lack of 
correlation between gene copies and expression levels became resources to articulate further 
questions. Thus, random insertion could give rise to mutations, some of them resulting in embry-
onic lethality, and several were reported at the Cold Spring Harbor meeting. Such mutants had 
been the staple of developmental genetics since the 1930s. However, with transgenic mice, the 
disruptive gene was known and a molecular probe could be designed to map and sequence the 
aﬀected chromosomal region, oﬀering a molecular take on gene hunting. 
Molecular tinkering with the injected DNA constructs drove attempts to circumvent unpredict-
able expression and define the key elements that were required. It fit well with the intense inter-
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est in eukaryotic gene regulation from molecular biologists. While the possibilities of genetic 
therapies and agricultural promises captured media attention, the immediate attraction of trans-
genic mice in their early years was the ability to examine eukaryotic gene function in space 
(across tissues) and time (during development). In 1982–88, a great variety of gene constructs 
were injected into mouse embryos, connecting experts across fields. Here, I will consider two ex-
amples of research with transgenic mice to illustrate the broader pattern of their use: the study of 
control sequences in human globin genes and work with oncogenes as the genetic basis of 
cancer.80  
As Chapter 2 showed, much impetus behind recombinant DNA research was to provide a new way 
to investigate and understand eukaryotic genes. With the ability to isolate genomic or cDNA, the 
study of expression exploded.81  The second edition of Benjamin Lewin’s Gene Expression (1980)was 
devoted to eukaryotic chromosomes, after the 1974 text on bacterial expression, and was a com-
pletely diﬀerent text intended as another volume rather than an update.82 Over a thousand pages, 
the book struggled to reflect the dramatic amounts of new knowledge made in only three years. 
Studies of the structure of eukaryotic chromatin – the combination between DNA and various 
protein that packaged it into chromosomes – and the eﬀect of diﬀerent sequence regions on ex-
pression levels was booming. Introns – regions of DNA sequence not found in the final RNA tran-
script – were a hot topic in the late 1970s.83
Promoters, well-described by bacterial molecular biologists, were already instrumental in the 
first gene transfer experiments. These elements initiated RNA transcription from DNA, and had 
to be located upstream of the gene, with their specific position in the sequence aﬀecting the rate 
of RNA production. Yet in eukaryotes, other regulatory elements worked at a long distance away 
from the gene were being identified. These ‘enhancers’ were first described in 1981 in the familiar 
tumour virus SV40. Their striking feature was demonstrated by Paul Berg in the same year, as he 
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showed that removing these bits of DNA and moving them downstream of the gene did not reduce 
expression. Initially, enhancers were suspected to be specific viral elements. However, by 1983 
similar sequences were detected in lymphocytes, suggesting they were cellular elements that the 
viruses hijacked and moved, and the search for new enhancers continued.84  
The vast majority of gene expression analysis in this period was performed in cultured cells or 
cell-free systems. Work with transgenic mice could build on in vitro experiments by showing 
whether the foreign gene expression was limited to the predicted tissues and to what extent the 
existing control elements could mimic expected quantities of protein. Human globin genes were a 
major genetic system for such projects as they were among the first genes to be cloned. Develop-
mental changes in the way human haemoglobin is made – the embryonic, foetal and adult mole-
cules combine diﬀerent globin subunits – were another attraction. Unlike other genes, significant 
expression of foreign beta globin in transgenic mice had not been achieved. Lacy and Costantini 
continued working with beta globins in New York, and while they managed to detect some ex-
pression, tissue specificity was a problem. They could detect the rabbit beta globin mRNA in some 
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tissues – skeletal muscle and testes – but not the expected blood cells.85 By 1985, however, the team 
published a paper with a mouse-human beta globin gene hybrid, including some mouse and hu-
man regulatory sequences upstream and downstream of the gene. The result showed specific ex-
pression in red blood cells, even though the levels remained low.86 In the same year, Brinster, Pal-
miter and collaborators at the universities of Alabama and Cincinnati reported tissue-specific 
expression of human beta globin with a diﬀerent construct.87 Removing prokaryotic sequences 
from the plasmids or phage vectors improved the levels, and was recommended for all subsequent 
transgenic experiments.88   
In 1987, after years of experimenting with the globin genes in cultured cells, Frank Grosveld and 
George Kollias at NIMR constructed a beta globin DNA that showed predictable expression. 
Through a contact with Hogan, Kollias had attended the second Cold Spring Harbor course and 
brought transgenic techniques into Grosveld’s lab.89  Drawing on extensive work on globin pro-
moters and enhancers in culture, studies of thalassaemia patient cells and transgenic experi-
ments, Grosveld and Kollias designed a control sequence that they expected to combine all the 
crucial features required for expression. The resultant transgenic mice showed very high expres-
sion, comparable to the levels observed in humans. Significantly, the levels of human globin pro-
tein also correlated with the number of foreign genes that incorporated into the germline – an 
indication that their combination of promoters and enhancers alone was suﬃcient to generate 
normal expression. This region, that they labelled the Dominant Control Region, became a key 
part in the regulator model of globin genes.90
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In parallel with the globin work, other groups made transgenic mice with new eukaryotic genes 
that had receiving dramatic attention circa 1980. These were oncogenes, associated with the mo-
lecular processes behind carcinogenesis. The research into origins of cancer, in which mice 
played a central role, had oscillated between emphasising genetic and environmental causes. Pro-
viding animals for cancer research persisted as a key agenda for mouse genetics, as the disease 
became a major locus of biomedical funding. Viruses were an important research programme for 
cancer causation in the 1930s and again in the 1960s and 70s, with major interest in animal tu-
mour viruses that I discussed in Chapter 2.91  In 1975, Dominique Stehelin, Harold Varmus and Mi-
chael Bishop used Southern blotting with a viral probe to detect a Rous sarcoma virus gene (later 
labelled src) in the chicken genome. While this result is celebrated as the beginning of oncogene 
research, work from other groups, detection in diﬀerent species and alternative methods that re-
lied on gene transfer were required to make a convincing case for their importance in cancer 
causation.92 In only a few years, oncogenes became the dominant concern of carcinogenesis stud-
ies and a key instrument for research.93
Several laboratories pursued inserting oncogenes into the mouse germline. Brinster and Palmiter 
attached the viral src gene to their metallothionein promoter in the summer of 1982, with no tu-
mours in the resulting mice. However, in the same summer, an experiment that relied on improv-
ing expression of the thymidine kinase gene by SV40 enhancers led to unexpected brain tumours. 
Palmiter’s construct included a large part of the viral ‘early’ region. In subsequent studies, Brin-
ster and Palmiter showed that the control region in the virus and the T-antigen gene were suﬃ-
cient for tumour formation, thus demonstrating that SV40 T-anitgen was an oncogene.94 In Le-
der’s Harvard lab, Tim Stewart was working with the cellular myc oncogene involved in Burkitt’s 
lymphoma – Leder’s long-term interest. Learning the molecular techniques, Stewart combined 
the gene with a promoter and enhancer sequence from the mouse mammary tumour virus 
(MMTV), in the hope that it would be a ‘strong’ control element. Gene expression was targeted to 
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the mammary tissue, leading to breast tumours in resulting mice. Papers from both groups were 
published in Cell in June and October 1984, respectively, and both experiments featured on the 
cover (Fig. 5-7).95  
Famously, a patent was filed on the Harvard mouse, in line with the agreement Philip Leder had 
with DuPont who sponsored his research and move to Harvard. It would appear that they re-
sponded to the promise of disease models that had been articulated in anticipation of successful 
gene transfer into mice, most coherently by Mintz. Yet Leder and Stewart’s mice were not initially 
presented as models of breast cancer. The major utility of these animals, reflected in the patent 
claims, was as instruments for expression analysis and carcinogen testing, potentially superior to 
the non-transgenic mice that had been used for similar purposes. They were presented as a source 
of novel tumour cell lines that could be derived from diﬀerent tissues, and a means of studying 
the MMTV promoter sequences further. 
Gene expression was one of the major issue at stake: was the mere presence of a single oncogene 
suﬃcient to cause tumours, or was gene regulation to blame?96 On top of that, the slow emergence 
of tumours fit with the already-articulated multi-step models of carcinogenesis, in which several 
things had to go awry for a tumour to emerge.97  With further results form Brinster, Hanahan and 
Wagner reported in 1985, mice were promoted over cell culture as tools for dissecting multi-step 
carcinogenesis. In a 1987 experiment, Leder’s group showed that when mouse strains with diﬀer-
ent oncogenes were crossed, tumour development increased dramatically in oﬀspring that carried 
two oncogenes.98 While this work relied heavily on knowledge generated in vitro, transgenic re-
searchers argued their mice were genetic animals that were best-suited to help solve genetic 
problems.99
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range 1997a.
97 Ibid., Keating & Cambrosio 2012: 306–14.
98 Sinn, et al. 1987.
99 Rigby 1985; Hanahan 1988, 1989.
For developmental biologists, the utility of transgenic mice was less immediate. Insertional muta-
tions were a promising line of work, but creating new lines was slow.100 Some oncogenes were 
implicated in diﬀerentiation and cell division, and the haemoglobin system held the promise of 
developmental switches to be determined. However, the interest in gene regulation fit well with a 
molecular take on diﬀerentiation that had been promoted in the 1970s by the like of Gurdon, 
Markert and Davidson. Thus, Azim Surani’s work on genomic imprinting – the idea that alleles of 
the same gene could behave diﬀerently depending on whether they were on a paternal or mater-
nal chromosome – initially relied on making parthenogenetic embryos by moving two male or two 
female pronuclei into a mouse zygote. While Illmensee had claimed such constructed embryos 
viable, both Surani and Davor Solter’s group argued their development was in fact severely ab-
normal. Surani proposed that the same genes could be regulated by means external to their DNA 
sequence, or epigenetically, and undertook a molecular demonstration to make a case for imprint-
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100 That embryonic mutations would lead to identifying important genes was also not immediately obvious. Gerry 
Rubin remarked: ‘The major limitation of this approach is that only a small minority of embryonic lethal muta-
tions will be in genes with functions of developmental interest. As Mary Lyon put it, “A lot of things can cause a 
mouse embryo to go wrong early.” – Rubin 1985: 907.
Fig. 5-7. Transgenic mice with oncogenes on the cover of Cell, 1984. Left, cross-section of a brain tu-
mour from the Brinster-Palmiter paper, June 1984. Right, mouse with a visible breast tumour from the 
Leder-Stewart article, October 1984.  
© Cell. 
ing. In 1987, Surani’s postdoc Wolf Reik – a former PhD student of Jaenisch’s – made transgenic 
mice with a gene whose methylation could be assessed. Methylation – presence of added methyl 
groups on chromatin – was known to aﬀect expression in vitro. Crucially, the pattern of methyla-
tion in the resulting mice changed depending on whether it was inherited from the mother or the 
father in subsequent crosses.101  
Transgenic mice were thus being embraced as a means to investigate gene function where diﬀer-
ences between tissues could be demonstrated and controlled. The ability to detect promoters and 
enhancers was assumed to correlate with gene numbers, and showed suﬃcient conditions for ex-
pression. Moreover, the very limitations of transgenesis by pronuclear microinjection were re-
cruited to pose new questions and generate novel experimental agendas. The promise of trans-
genic mice had been accepted before reliable gene expression was achieved, but the very process 
of controlling expression was informative for molecular biologists. These results were not chal-
lenged in print, but rather integrated into the growing knowledge about eukaryotic genes. The 
heavy focus on DNA made comparisons between systems as diverse as mice and yeast increasingly 
productive, especially since nucleic acid hybridisation showed high levels of evolutionary conser-
vation between many gene families.102 To revisit Rubin’s summary of the 1985 Cold Spring Harbor 
meeting: “The surprising finding of evolutionary conservation of a number of DNA sequences 
known to encode important functions has provided a way to relate observations made in diverse 
systems. The use of sequence cross-homology as a tool to utilize the advantages or advances of 
one experimental system in another was a recurring theme in this year’s Symposium.”103
Heralded by the supermouse, the study of gene expression was thus the primary focus and most 
celebrated application of transgenic mice in the 1980s. Yet, while most studies maintained a mo-
lecular focus without a clear goal at medical translation, transgenic researchers were not blind to 
the world of biomedicine, and biotech and medical researchers paid attention. As noted already, 
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while the studies may have focused on specific gene expression, the genes selected often had po-
tential medical relevance – insulin, interferon, globin genes and oncogenes were all hot subjects. 
Moreover, the number of transgenic researchers entering new niches in the biotech industry was 
considerable. While most early projects focused on the production of valuable proteins in animals 
and attempts to breed better farm animals, and not disease models per se, relevance to human 
health remained on the agenda, and became a priority after 1987. Thus, in their studies of on-
comice, Brinster, Leder and Hanahan built links with cancer researchers and clinical scientists 
who provided detailed descriptions of the cancers his mice developed. Between 1987 and 1990, a 
flurry of reviews and papers on transgenic animals targeted clinical audiences through medical 
journals, increasingly employing the language of “models”.104  
They easily achieved a high profile due to their novelty, scarcity and the ability to claim in vivo 
analysis. This status was reflected in the publication pattern. Even as the scale of transgenic work 
expanded considerably and entered more disciplines, the majority of transgenic papers were pub-
lished in high-profile journals – ‘bridge’ publications covering multiple fields such as Science, Na-
ture or PNAS, or generalist biological journals like Cell (Fig. 5-8). Yet such experiments were few in 
comparison to cell culture studies, they required more time, a rare combination of expertise and 
animal infrastructure. As I discuss in the next section, this focus on individual gene expression 
and the scarcity of transgenic animals aﬀected the way they were produced and defined.
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§4. “A boutique operation”: Standards and scales 
Today, transgenic mice are easily available through university ‘core facilities’ – to which their 
production was outsourced in the 1990s – as well as the Jackson Lab and the many commercial 
suppliers, both new and established. Yet most early users had to rely on their own ability to intro-
duce foreign DNA into the germline, or find willing collaborators. The resulting strains could then 
be studied in more detail or crossed to observe the eﬀects of multiple genes or control elements, 
yet the primary style of research was to produce new animals with an ever-expanding number of 
available cloned genes and control elements. The husbandry, record-keeping, disease manage-
ment and breeding of transgenic mice relied on established practices of mouse genetics that were 
propagated through demonstration, handbooks and existing institutional experience.105 Yet, de-
spite their place as tools and iconic symbols in the molecular interpretation of mammalian devel-
opment, the established mouse genetics community was barely involved in transgenic work until 
the 1990s. The focus on specific genes was the core interest for molecular biologists, and many 
cloned genes remained to be introduced and studied. Some transgenic experiments paid attention 
to the genetic background of the strains they were using and the designed mouse stocks had to be 
maintained, much like novel mutant strains produced through classical genetic means. But as this 
section will show, the institutional separation of transgenic research from traditional mouse 
genetics created modes of production and exchange outside of the usual supply networks.
Despite its role in all things murine, the Jackson Lab did not begin advertising transgenic mice 
until 1993, and even then served largely as a repository for external providers. The Lab was also 
marginal in research with transgenic animals.106  Thomas Wagner’s collaborator Peter Hoppe con-
tinued to work on making transgenics there, but anecdotal evidence suggests that he was hard-hit 
by the Illmensee aﬀair as the prime collaborator and co-author on the mouse cloning paper. He 
taught the techniques of mammalian development, including pronuclear microinjection, at the 
Jackson Short Course in Mammalian Genetics, but did not publish any further work on transgene-
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rameters in lab animal standardisation, such as physiology, disease management or environment, see Clause 
1993, Kirk 2008, 2010, 2012, Leonelli, Ramsden, Nelson & Ankeny Forthcoming, 2014.
106 Since then, the Jackson Lab has become a major transgenic producer and supplier.
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Fig. 5-8. Articles on transgenic mice by journal type, 1985–1990. 
Data obtained using Web of Science core database search for ‘transgenic AND mouse’, with relevance 
confirmed by title and abstract. Only journals that published more that two papers on transgenic mice 
throughout the six-year period were included in the analysis, with a total of 558 papers. Categorisation 
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sis until 1987. 
As an institutional strategy, leaders of the Jackson Lab focused the limited resources elsewhere. 
As a global repository of mouse strains, the lab was heavily involved in the techniques of embry-
onic cryopreservation. Another example of a technology that came from the intersection between 
mouse embryology and farm animal research, the ability to safely freeze and thaw embryos and 
transfer them to surrogate females had been established as a feasible technology in 1977 at a Ciba 
foundation meeting in London.107  In 1978, Jackson started its cryopreservation programme, with 
281 strains stored this way by the summer of 1982;108  similar eﬀorts were made at the MRC Har-
well unit in Britain. The Jackson Lab did recruit two molecular biologists in 1983 to establish 
cDNA libraries from well-known inbred strains of mice, in line with the institution’s archival mis-
sion, and to study cancer in existing mouse lines. In a 1986 oral history interview commissioned 
by the lab, David Baltimore, who had spent his high-school summers at the Jackson student 
courses, lamented that the laboratory was unlikely to become an eﬃcient site for molecular re-
search. While predicting an important role for the lab in mouse supply and quality control, Balti-
more felt that the narrow research focus, remote location and 9-to-5 work ethic were inadequate 
to rewrite the mouse in the language of DNA.109
Community-wide, there was some eﬀort to integrate transgenic mice into the existing genetic 
standards. In 1984, a group of the International Committee on Standardised Genetic Nomencla-
ture for Mice met at the Jackson Lab to discuss symbols for mouse globin genes, and in the process 
produced standard designations for transgenic mice. Their guidelines were published in the 
Mouse Newsletter as part of a 90-page nomenclature update.110  The transgenic designations sug-
gested criteria for what a geneticist would count as a good mouse. There were multiple options for 
the exclusion and inclusion of extra information, but the basic structure was as follows, to take an 
example: Tg(12OCUHba)N33. Tg stood for transgenic; the number in parentheses designated the 
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109 David Baltimore, interviewed by Susan Mehrtens on 12 November 1986, Jackson Lab Oral History Collection. 
110 International Committee on Standardised Genetic Nomenclature for Mice 1985. On the role of nomenclatures, 
see Bangham 2014. 
chromosome into which the gene had integrated (here, chromosome 12); the three-letter code in 
capitals indicated the species that the gene came from (here, OCU for the rabbit, Oryctolagus cu-
niculus); the italicised or underlined three letters represented the standard gene abbreviation 
(Hba for alpha-globin). The numbers after the brackets designated the Newsletter code for the in-
stitution where the mouse was made (N for NIH), and the the final number referred to the serial 
number of the insertion at that institution. 
The same document recognised the unwieldiness of this nomenclature by suggesting that full 
names be reserved for Materials and Methods sections. Despite this allowance, the Jackson no-
menclature set itself against the established short names of existing transgenic mice, named lo-
cally after the gene of interest. The laboratories that produced transgenic mice were happy to 
maintain their own naming systems in the scientific press, adding to the credit contribution they 
received in collaborative papers and future applications. The suggested nomenclature was not 
picked up. In 1989, when the committee published its nomenclature recommendations alongside 
the list of known mouse strains and genes – over 800 pages long – transgenic designations re-
mained tucked away as a few paragraphs in the section on globin genes, while inbred, congenic 
and recombinant strains received a chapter each.111
By contrast, existing accounts suggest that transgenic Drosophila were readily integrated into the 
practices and institutions of fly genetics.112  While also used heavily in gene expression studies, 
fruit flies modified with P-elements could be readily used in large-scale mutagenesis screens and 
in mapping projects via ‘chromosome walking’ that allowed mapping of unknown elements adja-
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cent to the known marker on the chromosome.113  Such approaches, however, were too laborious in 
mice, and chromosome walking was not achievable with any ease.114 
A number of factors might explain the gap between mouse genetics community and transgenic 
researchers. First, most scientists working with transgenic mice were trained in molecular biol-
ogy or mammalian development, and often had worked with diﬀerent species before. Communi-
cation networks had few overlaps – few transgenic labs contributed to the Mouse Newsletter, and 
few genetic labs carried the molecular expertise. Finally, the experimental focus, costs and genetic 
uncertainties of making transgenic mice made Jackson-style practices of genetic purity that had 
been established for inbred lines a secondary concern.
On one level, genetic specificity was a selling point for transgenic mice. Accessing and editing in-
dividual genes and observing the eﬀects in a well-studied mammal was a major attraction. The 
emphasis on bespoke production and designer genes – a term that had spread through news arti-
cles on genetic engineering since the mid-1970s – was not limited to transgenic animals. Mono-
clonal antibodies, another major biomedical innovation of the 1970s that attracted much more 
dramatic commercial interest promised to produce antibodies against any substance.115  In her 
neo-Marxist analysis of biotechnology, Melinda Cooper has argued that genetic intervention re-
placed the industrial emphasis on mass production and reproduction of standardised life forms in 
biomedicine with a destandardisation project.116 The tension between standards and specificity is 
also thematised in studies the of more recent uses of transgenic mice, in which the animals are 
described as simultaneously made-to-order and relying on established genetic standards.117  
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These studies tend to conflate the worlds of mouse genetics and transgenic work – an under-
standable state of aﬀairs since the mid-1990s, but one that ignores the historicity of “transgenic 
models” and the work involved in the uneasy reconciliation of the supply and maintenance of 
transgenic and inbred mice that had taken place in the preceding decade.118  The divisions between 
the diﬀerent institutions can be linked to the style and scale of research. Where a new mouse mu-
tant had been discovered, whether spontaneously or as part of a planned mutagenesis screen, for 
instance by exposing mice to radioisotopes or chemicals, it had first to be treated as a genuine 
novelty rather than as an anomaly to be ignored.119 To produce a recognised inbred strain, it then 
had to be crossed to its siblings or parents for at least twenty generations, where ideally an indi-
vidual mutation would be the clear source of variation in future crosses. 
The focus of most inbred strains remained on a single gene or a locus, with extensive inbreeding 
designed to make the remaining background uniform. Yet the core aim of the process was to make 
these mice useful in future crosses for large-scale mapping projects, or, crucially, for research into 
diseases in which concerns about genetic purity could be black-boxed. By contrast, transgenic 
mice were designed with a specific construct in mind that was central to the immediate investiga-
tion. If a mouse showed the presence of the foreign gene, its most likely destiny was that it would 
be killed, its organs separated, homogenised and assessed for tissue-specific expression. In most 
experiments, which specific strain the modified embryos came from was unimportant. The vast 
majority of transgenic experiments relied on the first-generation (F1) hybrids between common 
inbred strains – a strategy that had been common in mouse embryology where hybrids were val-
ued for their recalcitrance to manipulation (see Chapter 1 §2). Not all experiments would require 
further breeding, and many mice were discarded in the hope that they could be derived again.120
If there was an interest in establishing a new strain, the resulting transgenic “founder” mice were 
then bred to hybrids of similar crosses, allowing researchers to follow foreign genes through gen-
erations. The husbandry section of the Mouse Book dedicated four short paragraphs to the gen-
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eration of transgenic mouse lines, paying more attention to the pseudopregnant surrogates and 
sterile males required to make them receptive to embryo transfer after microinjection.121 While 
noting that some experiments would require specific inbred strains if the genetic background 
was important for specific purposes, the handbook recommended using the F1 hybrids in most 
cases and stressed the limitations of microinjection. It also had to warn against killing the foun-
der mice to assess their gene expression until a line was securely established and several genera-
tions of oﬀspring were able to show clear presence of foreign DNA. 
There were also issues of cost and scale. My oral history interviews, researcher survey and analy-
sis of transgenic papers in the late 1980s show that few mice had been sent oﬀ indiscriminately, in 
the manner of plasmids, but were mostly exchanged among collaborators with a view to shared 
authorship on resulting publications.122 First, little could be gained by using others’ strains that 
had already been published, as the key attraction of the technology was the ability to examine 
new molecular constructs. Second, production of transgenic mice was resource-intensive and 
uncertain. A 1989 report described microinjection as tedious and ineﬃcient, estimating the cost of 
the instrumental set-up at $50,000, with an annual colony cost that could fall anywhere between 
$10,000 and $100,000, depending on size.123  The timeframes required to establish new lines were 
often unaﬀordable, given the ineﬃciency of the procedure. Certain injected elements – for in-
stance the growth hormone gene – reduced fertility. Despite the relative standardisation of pro-
nuclear microinjection, its success rate remained low and was a continuous source of concern. To 
quote a review in BioTechniques,  
Typically, if 100 eggs are collected, approximately 85 will be suitable for injection, 60 will 
survive the injection, 6 of the implanted zygotes will be born and 1–2 of the mice will be 
transgenic. The inherent inefficiency of this process can be a source of frustration for the 
beginner.124
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With local diﬃculties in making transgenic mice, concerns more pressing than genetic purity oc-
cupied most workers. Yet despite these diﬃculties, the genetic status of mice was recruited to 
promote transgenic research. In 1989, the US Congress Oﬃce of Technology Assessment pub-
lished a report on Patenting Life in its New Developments in Biotechnology series, largely in response 
to the OncoMouse patent granted the year before. In its review of transgenic technology, it noted 
that despite the limited number of labs involved in such work – it estimated several hundred 
worldwide – and the scarcity of experts with the right skills, mice remained a promising animal 
for genetic modification. It listed several advantages for the species: being a “warm-blooded 
mammal with many similarities to humans in genetics and physiology”, small and inexpensive, 
with well-known genetics and physiology compared to other mammals and “available in a variety 
of diﬀerent, well-characterized, genetically consistent lines for use in diﬀerent types of 
studies”.125
The invention of a diﬀerent method for inserting or removing genes helped bridge the divisions 
between transgenic research and mouse supply. It relied on homologous recombination in embry-
onic stem cells that finally allowed the selection of cells in which foreign DNA was integrated at a 
known site, or where a wild-type gene was removed. The latter approach yielded ‘knockout mice’, 
the subject of the 2007 Nobel Prize, first reported in 1989.126 They allowed the generation of 
strains in which specific genes could be removed and phenotypes observed, making the strains – 
rather than individual animals – more valuable to outsiders. These new techniques, alongside the 
expanding number of conventional transgenic strains, generated an interest in integrating mo-
lecular embryology with mouse genetics. 
Another nomenclature case illustrates these changes, as a new eﬀort to establish transgenic des-
ignations was undertaken by a committee at the Institute of Laboratory Animal Resources at the 
US National Resource Council. Chaired by Jon Gordon, the Committee on Transgenic Nomencla-
ture published a report in 1992 that oﬀered a minor update on the existing but underused guide-
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lines, but it had more impact as the research interests shifted since 1984. The report highlighted 
the need to organise the boutique operation, citing several reasons:
Duplication of effort. Many different transgenic animals already exist (perhaps as many as 
10,000 strains). Without a catalog, investigators might needlessly reproduce existing 
models.
Loss of valuable transgenic models. Many transgenic models are not relevant to the re-
search programs of the laboratories in which they are made [...] In the absence of an ef-
fective method to make their existence known, such models would probably be dis-
carded, even though they might be extremely valuable to investigators in other laborato-
ries.
Loss of information. Many of the subtleties of gene regulation are discernible only by 
comparing the expression of closely related transgenes in different strains.127
In 1993, Jackson Lab created a resource and oﬀered to supply researchers with transgenic and 
knockout mice, insisting that it would only accept mice with no intellectual property 
restrictions.128  In the same year, the NIH gave a major grant to develop a database at Oak Ridge 
that then moved to Johns Hopkins. TBASE, as it was called, used the transgenic nomenclature in 
its computerised entries, making the management of cumbersome designations more 
straightforward.129 These changes went a long way towards centralising supply and easing com-
munication of transgenic animals, and set up the infrastructure that made these organisms much 
more routine in the 1990s.  
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From giant rodents to patented beings, transgenic mice created a new niche for research into the 
molecular genetics of higher animals. Their novelty and the dramatic results obtained in the early 
work attracted many biologists to the new technique. With multiple models of communication 
and sustained attention from molecular biologists, courses and handbooks allowed the technology 
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to be adopted in laboratories that could aﬀord to venture into a new system. The diﬃculties asso-
ciated with their production and considerable costs – financial, but also temporal – were a limit-
ing factor that kept the work concentrated in under a thousand laboratories worldwide. The pow-
erful and widely-circulating images of supermice promised a controlled way to study genes and 
make new kinds of animals. However, in practice multiple issues with controlling gene expres-
sion remained, especially in comparison with tissue culture and Drosophila. Yet these very prob-
lems were recruited to generate new questions about gene expression and attempts to control 
them made new knowledge about DNA elements, demonstrated in a whole animal. 
The prominent research questions, low eﬃciency of the procedures, limited control over integrat-
ing genes and limited communication with the established sites of mouse genetics restricted the 
circulation of the new animals. Transgenic mice were both valuable and diﬃcult to make and 
maintain, but their scientific worth was also more transient given the dominant scientific inter-
ests in the 1980s. The diﬀerence of scales between the local small laboratories and the big animal 
suppliers made widespread circulation and integration of transgenic animals into preexisting 
mouse networks problematic, and it was not a priority for either side. Much like in the case of 
gene mapping and sequencing, scaling up local laboratory practices required articulated agendas, 
resources, a critical mass of researchers and a new social order. With the expansion of transgenic 
enterprise – both academic and commercial, – conflicts over intellectual property, and new tech-
nologies such as knockout animals, transgenic research went through a series of standardisation 
attempts, centralisation of information and outsourced production. To this day, however, the 
craft-like procedures and local diﬃculties mean that making transgenic animals remains, to 
quote one researcher, a “boutique operation”.130   
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Conclusion: Transforming mice, transforming biology
This thesis has presented a multi-sited analysis of the development and early adoption of a hybrid 
set of techniques and a novel laboratory animal. Transgenic mice were born and made at a time of 
significant shifts in the way biological research was funded and regulated, especially in the USA. 
While the sparse historiography of 1980s biology has understandably focused on controversy, bio-
tech enterprise and expansion of intellectual property in academic research, transgenic mice of-
fer a less polarising case study that is better suited to highlight continuities as well as changes in 
this period. 
Introducing isolated DNA into mice had been envisioned since the 1960s, but the strategy for such 
a feat moved between disciplines and fashions in biomedical research: somatic cell geneticists, 
mouse developmental biologists and animal virologists variously imagined using their pet sys-
tems to manipulate mouse genetics in a molecular vein. Attempts to introduce foreign genetic 
material into the germline predated recombinant DNA, as manifested most clearly by the 
Jaenisch-Mintz experiments of 1972–74. However, these various experiments alone were not suf-
ficient to generate a large-scale programme of inserting isolated genes into mice, and researchers 
often pursued more pragmatic and immediate goals. New networks built around eukaryotic DNA 
and the circulation of experts, techniques and molecules made gene transfer into mouse embryos 
feasible. This agenda aligned the growing interest in higher animals as objects of molecular 
analysis with isolation and exchange of genes and control sequences, simplified dramatically by 
the recombinant DNA methods. 
The multiple and rapid success of pronuclear microinjection conferred credibility on the new 
method. Moreover, the competition for priority pushed the groups to elaborate the new proper-
ties of these new animals and pursue avenues of communication to a variety of audiences. These 
interventions steered away from controversy, but raised the profile of the new animals, epito-
mised by the dramatic images of supermice. The subsequent adoption of transgenic mice relied 
on their high profile, as well as the diversity of collaboration strategies and interests of the pio-
neer groups. In the 1980s, they were first and foremost a tool to study molecular gene function in 
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a whole developing animal and as such new mice had to be produced constantly, with little de-
mand to exchange strains. However, within the wider changes in the biomedical patronage, com-
mercial ventures were increasingly creating new networks for research, outside of the estab-
lished sites. 
While genetics provided a crucial set of knowledge, tools, practices and infrastructure for trans-
genic mice, it did not play a direct role in their invention and early adoption. These mice were 
made possible by a new alliance between molecular biologists working with viruses and isolated 
genes, and mouse embryologists drawing on the prestige and promise carried by the cutting-edge 
field of genetic modification. The molecularisation of the mouse embryo happened as new prac-
tices centred around molecules took centre stage in the 1980s, linking diverse groups of scientists 
and interested observers through exchanging DNA and driving interest in molecular explanation, 
and they met some resistance.1 Transgenic mice were not the sole or indeed most common way to 
apply molecular thinking and methods to the developing mouse embryo, but they were certainly 
the most symbolic and widely-publicised case in this transition.
The place of the mouse in biomedical researched transformed in this period. Domesticated as a 
genetic mammal useful for studies of cancer,  the post-war uses of the species diverged. The prac-
tices of genetic purity that were to sustain mass-production of mice relied on the dramatic scaling 
up of mouse work in institutions such as Oak Ridge and Harwell. Such expansions of scale en-
abled previously-diﬃcult mapping projects, expanded the infrastructures and focused the atten-
tion of key suppliers on maintaining the animals genetically standardised and free of disease. Yet 
these major projects, underwritten by the dramatic expansion in biomedical research in the USA 
and Europe, were challenged successfully by the outsiders who promoted diﬀerent strategies for 
handling variation. In a new niche, the mouse embryo became an experimental object that com-
bined techniques of mammalian embryology with genetic promise. By investing resources into 
culture techniques and building connections across disciplines, the growing community of mouse 
embryologists propelled their research object from a marginal and diﬃcult embryo to a widely 
used system. 
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This ability to attract new workers drew on the changing conceptualisation of embryology as de-
velopmental biology, and the molecular promise attached to the mouse. Existing mouse infra-
structure eased transitions from other laboratory animals. In the 1960s, a substantial fraction of 
these questions relied on the promise of molecular analysis and intervention, as molecular biol-
ogy was receiving greater funding and many practitioners were eager to expand the knowledge 
generated in bacteria and viruses to animals. The mouse became the only mammal suited for the 
job, and the challenges of embryonic manipulation and slow work were outweighed by its unique 
attractions in the menagerie of laboratory life – availability, comparatively low cost, genetic status 
and established connections to human biology. The existence of the quasi-embryonic teratocarci-
noma cells were another crucial link to the molecular world in the 1970s.
These transitions made transgenic mice possible, and these modified animals invited researchers, 
politicians and journalists to imagine a world where genetic engineering could be done with 
mammals. Despite the claims to human and farm animal applications, transgenic mice were not 
immediately made as models of human disease. Most dramatically, transgenic mice conferred the 
credibility of a whole developing living animal on molecular analyses of gene function. This work 
relied on the dramatic attention they received from molecular biologists and other outsiders, as 
well as the ability to ease comparisons with other species and in vitro systems by referring to con-
served molecular genes and the uniform techniques used for their analysis.
But long before they were made into models of human conditions, transgenic mice allowed sci-
ence writers, journalists and policy makers to approach the future of genetic intervention in hu-
mans. Despite severe public discomfort with genetic manipulation, journalists covered these ani-
mals in neutral tones, marginalising the activist voices and using the new experiments to reflect 
on changes in biology, future therapies and enterprise. Used extensively in laboratories for over 
80 years, mice themselves did not invoke a clear ethical threat and their origin in universities 
kept them away from the controversies that centred on privatising biological research until the 
OncoMouse patent. 
Circulation and exchange were crucial in transforming the species. The simultaneous generation 
of transgenic mice through microinjection relied on extensive movement of individuals, tech-
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niques and materials. While insertion of foreign genetic material into mouse embryos predated 
1980, most notably in Rudolf Jaenisch’s viral programme, it was the availability of isolated genes 
and the comfortable mastery of embryo manipulation that made the first gene transfer projects 
viable. I have shown that the power of recombinant DNA technology lay not only with the techni-
cal abilities it oﬀered – these were continuous with earlier approaches to gene transfer – but in 
their portability, the focus on eukaryote biology and the new networks of sharing isolated genes. 
These networks existed within a moral economy that resembled older cases of exchange in labo-
ratory animal biology in its emphasis on sharing and due attribution balanced against the motiva-
tions of maintaining priority. Unlike these older economies, however, these networks were rather 
decentralised, partly as a result of the dramatic expansion of biological research in the 1950s and 
60s, but also because cloned genes were highly mobile and extremely attractive. The dramatic 
pace of recombinant research made spontaneous sharing the rule. 
Another distinctive feature of recombinant DNA exchanges was that the troubled political climate 
emphasised containment of genetically modified organisms. Yet as I have shown, despite the 
common complaints about the stringency of the NIH guidelines and their real eﬀects on career 
trajectories, isolated molecules could travel easily though the postal system or with individuals 
moving between laboratories. The eﬀect of the guidelines was to limit the initial circulation of 
recombinant molecules to certain elite institutions, and while sharing was likely, accessing these 
networks relied on oﬀers of collaboration or the fortuitous moves of a postdoc.
In analysing the circulation of materials and claims, I have emphasised the themes of proximity 
and distance. Being in the right place and combining expertise was a crucial precondition for ex-
tending novel molecular work to mouse embryos. Thus, Jaenisch’s position at Salk brought him in 
contact with Paul Berg who would share some techniques. Mintz’s and Ruddle’s strategies to bring 
molecular and developmental biologists together in one laboratory paid oﬀ. At the same time, di-
visions of labour within these groups made this speculative work manageable and provided a 
safeguard for junior scholars in case they had failed. Other collaborations – Brinster and Palmiter, 
as well as Thomas Wagner and Hoppe – achieved similar results by keeping molecular and em-
bryological work separate between sites, each playing to their strengths. Such divisions were 
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maintained by the former group and were productive in terms of making transgenics in the 
1980s, with others emulating distant collaborations. However, as transgenic techniques were 
adopted widely through courses, a more synthetic approach took hold. That Frank Costantini and 
Elizabeth Lacy were involved in teaching at the Cold Spring Harbor course was largely a matter of 
proximity, with both of them based in New York City. However, their own experience in transi-
tioning from molecular biology to mouse development no doubt contributed to the success of 
teaching diverse audiences all aspects of the process. 
Between laboratories, the competition and isolated communication were productive, as rumours 
encouraged others to attempt similar work, while the credit for making a genetically modified 
mouse was up for grabs. But that the claims came from multiple sites within a very short period of 
time also generated credibility around the technique. That the news of the 1980 gene transfer was 
confirmed so rapidly at multiple sites, many of them eager to communicate to broad audiences, 
ended up crystallising the criteria around what counted as a transgenic mouse and allaying initial 
suspicions of artefact and uncertainties as to the fate of injected DNA. 
Taking the circulation of knowledge and materials seriously delivers a more complete picture of 
the way science functioned on a middle scale in this period and beyond, because it can accounts 
for spatially and temporally distributed changes in ideas, practices and values while still tracking 
the local. The focus on circulation oﬀers a specific explanation for the dynamics of a laboratory 
innovation, as transgenic mice were made as a desideratum, project, a potential result, a promis-
ing entity, a new word in the process of these interactions between multiple actors, technical tra-
ditions and audiences. Partially overlapping networks of communication and material exchange, 
relying on established infrastructures, drove the adoption of transgenic mice in multiple direc-
tions, and, despite considerable costs and experimental uncertainties, made them a fascinating 
and useful tool to generate and answer molecular questions about eukaryotic genes. 
This heavy focus on the molecular gene, combined with the diﬃculties and costs of production 
and control of gene integration, imposed limits on the scale of transgenic work and sharing, and 
defined the place of the modified lines.. Despite commercial interest in animal gene transfer and 
subsequent expansion of transgenic enterprise, in the 1980s the vast majority of transgenic mice 
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were produced in university laboratories, and travelled through academic networks. They were  a 
risky investment, especially when synthesising proteins in E. coli or making therapeutic and di-
agnostic products with monoclonal antibodies was a safer bet. Private initiatives did emerge, but 
the most successful ones revolved around sponsorship for established university sites. These ar-
rangements oﬀered an alternative sources of funding and communication networks, minor in 
scale but increasingly important in the 1990s and beyond. 
Direct intervention into the germline made transgenic mice resemble Drosophila as a ‘breeder re-
actor’, where new mutants could be generated and published. However, if the explosion of the 
fruit fly strains at a single location in the Columbia Fly Room provided conditions for extensive 
crosses and mapping experiments, the diverse vectors of transgenic research, attention to specific 
cases of gene expression and the greater cost of maintaining strains made the stocks much more 
transient. This bespoke mode of production placed little value on maintaining all the mutants, 
many of them potential failures, and kept a distance between transgenic workers and the tradi-
tional sites of mouse supply. Since most research questions relied on the ability to make new mice 
with a gene of interest rather than obtain existing strains, the enthusiastic but troubled commer-
cialisation attempts were premature.
The tension between local production – characteristic of both molecular and developmental biol-
ogy laboratories – and expanding scales was typical in this period. Gene mapping initiatives en-
countered similar problems in converting local molecular projects into the global networks of 
sequencing consortia, where competition, credit and potential commercial spin-oﬀs had to be 
negotiated against the common good. A new social order had to be established and enforced to 
enable large-scale collaboration and making comparable results.2 Moreover, potential for 
monetising research were a tension that aﬀected the circulation and imposed controls on sharing.  
Beyond the patronage, the changes in mediation of new science circa 1980 were symptomatic. 
They were caused by these very hybrid university-industrial arrangements and the emerging bio-
tech industry, as well as the expansion of science reporting. Biologists have been addressing wide 
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audiences throughout the field’s existence, and embryologists and molecular biologists were all 
too familiar with controversy before 1980. But the new incentives to communicate wide and far 
were considerable. Multi-directional communication could not only turn the work safe in an en-
vironment of severe mistrust towards genetic manipulation, as it did with the Yale gene transfer 
experiment or supermice. It was also a means to establish claims to priority and control the narra-
tives and expectations about a novel technology. As science sections expanded and reports of ge-
netic advances and failures became commonplace, the saturation of science stories in the media 
became dramatic. Media relations became a routine part of conducting high-stakes biological re-
search. 
Nowhere did this become clearer than in the next phase of the story. On 12 April 1988, the US 
Commissioner of Patents Donald Quigg held a press conference to announce the first US patent on 
an animal, Leder and Stewart’s ‘Harvard mouse’. While the decision followed the logic of Diamond 
v. Chakrabarty, the news caused a dramatic controversy.3 Capitalising on its exclusive licence deal 
with Harvard, DuPont moved to commercialise the new intellectual property which it marketed 
as OncoMouse™  and supplied via Charles River, the commercial animal supplier, at $50 a mouse 
(compared to $5–10 per inbred animal).4  After the controversy, the US Patent and Trademarks 
Oﬃce (USPTO) established a moratorium on issuing patents on further animals. The Ohio Univer-
sity application for the microinjection process was granted in 1989, but its lawyers had dropped 
the product claim, so it did not cover the resulting animals.5 Three more patents on mice were 
granted in 1992, to Ohio University, Bay Area start up GenPharm and Cambridge University. 
It remained unclear whether the Harvard patent extended to academic users, especially as uni-
versity research was increasingly expected to generate commercial spin-oﬀs. Most transgenic 
workers in a university setting ignored the intellectual property issues and continued producing 
their own animals.6 Yet resistance was growing, driven not so much by the price-tag as DuPont’s 
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prohibitive policy on breeding the animals, which required approval for mouse exchange and an 
annual update on all published and unpublished research. The small scale of the potential market 
for individual transgenic animals was another issue. The hope to mass-produce OncoMice as car-
cinogen test animals, with the claim that they could oﬀer greater sensitivity would did not justify 
the price tag and restrictions; established mouse strains were reliable, cheap and good enough for 
the task. Furthermore, the patent’s claims and DuPont advertising did not address the disanalogy 
between having select oncogenes activated in every cell, and clinical carcinogenesis. Similarly, 
despite receiving the patent on pronuclear microinjection in 1989, Ohio University made much 
larger profits from Hybriwix™, a rapid DNA isolation and testing method patented in 1989 by Di-
agnostic Hybrids, another spin-oﬀ with Thomas Wagner as co-founder.7  
Products of individual collaborations and sustained labour, transgenic mice were still presented 
as first and foremost tools to study gene regulation.8 With the need to introduce new genes for 
future work, establishing existing models required larger scales and many more converts, as well 
as alliances with clinicians. The costs required to develop and maintain new strains were not jus-
tified by the small academic market. In response to another patent granted on a knockout mouse 
in 1992, and similarly strict conditions of distributions, a group at the Cold Spring Harbour course 
staged a rebellion that led to a major National Academy of Sciences meeting.9 While no simple 
solutions were found, the resulting discussion highlighted commercial limitations on transgenic 
research, to the extent that the NIH discouraged mouse patent applications from its grantees ex-
cept in the most promising cases. Storage, line maintenance and standards were the key issues, 
and the NIH was urged to set up a facility to exchange transgenics.
The issues of infrastructures were a pressing concern. In 1991, David Baltimore penned the edito-
rial for the first issue of SEARCH, the Rockefeller University’s short-lived magazine dedicated to 
biomedical research.10 He declared that the 1990s would be ‘The Decade of the Mouse’. Recruiting 
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the “new experimental capabilities” in molecular manipulation, Baltimore argued that the “lowly 
mouse, a pest to many, is man’s and woman’s best surrogate. Although so diﬀerent from us – four-
footed, not very intelligent, a life span of two or three years, a gnawing rodent,” the animal was 
now “the ideal tool for investigating the functions of all mammalian genes, whether or not they 
have been associated previously with disease”. The enthusiastic conclusion called to improve 
animal supply and infrastructure for the glorious future of American science: “Fully realizing the 
potential of The Decade of the Mouse will test both our institutional flexibility and America’s 
commitment to rapid progress in health research”.
The continuities and changes during the ‘Decade of the Mouse’ require further critical examina-
tion. The focus on the alliances between academic, state and commercial institutions would help 
expand the historical understanding of the conditions familiar to today’s researchers. Synchro-
nising mouse genetics and transgenic work, the role of knockout mice and the establishment and 
marketing of disease models are all part of this story. The role of animal agriculture is another 
important direction for future research. Farm animal modification was the first trajectory for ap-
plying transgenesis globally, and a lot more controversial than mouse work. Farmer associations 
and property traditions were a key part of the debates and legislation around patenting life. Fur-
thermore, agricultural workers provided some of the crucial technologies in dealing with the em-
bryos, shipping and freezing them. Looking at crops and horticulture has adjusted our view of the 
history of genetics, and the plant GMO debates were the loudest and most lasting.11  Yet despite 
some historical attention,12  the animal farm remains a gap in our understanding of the life sci-
ences in the twentieth century, a missing area to be taken seriously alongside the laboratory and 
the clinic.
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